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ABSTRACT 
 
Cidofovir (CDF) has shown potential in vitro and in vivo antiviral activity against 
cytomegalovirus (CMV) retinitis. However, low CDF permeability due to its hydrophilic 
nature limits its effectiveness. Furthermore, physicochemical properties such as high water 
solubility (170 mg/mL) and log p (-3.9) of CDF are unfavorable for passive transcellular 
absorption. Therefore, we have tested novel transporter targeted lipid prodrugs of CDF and 
their nanoparticle formulations to achieve sustain drug delivery for the treatment of CMV 
retinitis. These prodrugs contains lipid linker of different carbon chain length (e.g. C2, C6, 
and C12) carrying minimum two functional groups to link one end with CDF and another 
end with ligand (biotin) targeting sodium dependent multivitamin transporter (SMVT). 
We have successfully synthesized three biotinylated (B) derivatives (B-C2-cCDF, B-
C6-cCDF, and B-C12-cCDF) and two lipid ester derivatives (C6-cCDF and C12-cCDF) of 
cCDF. Structure and purity of all the produgs were confirmed using 31P NMR and LC-
MS/MS analysis. All synthesized prodrugs were characterized in terms of its 
physicochemical properties, in vitro cellular accumulation, cytotoxicity, transporter affinity, 
ocular tissue stability and in vitro antiviral potency against various virus strains.  
iii 
Furthermore, prodrug loaded PLGA nanoparticle formulations were prepared and 
characterized.  
Overall, improvement in physicochemical properties, lipophilicity, interaction with 
SMVT transporter, higher tissue-buffer partition coefficient and rapid conversion into parent 
molecule (in retina–choroid) were observed with higher lipid chain length (B-C12-cCDF > 
B-C6-cCDF > B-C2-cCDF). In vitro antiviral activity shows B-C12-cCDF as the potential 
prodrug candidate for future in vivo evaluation. Sustained release (~3 weeks) formulation of 
B-C12-cCDF loaded PLGA nanoparticles may serve as a viable intravitreal delivery 
approach for the treatment of CMV retinitis. Based on the above finding we hypothesized 
that lipid raft facilitates enhanced prodrug interaction with cell membrane and thereby assist 
docking of targeted ligand into the binding domain of transporter. Therefore, current novel 
approach combines both lipids mediated facilitate diffusion and transporter targeted delivery 
to generate synergistic drug effect. Overall, these findings indicate that transporter-targeted 
lipid analogue of CDF could be a viable strategy for the treatment of CMV retinitis. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Drug Delivery to Eye 
The unique anatomy and physiology of the eye makes ocular drug delivery a 
challenging task due to its restrictive barrier functionality posed by various ocular 
barriers. Many of these barriers are inherent and unique to ocular anatomy and 
physiology, making it a challenging task for drug delivery scientists. Various ocular 
barriers prevent attainment of therapeutic drug concentration at the target tissues. 
These barriers are specific depending upon the route of drug administration e.g. topical, 
systemic, and oral. Anatomical and physiological barriers normally protect the eye from 
toxicants.  Therefore, various preformulation and formulation factors need to be 
considered while designing an ophthalmic formulation.   
 Furthermore, drug delivery to the back of the eye poses major challenges while 
treating various sight-threatening diseases such as diabetic macular edema, diabetic 
retinopathy, cytomegalovirus retinitis (CMV), proliferative vitreoretinopathy, and age-
related macular degeneration (AMD). Conventional delivery routes such as topical and 
systemic modes of administration have shown major limitation to deliver effective drug 
dose to the posterior segment tissues [1, 2]. Therefore, the intravitreal route of 
administration has gained a lot of attention to deliver therapeutic agents to the back of 
the eye. However, frequent drug administration is the major drawback of intravitreal 
injection which leads to severe ocular damage such as retinal detachment, 
endophthalmitis and elevated intraocular pressure. To overcome these limitations, 
 2 
 
various controlled delivery systems such as implants (biodegradable and non-
biodegradable), liposomes and nanoparticles have been developed with some success. 
Alternatively, the periocular route has also shown some advantage owing to the large 
surface area and relatively high permeability of the sclera. However, choroidal blood 
circulation, blood-retinal barrier and the presence of efflux transporters can critically 
hamper transport of therapeutic agents across to the retina.  
1.2 Routes of Drug Delivery to Eye 
1.2.1 Topical  
Topical administration, mostly in the form of eye drops is employed to treat 
anterior segment ocular diseases. Mostly, the site of action of topically applied drugs 
consists of different layers of cornea, conjunctiva, sclera, and other anterior segment 
tissues such as iris and ciliary body (anterior uvea). Anatomical barriers and precorneal 
factors such as solution drainage, blinking, tear film, tear turn over, and induced 
lacrimation negatively affect the bioavailability of topically administered formulations 
[3]. Tear film composition and amount are determinants of healthy ocular surface and 
offers resistance due to its high turnover rate. Mucin present in the tear film plays a 
protective role by forming a hydrophilic layer that moves over the glycocalyx of the 
ocular surface and clears debris and pathogens [4]. Human tear volume is estimated to 
be 8-10 μL, and the cul-de-sac can transiently contain around 30 μL of the administered 
eye drop. However, tear film displays a rapid restoration time of 2–3 min, and most of 
the topically administered solutions are washed away within 15–30 s after instillation. 
Considering all the pre-corneal factors, contact time with the absorptive membranes is 
 3 
 
lower, which is considered to be the primary reason for less than 5% of the applied 
dose reaching the intraocular tissues [5]. 
In addition, various layers of the cornea, conjunctiva, and sclera play an 
important role in drug permeation. The cornea, an anterior most layer of the eye, is a 
mechanical barrier which limits the entry of exogenous substances into the eye and 
protects the ocular tissues. It can be mainly divided into the epithelium, stroma, and 
endothelium. Each layer offers a different polarity and a potential rate-limiting 
structure for drug permeation. Furthermore, superficial corneal epithelial cells are 
joined to one another by desmosomes and are surrounded by ribbon-like tight junction 
complexes (zonulaoccludens) [6, 7]. Presence of these tight junction complexes retards 
para-cellular drug permeation from the tear film into intercellular spaces of the 
epithelium as well as inner layers of the cornea. 
The stroma, which comprises 90% of the corneal thickness, is made up of an 
extracellular matrix and consists of a lamellar arrangement of collagen fibrils. The 
highly hydrated structure of the stroma poses a significant barrier to permeation of 
lipophilic drug molecules. Endothelium is the innermost monolayer of hexagonal-
shaped cells. Even though endothelium is a separating barrier between the stroma and 
aqueous humor, it helps maintain the aqueous humor and corneal transparency due to 
its selective carrier-mediated transport and secretory function [8].  
Furthermore, the corneal endothelial junctions are leaky and facilitate the 
passage of macromolecules between the aqueous humor and stroma [9]. Thus, corneal 
layers, particularly the epithelium and stroma are considered as major barriers for 
ocular drug delivery. It is vital to understand that the permeant should have an 
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amphipathic nature in order to permeate through these layers. Compared to cornea, 
conjunctival drug absorption is considered to be nonproductive due to the presence of 
conjunctival blood capillaries and lymphatics, which can cause significant drug loss into 
the systemic circulation thereby lowering ocular bioavailability. Conjunctival epithelial 
tight junctions can further retard passive movement of hydrophilic molecules [10]. 
Certain amount of drug can also permeate across the sclera upon topical 
administration. The structural details of sclera, choroid and retina have been mentioned 
in the following sections. 
1.2.2 Systemic (Parenteral)  
Following systemic administration, blood–aqueous barrier (BAB) and blood–
retinal barrier (BRB) are the major barriers for anterior and posterior segment ocular 
drug delivery, respectively. BAB consists of two discrete cell layers located in the 
anterior segment of the eye namely, the endothelium of the iris/ciliary blood vessels 
and the nonpigmented ciliary epithelium. Both cell layers express tight junction 
complexes and prevent the entry of solutes into the intraocular environment such as 
aqueous humor. BRB restricts the entry of therapeutic agents from blood into the 
posterior segment. It is composed of two different cell types , retinal capillary 
endothelial cells and retinal pigment epithelium cells (RPE) also known as the inner and 
outer BRB, respectively.  
RPE located between the neural retina and the choroid is a monolayer of highly 
specialized cells. RPE aids biochemical functions by selectively transporting molecules 
between photoreceptors and choriocapillaris. Furthermore, it maintains the visual 
system by uptake and conversion of retinoids [8]. However, tight junctions of the RPE 
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efficiently restrict intercellular permeation. Following oral or intravenous 
administration, drugs can easily enter into the choroid due to its high vasculature 
compared to the retinal capillaries. The choriocapillaries are fenestrated resulting in 
rapid equilibration of drug molecules present in the bloodstream with the extravascular 
space of the choroid. However, the outer blood–retinal barrier restricts further entry of 
drugs from the choroid into the retina. Even though it is ideal to deliver drug to the 
retina via systemic administration however, BRB strictly regulates drug permeation 
from blood to the retina. Therefore, specific oral or intravenous delivery systems are 
needed to transport molecules through choroid into the deeper layers of the retina [11]. 
1.2.3 Oral  
Oral drug delivery has been investigated for different reasons treat ocular 
ailments [12-14]. Topical delivery alone failed to produce therapeutic concentrations in 
the posterior segment. Also, oral drug delivery was considered as a possible 
noninvasive and patient preferred route to treat chronic retinal diseases compared to 
injectable route. However, limited accessibility to many of the targeted ocular tissues 
limits the utility of oral administration which necessitates high dosage to observe 
significant therapeutic efficacy. This can result in systemic side effects. Hence, 
parameters such as safety and toxicity need to be considered when aiming to obtain a 
therapeutic response in the eye upon oral administration. A major prerequisite of the 
oral route for ocular applications is the high oral bioavailability of the drug. Following 
oral absorption, molecules in systemic circulation must also cross the BAB and BRB. 
The function and barrier property of these protective ocular structures have been 
already discussed previously. 
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1.2.4 Periocular  
Although not very patient compliant, periocular routes are employed partly to 
overcome the inefficiency of topical and systemic drug delivery to the posterior ocular 
segment. Moreover, systemic administration may lead to side effects making it a less 
desirable delivery route for geriatric patients. Periocular route includes 
subconjunctival, subtenon, retrobulbar, and peribulbar administration and is 
comparatively less invasive than intravitreal route (Fig. 1). The drug administered by 
periocular injections can reach the posterior segment by three different pathways: (i) 
transscleral pathway, (ii) systemic circulation through the choroid, and (iii) anterior 
pathway through the tear film, cornea, aqueous humor, and the vitreous humor [15].  
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Figure 1: Structure of the eye representing routes of administration (Reused with 
permission, [16]) 
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Subconjunctival injection obviates the conjunctival epithelial, which is a rate-
limiting barrier for permeation of water-soluble drugs. Thus, transscleral route 
bypasses cornea–conjunctiva barrier. Nevertheless, various dynamic, static, and 
metabolic barriers limit drug access to the posterior ocular segment. Dynamic barriers 
include conjunctival blood and lymphatic circulation. Various reports have 
demonstrated rapid drug elimination via these pathways following subconjunctival 
administration due to drug drainage into systemic circulation ultimately causing 
lowered ocular bioavailability [17-19].  Therefore, drug elimination from the 
subconjunctival space becomes a major determinant of the vitreous drug levels 
following subconjunctival administration. The drug molecules which escape 
conjunctival vasculature permeate through sclera and choroid to reach the neural 
retina and photoreceptor cells. Therefore, it is important to understand the structural 
features and barrier properties of sclera, choroid and retina to design a successful 
transscleral drug delivery system. These details are mentioned below. 
Sclera 
It is an elastic, microporous tissue which covers the entire globe except the 
cornea (16-17 cm2 surface area). It mainly comprises of proteoglycans and collagen 
fibers, especially type I collagen. Sclera contains aqueous pores and intracellular spaces 
through which many drug molecules can traverse. Compare to the other ocular tissues 
such as retina and cornea, sclera contains very few proteolytic enzymes. Sclera is 
relatively more permeable to drug molecules compared to the cornea. The permeability 
of various drug molecules across the sclera has been reported in the literature. Various 
physicochemical properties of drug molecule such as molecular radius, molecular 
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weight and shape affect its transport across the sclera. It is observed that as the size of 
the molecule increases the permeation across sclera decreases. Recent reports suggest 
that sclera is permeable to large molecular weight compounds such as IgG (150 kDa), 
bovine serum, albumin (66.3 kDa) and dextrans [20]. Molecular radius has been shown 
as a better predictor of scleral permeability compared to the molecular weight. 
Permeation of BSA (molecular radius: 3.62 nm) was found to be more across the sclera 
than the dextran of equivalent molecular weight (molecular radius: 4.5 nm). Other 
factors which influence the permeation of drug molecules across the sclera include 
hydration of the tissue, solubility (in water and lipid) and charge. Permeation across 
sclera increases with elevated tissue hydration, water solubility and negative charge of 
the molecule [3, 20]. 
Bruch’s Membrane-Choroid 
 It is a vascular tunic part of the eye which supplies blood to the retina. There are 
some structural similarities between sclera and choroid. Choroid is also a matrix like 
structure made up of collagen. However, it contains higher content of melanin. Various 
drug molecules were shown to bind with the melanin and affect disposition or 
pharmacokinetics of the drug molecule. Choroid poses a significant barrier to the drug 
transport due to the presence of lipidic plasma membrane of endothelial cells. 
Furthermore, the highly vascularized tissue causes rapid drug drainage into systemic 
circulation which results in limited retinal drug diffusion. Some structural changes have 
also been reported in the Bruch’s membrane and choroid due to ageing. Hydrophilicity, 
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molecular radius and charge are important determinants for the drug transport across 
choroid.  
Retina  
It is a multilayered membrane which mainly comprised of neural retina and 
retinal pigment epithelium (RPE). The main role of neural retina is signal transduction 
which leads to vision. RPE is a single layer of cuboidal cells which consist of tight 
intracellular junctions and acts as a barrier for drug transport. Upon transscleral 
administration, drug molecule must cross the sclera, choroid and RPE in order to reach 
to the inner retinal tissues. The details of RPE have been mentioned in an earlier 
section. RPE acts as a barrier for drug molecules especially hydrophilic drugs [21]. 
Various permeability studies have been reported comparing drug transport across 
sclera and retina-choroid-sclera (RCS). These studies have demonstrated higher drug 
permeability across sclera compared to RCS. 
1.2.5 Intravitreal  
Unlike periocular injections, intravitreal injection offers distinct advantages 
since, the drug molecules are directly inserted into the vitreous. However, drug 
distribution in the vitreous is non-uniform. Small molecules can be rapidly distributed 
through the vitreous, whereas diffusion of larger molecules is restricted. This 
distribution also depends on the pathophysiological condition and molecular weight of 
the administered drug [16]. Vitreous half-life of the drug is another factor which can 
determines the therapeutic drug efficacy. Following intravitreal injection, drug 
elimination occurs via anterior or posterior route. Anterior elimination route involves 
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drug diffusion across the vitreous into the aqueous humor through zonular spaces 
followed by elimination through aqueous turnover and uveal blood flow.  Whereas 
posterior elimination pathway involves drug permeation across BRB and requires 
optimum passive permeability or active transport mechanisms. As a result, 
hydrophilicity and large molecular weight tend to increase the half-life of the 
compounds in the vitreous humor [11]. 
1.3 Approaches to Improve Ocular Drug Delivery 
1.3.1 Particulate Drug Delivery Systems 
Nanoparticles 
Nanoparticles are colloidal solid particles with the size range of 10 to 1000 nm. 
Generally, nanoparticles are fabricated from biodegradable or non-biodegradable 
materials such as natural or synthetic polymers, lipids, phospholipids or metals [22, 
23]. Depending on the type of fabricated materials, nanoparticles can be allocated into 
three major categories: polymeric nanoparticles, solid lipid nanoparticles, and inorganic 
nanoparticles. 
Polymeric Nanoparticles 
Polymeric nanoparticles are the most common type of nanoparticles employed 
for drug delivery application. Polymeric nanoparticles are developed from various 
natural, synthetic biodegradable as well as non-biodegradable polymers. Polymers such 
as polyacrylates, polyalkylcyanoacrylates, polylactide (PLA), polylactide–polyglycolide 
(PLGA), polycaprolactones, dextran, albumin, gelatin, alginate, collagen, hyaluronic acid, 
and chitosan are prevalent in constructing polymeric nanoparticles. Polymeric 
nanoparticles can be engineered as nanocapsules or nanospheres (Fig. 2). In case of 
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polymeric nanocapsules, drugs are enclosed within the polymeric membrane, while in 
nanospheres, drugs are evenly distributed within the polymeric matrix [24]. Aksungur, 
et al. have fabricated nanoparticle (either poly-lactide-co-glycolide (PLGA) or a mixture 
of PLGA with Eudragit®RL ) encapsulated Cyclosporin A (CsA) for the treatment of eye 
inflammation via topical administration [25]. 
Solid Lipid Nanoparticles (SLNs) 
SLNs have been developed as an alternative to other colloidal systems, such as 
polymeric nanoparticles, liposomes and emulsions. These are colloidal carriers 
composed of physiologically compatible solid lipids. The major components of SLNs are 
solid lipids and surfactants. Most commonly employed solid lipids in SLNs include 
triglycerides, beeswax, cetyl alcohol, cholesterol, and cholesterol butyrate. Active 
ingredients can be incorporated into SLNs by various preparation methods including 
high shear homogenization, hot homogenization, cold homogenization, solvent 
emulsification/evaporation and supercritical fluid method. SLNs combine advantages of 
both polymeric nanoparticles and liposomes which include controlled drug release, 
high entrapment of lipophilic drugs, easy production and scale up, enhanced drug 
stability and bioavailability. Additionally, excellent biocompatibility and 
biodegradability make SLNs unique over other nanocarriers [26, 27].  Jiawei, et al. have 
formulated a tetrandrine-loaded cationic solid lipid nanoparticles (TET-CNP) and solid 
lipid nanoparticles (TET-NP) by the emulsion evaporation-solidification. The result 
clearly revealed that the AUC values of TET-CNP and TET-NP were 1.96-fold and two-
fold higher than that of TET-SOLUTION [28].  
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(A)                                                                                  (B) 
Figure 2: Schematic diagram of polymeric nanoparticles (A) nanocapsules, and (B) 
nanospheres 
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Inorganic Nanoparticles 
The term inorganic nanoparticle is generally utilized for nanoparticles fabricated 
from alumina, silica, metal, metal oxides or metal sulfides.  Inorganic nanoparticles 
gained immense interest over past few years due to their unique physicochemical 
properties, such as small size and inertness. In addition, optical and magnetic 
properties of some inorganic nanoparticles make them an attractive alternative to 
organic nanoparticles. Inorganic nanoparticles including magnetic nanoparticles, gold 
nanoparticles, and quantum dots (QDs) have been successfully developed as contrast 
agents for bio imaging applications. Recently, inorganic nanoparticles have also been 
explored for drug delivery, specifically anti-cancer drugs. Furthermore, inorganic 
nanoparticles can be functionalized to achieve targeted drug delivery [29]. 
Liposomes 
A liposome is a vesicular structure entirely enclosed by a membraneous lipid 
bilayer. The basic molecular building block of a typical liposomal membrane is a 
phospholipid. Phospholipids are known as polar lipids because phosphorelated portion 
is polar or water soluble whereas fatty acid (saturated or unsaturated) tails of the 
molecules are non-polar or fat soluble. In an aqueous environment phospholipids orient 
themselves in to a thermodynamically stable structure called a bilayer. Liposomes can 
encapsulate both hydrophilic and lipophilic drugs which are slowly release as 
liposomes are broken down by enzyme and acids found in tissues and cells especially at 
the diseased sites [30, 31]. Jain, et al., have formulated ciprofloxacin-eluting contact lens 
to provide controlled release of drug for a longer period of time, using liposomes as a 
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drug delivery system and found that highly specific in terms of localized and sustained 
application of the ciprofloxacin [32].  
Based on the structural morphology, liposomes can be classified as a small or large 
unilamellar vesicles (SUV, LUV), multilamellar vesicles (MLV), giant unilamellaror 
multilamellar vesicles (GUV, GMV), and multi-vesicular vesicles (MVV) (Fig. 3). The 
bilayers of all MVV and MLV have identical lipid composition, which is their 
characteristic feature. Liposomes are mainly prepared by a passive or active loading 
method. Passive loading method involve drug loading before or during the liposome 
formation whereas, drug loading into pre-made liposomes is known as active or remote 
loading process.  
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Figure 3: Structural morphology of liposomes 
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1.3.2 Chemical Approach (Prodrug Strategies) 
The prodrug concept has turn out to be an important part of the ocular drug design 
and delivery.  Synthesizing prodrugs which accomplish most if not all requirements of 
an ideal formulation is very challenging.  
Important considerations while designing ophthalmic prodrugs are 1) Parent drug 
must hold functional group susceptible to chemical derivatization, 2) Chemical 
modification at the functional group site of parent drug must be reversible, 3) Parent 
drug, prodrug, and the pro-moiety attached to parent compound must be safe and non-
toxic and pro-moiety should exert rapid elimination from the body (Generally amino 
acid, small peptide or vitamins has been used as a pro-moiety which is very safe and 
easily removable natural body substrates), 4) In vivo prodrug bioreversion must be 
governed by functionally active biological enzymes such as esterase and peptidase. The 
rate of bioreversion should be optimized in order to avoid pro-moiety detachment and 
parent drug release at non-target site, 5) Prodrug must possess sufficient shelf life and 
stability in final formulation, 6) Majority of ocular preparations are delivered in the 
form of liquid such as eye drops, hence, aqueous solubility of prodrug is a critical 
parameter to consider when parent drug is lipophilic in nature and possess low water 
solubility, 7) Prodrug should also possess optimal lipophilicity in order to accomplish 
higher diffusion across lipophilic ocular barriers (dynamic and static), 8) Finally the 
prodrug should have ability to evade unfavorable physicochemical as well as 
biopharmaceutical properties of a parent molecule.  
In addition to resolving formulation issues associated with drug, prodrug should 
also exhibit high affinity and site specific delivery of parent drug molecule. These 
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characteristics will not only overcome side effects associated with parent molecules but 
it will also help reducing dose of final formulation [33-35]. 
 
Functional Group Approach 
The common functional groups that have been utilized in ophthalmic prodrug 
design are carboxylic, hydroxyl, amine, and carbonyl groups. Modification of these 
functional groups which includes esters [36-38], carbamates [39], phosphates [40-43] 
and oximes [44, 45] to yield in ophthalmic prodrugs. Table 1 represents such prodrug 
structures of the most common functionalities. 
 
Ester Prodrugs 
The most common ophthalmic prodrugs developed so far are esters derived 
from either COOH or OH functional groups present in the drug molecules. Usually, the 
COOH functional group in drug molecules exists in an ionized form under physiological 
conditions and thus significantly reduces lipophilicity of the molecule, resulting in 
unfavorable pharmacokinetic properties. Appropriate esterification of active molecules 
with other promoieties can generate ester derivatives with desirable hydrophilicity, 
lipophilicity and in vivo lability.  
As shown in Fig. 4, ‘A’ type ester prodrugs can be prepared from carboxylic acid 
drugs and alcohol promoieties, whereas ‘B’ type of ester prodrugs can be made from 
alcohol drugs and acid promoieties. 
 To prepare ester prodrugs mostly Steglich esterification reaction conditions 
have been applied with N,N'-Dicyclohexylcarbodiimide (DCC) or Ethyl-3-(3-
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dimethylaminopropyl) carbodiimide (EDC) as a coupling reagent and 4-
Dimethylaminopyridine (DMAP) as a catalyst. 
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Figure 4: Ester prodrugs from (A) COOH, and (B) OH functionalities  
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Table 1: Ophthalmic prodrug design from the most common functionalities 
Prodrug 
Functional 
Groups 
Prodrug 
form 
Drugs 
Hydrolytic 
enzyme 
Comments 
Ester 
-OH 
-COOH 
O C
O
R  
Antimetabolites 
[46] 
Prostaglandins 
[47] 
Esterases[48] 
Enhanced corneal penetration 
and IOP reduction,chemical 
instability in aqueous solution 
[49] 
Phosphate 
Ester 
-OH O P
O
OH
OH  
Vidarabin [50] 
Cannabinoids [43] 
 
Phosphatases 
[51] 
Enhanced aqueous solubility 
[40], excellent chemical 
stability and high susceptibility 
to enzymatic reconversion 
[52] 
Carbamate 
Ester 
-NH2 
H
N C
O
OR
 
Timolol [39] Esterases [39] 
Enhanced corneal 
penetration[39], high 
enzymatic stability [53] 
Oxime C O
 
C N R
 
β-adrenergic 
blockers [54] 
Oxime 
hydrolase, 
Ketone 
reductase [54] 
Prolonged IOP reduction and 
improved therapeutic index 
[55], site-specific enzyme 
activity [54] 
Oxazolidin
es OH
N
H  
C
O
N  
Phenylephrine 
[56] 
  
- 
Enhanced corneal penetration 
and improved therapeutic 
index, poor aqueous stability 
[56] 
N-
sulfonylim
idates 
SO2NH2  
SO2N C
R1
OR2
 
Carbonic 
anhydrase 
inhibitors [57] 
- 
Enhanced aqueous solubility, 
slow hydrolytic rate and poor 
aqueous stability [57]  
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In 1976, Hussain et al. [58]reported the first ophthalmic prodrug dipivefrin, 
where two hydroxyl functional groups of epinephrine have been esterified to prepare 
dipivalyl epinephrine. Dipivefrin showed enhanced corneal penetration with 10 times 
improved therapeutic index compared to epinephrine [49, 59]. Since then, a plethora of 
ester prodrugs including adrenergic agonists [60, 61], adrenergic antagonists [62, 63], 
cholinergics [64, 65], carbonic anhydrase inhibitors [66], prostaglandins [37, 47], 
antimetabolites [38, 46]and steroids [67, 68] have been prepared and their 
pharmacokinetic behaviors have been thoroughly explored. Ester prodrugs can 
enhance corneal penetration with improved therapeutic index. However, in some 
instances these components appear to be chemically unstable in aqueous eye drop 
formulations. 
Ester prodrugs can be converted back to active parent drugs via esterases 
present in the eyes. Esterases appear to be to be concentrated in the iris-ciliary body, 
corneal epithelium, retina and optic nerve. Different classes of esterases i.e., 
acetylcholine esterase, pseudocholine esterase, butyrylcholine esterase and carboxyl 
esterases are responsible for facile conversion of the ester prodrugs to parent drugs 
[48]. Enzyme catalyzed ester hydrolysis is highly dependent on the acyl and the alcohol 
moieties surrounding the cleavable ester bond. Sterically unhindered straight chain 
aliphatic esters of timolol (i.e o-acetyl/o-propionyl/o-butyryl timolol) can be rapidly 
hydrolyzed both enzymatically and chemically, whereas sterically hindered esters such 
as the 1´-methylcyclopropanoyl, cyclopropanoyl, 3,3-dimethylbutyryl derivatives are 
stable enough to generate aqueous solutions with shelf-lives larger than two years at 
10-15 °C .  
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Phosphate Ester Prodrugs 
Phosphate ester prodrugs are typically designed for hydroxyl functionalities of 
poorly water-soluble drugs. The presence of dianionic phosphate promoiety in 
phosphate prodrugs enhances aqueous solubility of the parent drugs [40-43]. These 
compounds exhibit adequate to excellent chemical stability which opens up the 
possibility of developing topical eye drop formulations [52]. These prodrugs can be 
rapidly hydrolyzed to parent drugs by alkaline phosphatases present in the eye tissues 
[52].  
Carbamate Prodrugs 
Carbamate prodrugs can be prepared from amine and carboxyl functionalities. 
Although amines can be easily acylated, carbamate prodrugs are rarely used in 
ophthalmic delivery because of the relatively high in vivo enzymatic stability. However, 
the problem can be overcome by introducing an enzymatically labile ester group in the 
carbamate structure resulting in N-(acyloxy)alkyl carbamates, which are highly stable 
in aqueous solutions [39]. These compounds also exhibit improved in vitro   corneal 
penetration. N-(acyloxy) alkyl carbamates exhibit high susceptibility to enzymatic 
reconversion to the active parent. Esterase-catalzed hydrolysis of terminal ester linkage 
in these derivatives lead to an unstable (acyloxy)alkyl carbonyl intermediate which 
undergoes spontaneous decomposition to parent amine via a labile carbamic acid. 
However such a prodrug approach has limited applicability to primary amines since N-
(acyloxy)alkyl carbonyl derivatives of primary amines undergo intramolecular acyl 
transfer reaction leading to formation of stable N-acylated derivatives [39]. 
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Oximes Prodrugs 
Oximes are derivatives of ketones, which provide an opportunity to modify drug 
molecules, lacking hydroxyl, amine or carboxyl functionalities. Several oxime or 
methoxime derivatives of known β-adrenergic blockers i.e. alprenolol [69], betaxolol 
[45], propranolol [70] and timolol [55], have been synthesized and studied as potential 
antiglaucoma agents [45, 71-74]. Synthesis of these derivatives involves oxidation of 
secondary hydroxyl functional groups present in the original β-blocker alcohols, using 
activated dimethyl sulfoxide (Pfitzner-Moffat oxidation) followed by coupling of 
resulting ketone by additing either hydroxylamine or methoxyamine in the same 
reaction mixture [54]. Oxime or methoxime derivatives exist in alternative Z (syn) or E 
(anti) configurations. These compounds exhibit significant and long lasting intraocular 
pressure (IOP) lowering activity with improved therapeutic index [54]. Oxime prodrugs 
undergo sequential hydrolysis to parent β- blockers. The activation process involves 
initial hydrolysis (by oxime hydrolase) of oxime derivatives to ketone which undergoes 
enzymatic hydrolysis by ketone reductase to parent β- blockers (S-(-) stereoisomer). 
Ocular distribution of oxime hydrolase and ketone reductases is primarily limited to 
iris-ciliary body [54].  
Transporter Targeted Prodrug Approach 
Recent progress in transporter identification has greatly contributed to the field 
of prodrug derivatization. Various transporters have been explored and recognized for 
transferring exogenous and endogenous nutrients across the cell membranes [75]. 
Various influx and efflux transporters have also been identified on the various region of 
the eye (Table 2). A major role of these influx transporters is to deliver essential 
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nutrients which can be utilized to deliver therapeutic molecules across various ocular 
barriers. However, an efflux transporter relatively lowers ocular bioavailability of 
therapeutic drug by pushing molecules out of a cell.  
Anticancer [76], antifungal [77], antiviral [78], steroids [79] and fluroquinolones 
[80, 81] are known substrates of efflux transporters, which lowers ocular 
bioavailability. Several strategies have been applied to evade drug efflux, among which 
prodrug derivatization is one of the most successfully utilized approach for improving 
ocular bioavailability of therapeutic agents.  
Prodrugs have been synthesized in such a way that (a) chemically modified drug 
will have lower affinity towards efflux transporter such as quinidine prodrugs [82-84], 
or (b) chemically modified drug will have higher affinity towards influx transporter 
which otherwise are not recognized as such by a transporter such as peptide and amino 
acid prodrugs (acyclovir [85-87] and ganciclovir [88-90]). Hence, higher ocular 
bioavailability of therapeutic agents can be achieved.  In addition to peptide (PepT1) 
[88, 91], amino acid (LAT1, LAT2, B(0,+)) [85, 92] and monocarboxylic acid (MCT) [93, 
94]  transporters, recently various vitamin transporters such biotin [95] and ascorbic 
acid (SVCT2) [96-99] have been utilized for the delivery of various ocular prodrugs.  
In a transporter targeted prodrug approach, a promoiety such as amino acid, 
peptide or vitamin, which is a substrate of respective transporter, is conjugated to 
parent drug molecule with ultimate aim of improving its bioavailability at the target 
site. Various transporters have been targeted in the eye for improving drug 
bioavailability following topical route. For successful prodrug delivery an ideal 
transporter must be highly expressed at desired ocular region in order to facilitate 
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optimal and rapid drug uptake. In addition, it must have high capacity to avoid 
inhibition of an excess prodrug or nutrients recognized by the same transporter. This 
approach has distinct feature relative to other approaches as the prodrug is specifically 
recognized by a particular transporter expressed on the cell surface. 
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Transporters 
Substrates Cornea Conjunctiva Retina 
Retinal Pigment 
Epithelium (RPE) 
Blood-Retinal Barrier 
(BRB) 
PepT1 Dipeptides Rabbit [100] 
Primary cultured 
rabbit 
conjunctival 
epithelial cells 
[101] 
Rabbit [102] 
Rabbit [102] 
 
Rabbit [103] 
GLUT1 Glucose 
Rat [104] 
Human [105] 
Human [106] Human [107] 
Human [107] 
Rat [108] 
 
Human [107], Rat [108-
110] 
ENT1 Nucleoside 
Rabbit [111]Rabbit 
corneal epithelial cell 
line [112] 
Rabbit [113] 
Rabbit [114] 
Cultured human retinal 
cell line [115] 
Human RPE cell line, 
ARPE-19 [114] 
Rat inner BRB cell line, 
TR-iBRB2 [116] 
MCTs Monocarboxylate Rabbit [117]  Rat [118] 
Rat [118],Human RPE 
and ARPE-19 cells 
[119] 
Rat inner BRB cell line, 
TR-iBRB2 [93] 
SVCT2 
Vitamin C 
(Ascorbic acid) 
Rabbit corneal 
epithelial cells [120] 
 Rat [121] 
Rat [121], Human RPE 
cells [97], Primary 
cultures of cat RPE 
[122] 
Rat [123] 
SMVT Biotin 
Rabbit corneal 
epithelial cell line 
[124] 
 Rabbit [95] 
Human  RPE cell line, 
ARPE-19 [95] 
Rat inner BRB cell line, 
TR-iBRB2 [125] 
Riboflavin 
Riboflavin 
(vitamin B2) 
Rabbit cornea and 
Rabbit corneal 
epithelial cell line 
[126] 
 
Human-derived 
retinoblastoma cell 
line, Y-79 [127] 
Human  RPE cell line, 
ARPE-19 [128] 
 
LAT1, LAT2 
Large neutral 
amino acids 
Human and rabbit 
cornea [129] 
 
Human [130] 
Human  RPE cell line, 
ARPE-19 [131] 
Rat inner BRB cell line, 
TR-iBRB2 [132] 
ASCT1 
Neutral amino 
acids 
Rabbit corneal 
epithelial cell culture 
and rabbit cornea 
[133] 
  
Rat inner BRB cell line , 
TR-iBRB2 [134] 
B(0,+) 
Neutral and 
cationic amino 
Human, Rabbit [135] 
Rabbit [136] 
Rabbit [137] 
 Rat [139] 
Table 2: Transporters and receptors in various ocular tissues 
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acids Human [138] 
Reduced-folate 
transporter(RFT) 
Reduced folate   Rabbit [21] 
Human RPE cells [140, 
141], Rabbit [21], 
Mouse [140] 
Mouse [140], Rat inner 
BRB cell line, TR-iBRB2 
[142] 
Proton-coupled 
folate transporter 
(PCFT) 
Folate   Mouse [143, 144] Mouse [143] 
Rat inner BRB cell line, 
TR-iBRB2 [142] 
Folate receptor 
alpha 
Folic acid   
Human [145], Mouse 
[143] 
Mouse [140, 145], 
Human RPE cells [140] 
Mouse [140] 
Transferrin Transferrin 
Human [146], Bovine 
[147] 
Human [146], 
Bovine [147] 
Rat [148] 
Human [146, 149], Rat 
[148, 149] 
 
Human and Rat [149] 
P-glycoprotein, 
MDR 1 
 
Corneal epithelial cells, 
Human and rabbit 
cornea [150] 
Rabbit 
conjunctival 
epithelial cells 
[151] 
Bovine retinal 
endothelial cells    
[152], Rabbit retina 
[84] 
Human  RPE cell line, 
ARPE-19 [153] 
Human RPE [154] 
Mouse [155] 
Multidrug 
resistance 
associated proteins 
(MRPs) 
 
Rabbit cornea  and 
Human corneal cells  
[156], Freshly excised 
human corneal 
epithelial [157] 
Human [1]  
Human  RPE cell line, 
ARPE-19 [153] 
Mouse [155] 
Breast cancer 
resistance protein 
(BCRP) 
 
Human corneal 
epithelial cells [158], 
Freshly excised human 
corneal epithelial [157] 
  
Human  RPE cell line, 
ARPE-19 [153] 
Mouse [155] 
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Receptor Targeted Prodrug Approach 
In addition to transporter targeted delivery, drug targeting to specific receptor 
using carrier mediated absorption is emerging as a clinically significant approach. 
Receptors useful for prodrug targeting have been identified in various region of the eye 
(Table 2). Receptors are responsible for the internalization of nutrients, such as folate, 
vitamin B12 and transferrin. Due to the importance of these receptors, numbers of 
investigator have examined the use of drug-receptor conjugation for drug delivery and 
drug targeting. Internalization of such conjugates has been achieved successfully by 
receptor-mediated endocytosis. So far folate receptor has been utilized as an ideal 
candidate for tumor targeted drug delivery but less attention has been given to receptor 
theory for ocular drug delivery [159]. Recently our laboratory has started working on 
the extension of targeted prodrug approach by synthesizing receptor targeted prodrugs 
for ocular drug delivery. However, much attention is needed to explore and extend 
receptor based prodrug approach. 
Stereoisomeric Dipeptide Prodrug Approach 
An idea of modulating the enzymatic hydrolysis rate of prodrugs and its 
implications in drug delivery is a growing concept which has high clinical significance. 
Extended availability of intact prodrug at the target site is a crucial requirement for 
effective drug absorption and higher bioavailability. Systemic drug delivery 
(intravenous or oral) is a potential route for the treatment of various ophthalmic 
disorders [160]. Transporter targeted prodrug strategy has been utilized to increase 
the ocular bioavailability of various drug molecules following systemic administration 
[100, 103, 161-163]. Among all, peptide transporter (PepT) was utilized most 
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significantly for dipeptide prodrug delivery due to availability of this transporter at 
various ocular tissues (Table 3).  
A major problem associated with orally administered dipeptide prodrugs is their rapid 
metabolism into parent compound resulting in limited availability of intact prodrug at 
transporter site of target ocular tissue [161, 164, 165]. Our laboratory has addressed 
this problem by designing novel stereoisomeric dipeptide prodrug concept to increase 
residence time of intact prodrug in the systemic circulation so that its translocation by 
ocular transporter can be maximized. Basic theory behind this concept is to synthesize 
enzymatically stable prodrugs by preventing its premature hydrolysis and increasing 
oral as well as ocular bioavailability after oral administration [166]. Hydrolytic enzymes 
(peptidases and esterases) responsible for the bioreversion of dipeptide prodrugs are 
stereospecific and have high affinity for L-isomers. All dipeptide prodrugs studied so far 
were based on L-amino acid isomers, which are natural substrates for these enzymes. 
Hence, our laboratory has designed series of stereoisomeric prodrug by incorporating 
D-isomers into the dipeptide moieties at a particular position to modulate its rate of 
metabolism. Results from this work are consistent with other studies and clearly 
indicate that incorporation of one D-amino acid into a dipeptide does not abolish its 
affinity towards PepT transporter [167]. Moreover, it also confers high stability against 
metabolizing enzymes which could result in higher cellular permeability (Table 3). 
However, we have further observed that incorporation of two D-amino acid moieties 
into a dipeptide moiety can enhance the enzymatic stability but also abolishes to a large 
extent its affinity towards PepT transporter [166]. This novel concept has shown that 
the metabolic stability as well as the cellular permeability can be modulated with the 
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incorporation of a D-isomer of an amino acid at a definite position into a dipeptide 
conjugate. This concept can be extended to various other drug molecules. 
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Table 3: Half-lives of stereoisomeric acyclovir (ACV) dipeptide prodrugs in tissue and 
cell homogenates (table regenerated from reference [166]) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prodrug t1/2 (hrs) 
Rat liver  
Homogenate 
Rat intestinal 
homogenate 
Caco-2 cell  
Homogenate 
LLACV <0.08 <0.08 7.52 ± 0.40 
LDACV 0.49±0.02 1.01±0.07 52.80 ± 8.42 
DLACV 2.82±0.18 6.27±0.25 no degradation 
DDACV no degradation no degradation no degradation 
 33 
 
Lipid Prodrug Approach 
Molecules can cross cell membranes through passive diffusion. In the eye, drug 
absorption takes place either through corneal route (cornea- aqueous humor-
intraocular tissues) or non-corneal route (conjunctiva-sclera-choroid/RPE) [16]. Due to 
lipophilic nature of cornea and other intraocular tissues, both hydrophilic and 
hydrophobic drugs take transcellular pathway to cross ocular membrane. Therefore 
lipophilicity of drug molecules plays a significant role to achieve optimum ocular 
bioavailability. In addition to these, sustained drug delivery for prolonged periods of 
time at the target site is required especially for the treatment of eye diseases at 
posterior segment of eye like vitreous, retina and choroid. In order to improve 
lipophilicity of hydrophilic drug molecules and hence to improve corneal permeation, 
the lipid prodrug approach has been developed. Lipid prodrugs are chemical entities 
where a drug molecule is covalently bound to a lipid moiety, such as fatty acid, 
diglyceride or phosphoglyceride. Lipid prodrugs diffuse readily across cell membrane 
by facilitated diffusion and thereby result in improved cellular absorption (Table 4). It 
also shows sustained delivery of parent drug molecule at the site of action [168, 169].  
However, high lipophilicity of molecules can result in limited permeability as it 
will stick inside the lipid membrane of cornea. Schoenwald and Ward reported a 
parabolic relationship between the lipophilicity and permeability of drug molecules 
across the rabbit cornea. Maximal permeability is observed for prodrugs with log P 
value of about 2-4 where P is defined as octanol/pH 7.4 buffer partition coefficients. So 
depending on the hydrophilicity of each drug molecule, lipid chain length needs to be 
adjusted in order to get maximum permeability across the cornea. Intraocular 
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permeation can be further enhanced by conjugating a targeting moiety 
(receptor/transporter) at one end of lipid prodrug, which is currently being explored 
(Patent: WO 2009/158633 A1) in our laboratory. 
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Table 4: Recent trends in lipid prodrug derivatization 
Drug 
Chemical 
Modification 
Disease Inferences 
Cidofovir 
(CDV) 
Hexadecyloxypro
pyl (HDP-CDV) 
and 
Octadecyloxyethy
l (ODE-CDV) ester 
derivatives 
Poxvirus, Herpesvirus, 
Adenovirus, 
Polyomavirus 
Immensely improved antiviral 
efficacy (EC50) from μM range 
(for parent compound) to nM 
range (for lipid conjugates) [170-
176] 
 
Ganciclovir 
(GCV) 
1-O-
hexadecylpropan
ediole-3-
phospho-
ganciclovir (HDP-
p-GCV) 
Herpes simplex virus 
(HSV), 
Cytomegalovirus 
(CMV) in retinitis 
Prolonged in vivo antiviral activity 
(for 4-6 weeks) with no significant 
toxicity relative to parent 
compound (less than 1 week) 
upon intravitreal injection. [177] 
Elicidic acid 
conjugates of GCV 
(E-GCV) 
Human 
cytomegalovirus 
(HCMV), Herpes 
simplex virus (HSV) 
and varicella zoster 
virus (VZV) 
Improved in vitro   efficacy (5-30 
fold reduction in antiviral dose) 
against HCMV and HSV. E-GCV 
compared to GCV at equimolar 
doses proved more efficacious 
with reduction of mortality 
rate.[178] 
Foscarnet 
or 
Phosphono
formic acid 
(PFA) 
1-O-octadecyl-sn-
glycerol-3-
phosphonoformat
e (ODG-PFA) 
Human 
cytomegalovirus 
ODG-PFA had longer vitreous half 
life and sustained drug level in 
retina at the end of tenth week 
after intravitreal injection 
(concentration of 32 μM at the 
10th week was 10 times higher 
than IC90 value against HCMV for 
foscarnet) in rabbits.[179] 
Peptide 
nucleic acid 
(PNA) 
Cationic peptide-
decanoic acid-
Nuclear 
Antisense 
 
-- 
Nuclear antisense activity of 
peptide nucleic acid was higher up 
to 2 orders of magnitude for 
cationic peptide-decanoic acid-
nuclear antisense compare to 
peptide nucleic acid alone. [180] 
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1.4 Cytomegalovirus Infection 
Cytomegalovirus (CMV) is the prototype member of ß-herpesvirinae in the 
subfamily of herpesviridae. CMV is an important and common cause of mortality and 
morbidity in immunocompromised patients such as those with HIV/AIDS, transplant 
recipients on immunosuppressive therapy, and malignant hematological disease. After 
primary infection with CMV the virus becomes latent in multiple organs and can later 
be reactivated during severe dysregulation of an immune system. A large population 
carry dormant virus and are thus at risk for reactivation [181].   
CMV is a double-stranded DNA virus of approximately 220 kb and is a member 
of the beta class of human herpesviruses. CMV is easily transmitted, usually through 
contact with bodily fluids or by placental transfer. CMV has a longer replication cycle 
and it encodes for a diverse array of gene products, many of which play an 
immunomodulatory role in the host. Its genome codes sequentially for three genes, 
which encode for immediate early and early and late proteins, respectively. The 
immediate early (IE) proteins are regulatory and the late proteins are structural. Many 
late proteins such as pp65 antigen have antigenic properties which can be used for 
diagnosis of CMV infection [181]. Primary infection in immunocompetent individuals is 
usually benign, with minimal or no clinical manifestations (although approximately 
10% of mononucleosis syndromes are a result of CMV infection). Following primary 
infection, the virus establishes latency, and viremia is mainly controlled by cell-
mediated immunity. Virus reactivation occurs when this protective immune 
surveillance fails as a result of chemotherapy or in patients who have AIDS or who are 
immunosuppressed for transplantation purposes. Such reactivation or primary 
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infection in context of disabled immune system can lead to overt disease. In case of 
vertical transmission of CMV to the developing fetus, adverse outcomes are most 
commonly associated with the primary infection to the mother, although significant 
morbidity has also been associated with the secondary infection [182]. 
1.4.1 Life Cycle, Epidemiology and Pathogenesis of CMV 
CMV infection occurs mainly in three stages. The first stage called “Initial 
infection” which involves spreading of HCMV virus through body secretions by both 
sexual and nonsexual means. Infected people have the virus in their urine, saliva, 
vaginal secretions, semen and breast milk after the initial infection. The disease may 
also be acquired through infected blood transfusions or organ transplants. While HCMV 
is not very contagious, it is often easily spread by children within school or day-care 
environments. Once within the host, the virus will fuse to the plasma membrane of a 
permissive cell in the host. The second stage called “The cellular stage” where, the virus 
will enter into the cytoplasm of the cell and move on to the nucleus. The virus gains 
entry and deposits viral DNA into the nucleus. The virus then replicates its genome 
within the nucleus. Once complete, virus particles will leave the cell and entered into 
the surrounding tissues to infect other cells within the host. This is a recurring process. 
The third stage called “The infectious stage” where; once the virus has proliferated it 
will shed into body secretions often without host being exhibiting any signs or 
symptoms. The virus usually spread to uninfected hosts by these secretions. Once 
acquired, the infection remains within the host for life.  
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CMV is endemic in most areas of the world. CMV infections vary in different 
geographical areas and it ranges from 30-100% [183, 184]. CMV infection is usually 
asymptomatic in immunocompetent individuals. However, reactivation of CMV in 
immunosuppressed individuals is associated with the adverse clinical outcomes.  
HCMV rarely causes complications in the healthy individual however, in the 
fetus, neonate and immunocompromised patients, HCMV infection can cause an array of 
damaging clinical effects. The clinical outcomes of CMV infection are summarized in the 
Table 5.  Primary HCMV infection in the “immunocompetent host” or “healthy 
individual” is usually asymptomatic and rarely causes illness. In some cases, it may 
cause mononucleosis syndrome, which is clinically indistinguishable from primary 
Epstein-Barr virus (EBV) infection, fever, myalgia, lymphadenopathy, and 
hepatomegaly [185, 186]. Tonsillopharyngitis, lymphadenopathy, and splenomegaly are 
less common symptoms of HCMV infection compared to EBV infection [185]. Other rare 
complications of primary HCMV infections include arthralgia, arthritis, ulcerative colitis, 
pneumonitis, hepatitis, aseptic meningitis, and myocarditis [185]. Congenital HCMV 
infection causes severe morbidity and mortality in newborns and is the leading cause of 
deafness and neurodevelopmental abnormalities in children [187, 188]. The frequency 
of congenital HCMV infection may cause by primary maternal infection or reactivation 
of HCMV in a seropositive mother however, an incidence can vary considerably among 
different study populations [189]. The risk of primary infection in a seronegative 
mother is 1 to 4%, which carries 30 to 40% risk of congenital infection [189, 190].  
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Table 5 : General clinical outcomes of human cytomegalovirus (HCMV) infection [183]. 
Infection Clinical features 
Healthy individual 
It remain usually asymptomatic, 
infrequently mononucleosis with fever, 
myalgia, adenopathy, splenomegaly. 
Fetus/infant with congenital 
Infection 
Jaundice, hepatosplenomegaly, petechiae, 
microcephaly, hypotonia, seizures and 
lethargy. 
Solid organ transplant patient 
Febrile illness with leukopenia and 
malaise; pneumonitis; enterocolitis, 
esophagitis, or gastritis; hepatitis; 
retinitis; other tissue-invasive diseases 
(nephritis, cystitis, myocarditis, 
pancreatitis) 
Hematopoietic stem cell transplant 
recipient 
Pneumonitis; enterocolitis, esophagitis, or 
gastritis; less commonly retinitis, 
encephalitis, hepatitis 
HIV/AIDS patient 
Retinitis; enterocolitis, esophagitis, or 
gastritis; immune recovery vitritis-
posterior segment inflammation;  
neumonitis; hepatitis 
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The risk and severity of HCMV infection is greatest if primary infection in a 
seronegative mother occurs during the first trimester [191]. The reactivation of HCMV 
infection during pregnancy can still cause symptomatic congenital infection however, 
the risk is lower since, preexisting maternal HCMV antibodies have a protective role 
against intrauterine transmission [192, 193]. Approximately 10 to 15% of congenitally 
infected babies are symptomatic at birth exhibiting intrauterine growth retardation; 
hepatitis with jaundice and hepatosplenomegaly; thrombocytopenia with petechiae; 
pneumonitis; and severe central nervous system damage with microcephaly, 
intracerebral calcifications, chorioretinitis, and sensorineural hearing loss [189, 194]. 
Of those symptomatic infants, a mortality rate of 30% has been reported, while many 
others display serious neurological, visual, and hearing impairment [194]. The majority 
of congenitally infected babies are asymptomatic at birth however, 10 to 17% 
subsequently develops hearing defects or neurodevelopmental sequelae [185].  HCMV 
is an opportunistic infection in immunocompromised individuals such as human 
immunodeficiency virus (HIV)-infected individuals and transplant patients on 
immunosuppressive medication due to an impaired adaptive immune system. Prior to 
the introduction of highly active antiretroviral therapy (HAART) in developed 
countries, approximately 40% of HIV-infected patients suffered from HCMV disease 
[195]. An incidence of HCMV in patients with AIDS has significantly declined with the 
availability of HAART, as fewer patients have a CD4 T-cell count below 100 cells/µl, a 
threshold below which a major risk occur for HCMV disease in HCMV-seropositive HIV-
infected patients. Despite lowered incidences, HCMV infection continues to be a major 
risk for HIV patients, and evidence suggests that it can directly and/or indirectly 
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accelerate the progression of AIDS and death [196-198]. The most common 
manifestation of HCMV infection in HIV patients is retinitis, which accounts for ≤85% of 
all cases and is characterized by hemorrhagic retinal necrosis [195, 199, 200]. However, 
the use of HAART therapy has led to a newly recognized syndrome, “immune recovery 
vitritis,” associated with posterior segment inflammation [201]. This occurs almost 
exclusively in patients with a previous history of HCMV retinitis as the CD4 T-cell count 
reconstitutes upon antiretroviral therapy [201]. Other manifestations of HCMV-
associated disease include enterocolitis, gastritis, esophagitis, hepatitis, encephalitis, 
and pneumonitis being a rare cause of lung disease in HIV-infected patients [195]. 
1.4.2 Cytomegalovirus Retinitis  
Cytomegalovirus (CMV) retinitis is the viral inflammation of the retina. It is the 
most common and severe intraocular complication in patients with HIV. Clinical 
manifestation of CMV retinitis involves chorioretinitis, pneumonitis and central nervous 
system infections. CMV retinitis is characterized by dense retinal whitening which can 
vary in appearance from “fluffy” to “dry and granular”. Ocular hemorrhage is frequently 
present, but in highly variable amounts. The retinitis tends to follow vessels, spreading 
centrifugally often in a brush-fire fashion with central clearing where the retina has 
already been completely destroyed. The border of active retinitis is irregular and small 
white satellite lesions are highly characteristic [202].  
In untreated patients with AIDS, the natural history of CMV retinitis is slow but 
relentlessly progressive towards necrotizing retinitis with the destruction of entire 
retina in three to six months [202-204]. The zone of retinitis advances at a rate of 
approximately 750 microns or half a “disc diameter” every three weeks. Based on the 
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rate of spread, the most common condition confused with CMV retinitis with “cotton-
wool” spots can easily be distinguished by repeated examination after three to four 
weeks. “Cotton-wool” spots condense or fade while CMV retinitis advances [202]. 
Blindness from CMV is permanent and may occur well before full destruction of 
the retina. There are three mechanisms for vision loss and for each mechanism early 
diagnosis is crucial to preserve vision. First, blindness may occur from direct damage to 
the macula or optic nerve. Second, blindness can result from retinal detachment, either 
during the acute infection or later, even years after the CMV retinitis has resolved. In 
the pre-HAART era in western countries, patients with CMV retinitis developed retinal 
detachment at a rate of 33% per eye/per year [205]. In poor-resource settings, a patient 
who develops a CMV-related retinal detachment will be left with a permanently blind 
eye. Finally, up to 20% of the patients with CMV retinitis may develop immune recovery 
uveitis (IRU) after reconstitution of the immune system by HAART [205]. IRU may 
cause vision loss from vitritis, retinal membrane formation, cystoid macular edema, or 
cataract. The larger the area of CMV retinitis, the greater the risk of both retinal 
detachment and IRU [206, 207], again providing a compelling rationale for the benefit 
of early diagnosis and treatment [202].  
1.4.3 Treatment of CMV Retinitis 
Three antiviral agents Ganciclovir, Cidofovir, and Foscarnet (Fig. 5) have been 
highly recommended for the treatment of CMV retinitis and have received marketing 
approval for the systemic treatment of CMV infection. Acyclovir has also received 
marketing approval in various European countries for prophylaxis of CMV disease in 
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solid organ transplant (SOT) recipients, but has shown lack of sufficient potency to be 
used for the treatment of active CMV disease. Fomiversen, an oligonucelotide anti-sense 
RNA  is also approved for the local treatment of CMV retinitis by 
intraocular/intravitreal administration [208]. 
 Ganciclovir (GCV) 
GCV is an acyclic nucleoside analogue of 2’-deoxyguanosine. GCV sodium is 
marketed under the trade names Cytovene and Cymevene (Roche, California, USA). GCV 
for ocular use is marketed under the trade name of Vitrasert (Bausch & Lomb, NY, 
USA)). A prodrug form with improved oral bioavailability (valganciclovir) has also been 
developed. GCV was the very first antiviral agent which is approved for treatment of 
CMV related disease and was the first-line treatment for CMV infection [209]. GCV 
mechanism of action involves multi-step process containing both viral and cellular 
enzymes to convert GCV in to GCV triphosphate, the chemical form that is active against 
CMV. GCV triphosphate formed by cellular enzyme, competitively inhibits DNA 
synthesis catalyzed by viral DNA polymerase by slower chain elongation, which results 
from integration of GCV triphosphate in place of dGTP into the growing viral DNA chain.  
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Figure 5: Chemical structure of ganciclovir, cidofovir, cyclic cidofovir and foscarnet  
 
 
 
 
 
 
 45 
 
The side effects of GCV include hematologic abnormalities (primarily 
neutropenia, anemia, and thrombocytopenia) and probable long-term reproductive 
toxicity [210]. The first ever GCV as an intravenous (IV) formulation (Cytovene-IV®, 
Roche) was approved in 1989 for treatment of CMV retinitis in AIDS patients. The IV 
formulation was also lately approved and marketed for prevention of CMV disease in 
solid organ transplant (SOT) recipients and in individuals with advanced HIV infection 
at risk of CMV disease. To overcome the risks and troublesomeness for the patients 
associated with the use of continuous intravenous administration of GCV, an oral 
formulation was developed. Oral GCV (250 and 500 mg GCV capsules; Cytovene®, 
Roche) was approved in 1994 for treatment of CMV retinitis only as a maintenance 
therapy since, low bioavailability (approximately 5%) of the oral formulation was 
considered insufficient for induction therapy. To improve the low oral bioavailability of 
GCV, a sustained-release GCV intraocular implant (Vitrasert®; developed by Chiron, 
now marketed by Bausch and Lomb) for treatment of CMV retinitis in AIDS patients was 
approved in 1996. A clinical study comparing an intravenous GCV to its implant for 
treating HIV-1-infected patients with CMV retinitis have been reported. An implant 
have shown significant activity in the affected eye however, these patients were at 
greater risk to develop CMV infection in the contralateral eye or in the other organs 
relative to patients treated with systemic GCV [211]. Moreover, oral GCV was 
recommended over implant as a maintenance therapy since, it has shown major 
advancement in prophylaxis treatment whereas, implants offers only sustained and 
local therapy [212].   
 46 
 
Furthermore, prodrug approach has been also developed to improve oral 
bioavailability of GCV. Valganciclovir (Valcyte®, Roche) is the L-valyl ester of GCV (Fig. 
6). Following oral administration, valganciclovir rapidly metabolized in to the active 
form (ganciclovir) due to enzymatic reversion in the intestinal wall and liver. 
Valganciclovir has an oral bioavailability of around 60% [213]. Once-daily 
administration of valganciclovir (900 mg) produces systemic exposure of GCV that is 
equivalent to once-daily administration of IV GCV (5 mg/kg) and 1.7-fold greater than 
systemic exposure produced by oral GCV (1000 mg) given thrice a day [214]. 
Valganciclovir was approved in 2000 for CMV retinitis treatment in AIDS patients [214]. 
Till 2006, no anti-CMV agent has been approved for the treatment of congenital CMV 
disease, although the Collaborative Antiviral Study Group (CASG) of the National 
Institute of Allergy and Infectious Diseases has conducted Phase II and III trials 
evaluating twice-daily dosing of IV GCV (6 mg/kg) for the treatment of infants with 
symptomatic congenital CMV [182]. Results showed clear benefits for neonates 
suffering with severe CMV disease and outweighed the risks of acute toxicities and long-
term reproductive toxicities associated with intravenous GCV [215, 216].  
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Foscarnet 
In 1991, foscarnet (Foscavir®, AstraZeneca) became the second drug approved 
for treatment of CMV retinitis in AIDS patients. Foscavir® or foscarnet sodium is the 
trisodium salt of phosphormophonic acid (a pyrophosphonate analogue). The 
mechanism of action of foscarnet (FOS) involves inhibition of viral DNA polymerase by 
binding to its pyrophosphate binding site and blocking cleavage of pyrophosphate from 
the terminal nucleoside triphosphate in growing DNA chain. The major FOS associated 
toxicity is renal toxicity which demands sufficient hydration and frequent serum 
creatinine level monitoring in patients taking FOS medication. In addition, mineral and 
electrolyte abnormalities resulting from FOS mediated renal toxicity can also leads to a 
number of cardiac or neurologic disorders including seizures. 
Although, FOS is measured as a second-line therapy, it is the preferred drug for 
patients showing resistance to GCV therapy or those who cannot be treated with GCV 
due to dose-limiting neutropenia or leucopenia [209].  
Cidofovir 
Cidofovir (Vistide®, Gilead) (CDF), is an acyclic nucleoside phosphonate (Fig. 5). 
CDF is a broad-spectrum antiviral agent against herpesviruses and other DNA viruses 
such as smallpox virus [217]. CDF has shown activity against polyomavirus, human 
papilloma virus (HPV), adenovirus, herpesvirus (herpes simplex virus type 1 [HSV-1] 
and type 2 [HSV-2], varicella-zoster virus [VZV], Epstein-Barr virus [EBV], human 
herpesvirus type 6 [HHV-6], type 7 [HHV-7], and type 8 [HHV-8]), and poxvirus (variola 
[smallpox], vaccinia [VV], cowpox [CPX], and molluscum contagiosum) infections [218].  
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CDF mechanism of action involves its phosphorylation by pyrimidine nucleoside 
monophosphate kinase to CDF-monophosphate (CDF-MP), which is further 
phosphorylated by nucleoside diphosphate kinase, pyruvate kinase or creatine kinase 
to the active metabolite, CDF-diphosphate (CDF-DP) (Fig. 7) [219]. CDF-DP exerts its 
antiviral activity by acting as a competitive inhibitor and alternative substrate with 
respect to dCTP (deoxycytidine triphosphate) for DNA polymerase [220]. The long half-
lives of CDF-DP derivative and the phosphocholine adduct provide an additional 
advantage to the use of CDF therapeutically [221]. Due to its unique features, CDF does 
not possess a threat of viral resistance [222]. Although, resistant isolates have not been 
reported in the clinic, this may reflect the shorter treatment regimens and limited use of 
this agent. CDF received US marketing approval in 1996 for the treatment of CMV 
retinitis in AIDS patients. Currently CDF is available and marketed only as an IV 
formulation and it possess low oral bioavailability, less than 5%. One of the 
characteristic features of CDF involves stability of its active form inside the cells. The 
intracellular half-life of CDF-diphosphate (CDF-DP) is reported to be >24 h and efficacy 
in both animal models and humans can be achieved with infrequent dosing [217]. 
Recommended dose for the treatment of CMV retinitis in AIDS patients consists 5 
mg/kg once a week for two consecutive weeks followed by 5 mg/kg once every 2 weeks 
(maintenance phase) [182]. Typically, kidney is the major route of drug elimination and 
the major limitation of CDF as an antiviral agent is severe renal toxicity [223]. It was 
confirmed that human organic anion transporter (hOAT) expressed on the convoluted 
proximal tubules of kidney interacts with CDF with high affinity which leads to an 
accumulation of CDF in the renal cortex [224]. In clinical studies, it was recommended 
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that patients receiving intravenous CDF must be given oral probenecid to protect 
against kidney failure and patients must be prehydrated before infusion [225].  
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Figure 7: Chemical structure of cidofovir-diphosphate 
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Cidofovir Ester 
Renal toxicity is the major side effect associated with the intravenous CDF 
infusion which has restricted its use in spite of having high efficacy against CMV. To 
Recent reports have demonstrated promising conjugates of CDF to overcome this 
limitation. Alkoxyalkyl esters of CDF have been developed to preserve or improve an 
efficacy of parent compound [175] without producing renal toxicity [226]. Moreover, 
these derivatives of CDF have shown improved uptake, absorption and oral 
bioavailability in mice ranging from 88–97% compared to less than 5% in parent CDF 
[226]. Another conjugates, CMX001 or hexadecyloxypropyl-cidofovir (HDP-CDV), is also 
currently under development by Chimerix for oral delivery to treat smallpox infection 
[227].  
Fomivirsen 
Fomivirsen (Vitravene®; by Isis Pharmaceuticals, licensed to Novartis   
Ophthalmics) is a 21-nucleotide anti-sense RNA (5’-GCG TTT GCT CTT CTT CTT GCG-3’), 
specifically targeted against mRNA from the early transcriptional unit of CMV. 
Fomivirsen was approved in 1998 as a second-line therapy for local treatment of CMV 
retinitis in AIDS patients. Fomivirsen in practice is delivered via an intraocular 
injection; however, it has shown side effects such as ocular inflammation (uveitis) due 
to frequent administration [228].  
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CHAPTER 2 
NOVEL TRANSPORTER TARGETED LIPID ESTER PRODRUGS OF CYCLIC 
CIDOFOVIR FOR TREATMENT OF CYTOMEGALOVIRUS INFECTION 
2.1 Overview 
Cytomegalovirus (CMV) retinitis is by far the most common ocular opportunistic 
infection in HIV-infected patients. Epidemiologic studies showed that 15% to 35% of 
HIV-infected patients developed CMV retinitis during course of their illness [229-232]. 
CMV retinitis is a chronic, sight-threatening infection of the retina, the light-sensing 
tissue that lines the posterior segment of the eye, and other organs of those with 
weakened immune systems due to HIV infection. Current therapies include various 
antiviral drug molecules such as cidofovir, ganciclovir, foscarnet and fomvirsen. 
Cidofovir (CDF) and its cyclic form (cCDF) (Fig. 5) is a potent new antiviral agent shown 
to have in vitro and in vivo activity against a broad spectrum of herpesviruses, CMV, 
Herpes simplex virus types 1 and 2, varicella-zoster virus, Epstein-Barr virus, 
adenoviruses, and various orthopoxviruses [233]. It has been widely evaluated for its 
antiviral efficacy against CMV retinitis and HSV keratitis [234, 235]. 
Current delivery strategy for CDF for treatment of CMV infection includes 
intermittent intravenous administration. However, the absorption of CDF is often 
limited by low permeability due to its hydrophilic nature. Its physicochemical 
properties (high water solubility 170 mg/mL and log p -3.9) are unfavorable for passive 
transcellular absorption. Moreover, CDF is associated with renal impairment upon 
intravenous administration. 
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Drug delivery to the vitreous, retina, and choroid is a challenging task due to the 
formidable obstacles posed by the blood-retinal barrier and tight junctions of the 
retinal pigment epithelium. Only small fractions of drug administered orally, 
intramuscularly, or intravenously reach out the ocular target site [236]. Hence, to 
improve the treatment and quality of patient life, researchers have sought alternative 
safe and effective therapies for CMV retinitis which can also spare patients from daily 
inconvenient dose of intravenous treatment [237]. Intravitreal and topical route of drug 
delivery are still remains as the most acceptable options for treatment of ocular disease. 
However, permeation of hydrophilic antiviral agents through lipophilic tissues such as 
cornea (for HSV keratitis) and other intraocular tissues such as RPE and Bruch’s 
membrane (for CMV retinitis) is highly restricted making topical route inefficient in 
generating adequate drug levels at desired tissues for treating CMV retinitis. Hence, a 
development of efficient intravitreal suatined drug delivery system is very much 
improtrant for the chronic treatment and patience compliance. 
2.2 Statement of the Problem 
To improve the bioavilibilty and reduce side effects of CDF for the treatment of 
CMV infection, different strategies have been explored. Some researchers have tested 
lipid prodrug strategy that allows rapid CDF diffusion across cell membrane by 
facilitated diffusion mechanism following oral administration [238]. There are other 
reports available demonstrating transporter targeted (hPepT and amino acid) prodrug 
of CDF or cCDF, where enhanced drug translocation across cell membrane via active 
transport [239, 240]. However, both approaches have individually shown marginal 
improvement in cellular uptake due to low partition of lipid prodrugs into the 
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cytoplasma of cell, where low capapcity of transporter to translocate molecules across 
cell membrane for transporter targeted prodrugs. Hence, in this study, we hypothesize 
(Fig. 8) that cellular uptake of CDF can be significantly enhanced by designing novel 
transporter targeted lipid prodrugs, where cCDF can be linked to the ligand for a cell 
membrane transporter via lipid raft. We assume that lipid raft facilitates enhanced 
interaction of prodrug with cell membrane and thereby assisting docking of targeted 
ligand into the binding domain of transporter. Therefore, current novel approach 
combines both lipid mediated facilitate/passive diffusion and transporter mediated 
active transport to generate synergistic drug effect for treating ocular diseases. 
Intravitreal injection is more promising route to deliver drugs locally and in an 
adequate amount for ocular ailments of posterior segment of eye. However, repeated 
intravitreal injection can cause retinal damage and may cause vision loss. Hence, 
development of sustained release formulation is more desirable strategy to overcome 
problem associated with the repeated intravitreal injections. Poly lactic-co-glycolic acid 
(PLGA) is FDA approved and has been among the most attractive polymeric candidates 
used to prepare sustained release drug delivery system for ocular application [3, 241]. 
PLGA is biocompatible and biodegradable polymer which exhibits a wide range of 
erosion time and also has tunable mechanical properties. Therefore, in this project we 
aim to synthesize transporter targeted lipid ester prodrugs of cCDF and to formulate 
nanoparticulate (NP) formulation of these prodrugs. We intend to administer proposed 
sustained delivery formulation via intravitreal injection to achieve prolonged prodrug 
release and to avoid frequent administrations.  
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Figure 8: Possible mechanism and design of transporter targeted lipid prodrugs  
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2.3 Objectives 
Therefore, objective of current proposal will be as follow. To design and synthesize 
novel transporter targeted lipid prodrugs of cCDF using lipid linker of different carbon 
chain length (e.g. C2, C6, and C12) carrying minimum two functional groups for linking 
one end with cidofovir and the other end with ligand of sodium dependent multivitamin 
transporter (SMVT). Biotin will be utilized as ligand for transporter. All prodrugs will be 
synthesized and confirmed using Mass-spec and NMR (13C, 1H and 31P). Further, to 
evaluate physicochemical properties of targeted lipid prodrugs with respect to buffer 
stability and octanol/water partition coefficient. The synthesized prodrugs will further 
evaluate for biochemical pharmacology (bioreversion and metabolism) in ocular fluids 
and tissue homogenates of posterior segment of eye i.e retina/choroid and vitreous 
humor and to evaluate ocular tolerability by performing in vitro cytotoxicity on retinal 
cell lines (ARPE-19). These prodrugs will be studied for the interaction with SMVT 
transporter in a model cell line. This interaction will be investigated by conducting 
uptake experiment using [3H]-Biotin as a substrate for SMVT and targeted lipid 
prodrugs as a competitive inhibitor. This experiment will provide comparative affinity 
of targeted lipid prodrug towards SMVT transporter. Prodrug with highest stability and 
affinity towards SMVT transporter will be selected for further evaluation. Further, our 
aim is to develop nanoparticulate formulation of targeted lipid prodrugs of cidofovir. 
Targeted lipid prodrug of cidofovir will be encapsulated in PLGA nanoparticle by 
different methods such as single (oil in water (O/W) or water in oil (W/O)) and 
multiple emulsions (oil in water in oil (O/W/O) or water in oil in water (W/O/W). 
Different PLGA ratio such as 85:15, 75:25, and 50:50 will be used to optimize higher 
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encapsulation efficiency of prodrug loaded nanoparticles. Our next aim will be to 
evaluate size determination, surface morphology (scanning electron microscopy (SEM), 
zeta potential, encapsulation efficiency, and prodrug loading in PLGA nanoparticles. 
Different parameters will be optimized for developing optimum formulation of targeted 
lipid prodrugs of cidofovir. Further, we will evaluate in vitro prodrug release in buffer 
from optimized nanoparticle formulation and release profile will be fitted into the 
model equations in order to determine release mechanism of targeted lipid prodrugs 
from nanoparticles. 
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CHAPTER 3 
SYNTHESIS, CHARACTERIZATION AND ANALYTICAL METHOD DEVELOPMENT OF 
TRANSPORTER TARGETED LIPID AND LIPID ESTER PRODRUGS OF CYCLIC CIDOFOVIR 
3.1 Rationale 
Cidofovir (CDF) and its cyclic form (cCDF) are broad-spectrum antiviral agent 
and currently used to treat AIDS-related human cytomegalovirus (HCMV) retinitis. Its 
therapeutic potential has also been recognized for herpes, orthopox and papillio virus 
infections [239]. Despite its broad spectrum of antiviral efficacy, CDF is used as a 
secondary line of antiviral agent due to its low cell membrane permeability and oral 
bioavailability. Moreover, due to low oral bioavailability, CDF is prescribed in 
intermittent does for intravenous administration.   
A number of alternative prodrug strategies to enhance oral delivery of CDF have 
been reported in the literature such as lipid ester prodrug of CDF [168, 242-244], 
peptide and amino acid prodrugs of CDF [245-247].  Although, these strategies has been 
successful in improving oral delivery as well as antiviral efficacy of CDF, the lipid 
prodrugs might suffer from enough partition into the cytoplasm and may leads to low 
transport of prodrugs across cell/tissue. Moreover, the peptide/amino acids prodrugs 
might suffer disadvantage of low/minimal capacity of transporter to translocate the 
prodrugs across cell/tissue membrane. To overcome these limitations, a dual approach 
of using lipid mediated enhanced passive diffusion and transporter targeted active 
diffusion is proposed in this project. We hypothesized that lipid raft of targeted lipid 
ester prodrug will facilitate enhanced interaction with the cell membrane and thereby 
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will assist docking of targeted moiety into the binding domain of transporter. The net 
effect will be rapid translocation of targeted lipid prodrug across the plasma membrane 
improving cellular absorption and oral bioavailability. For the current project, we have 
targeted sodium dependent multivitamin transporter (SMVT), which is ubiquitously 
present on ocular and intestinal cells [95, 248]. Therefore, primary objective of current 
project was to design and synthesize biotinylated lipid ester conjugates of cCDF. The 
lipid linker with varying carbon chain length (e.g. C2, C6, and C12) carrying minimum 
two functional groups for linking one end with cCDF and another end to transporter 
ligand was used for prodrug synthesis. SMVT transporter was targeted using biotin (B) 
as a transporter ligand. 
3.2 Materials and Methods 
Materials 
Cidofovir was a generous gift from the Gilead Science. Biotin-N- 
hydroxysuccinimide (Biotin-NHS) and Benzotriazole-1-yl-oxy-tris (pyrrolidino) 
phosphonimhexa-flurophosphate (PyBOP) were obtained from Chem-impex 
International. The reagent 1-dodecanol, 1-hexanol, 6-amino 1-hexanol, and 12-amino 1-
dodecanol were obtained from TCI America (Portland, OR). N,N-dimethylformamide 
(DMF),N,N-Diisopropylethylamine (DIPEA), methanol, dichlormethane were purchased 
from Sigma-Aldrich (St. Louis, Missouri). All other reagents of analytical grade were 
purchased from local suppliers and used as such received. Double deionized water 
(DDW) was used to prepare buffer and mobile phase. NMR spectra were collected by 
Bruker 400 MHz NMR with sample dissolved in d6-DMSO. 
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Synthesis of cCDF Lipid Prodrugs  
Biotin-Lipid Conjugates 
To biotin-N-hydroxysuccinimide (1 equiv), anhydrous DMF and 1.2 equivalent of 
lipid moieties (2-amino 1-ethanol/6-amino 1-hexanol/12-amino 1-dodecanol) were 
added and the reaction mixture was stirred overnight under N2 at room temperature. 
The reaction was monitered by TLC (dichloromethane : methanol, 80:20) and LC/MS 
infusion by monitoring  presence of  starting product and  final conjugates. Solvent was 
removed under vacuum at 40 0C for 12 h and the resultant white residue was purified 
by the repeated silica gel column chromatography with 20% dichloromethane in 
methanol as the eluent to yield final products (biotin conjugated lipid moieties: B-C2/B-
C6/B-C12) as white solid (Fig 9A). The final product purity was checked by TLC and 
LC/MS before proceeding to the next step.   
Synthesis of Biotin-Lipid Conjugates with cCDF 
In a separate flask, CDF (1 equivalent), 20 mL of anhydrous DMF and 2.1 mL of 
dry DIPEA were added. The reaction vessel was warmed using a heat gun to facilitate 
the dissolution of the CDF-DIPEA salt. The solvent was then removed under vacuum for 
40 0C for 16 h. To residue, 20 mL of anhydrous DMF, DIPEA (5 equivalent), the relevant 
biotin conjugated lipid (1.5 equivalent) in anhydrous DMF and PyBOP (2.1 equivalent) 
were added and the reaction mixture was stirred under N2 at 45 °C for 48-60 h. The 
reaction was monitored by 31P NMR and additional portions of PyBOP were added as 
necessary (Fig. 9B). After completion of reaction, solvent was removed under vacuum 
and the brownish-red residue was purified by repetitive silica gel column 
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chromatography using gradient solvent combinations of dichloromethane and 
methanol as the eluent to yield products (B-C2-cCDF, B-C6-cCDF and B-C12-cCDF) as a 
brownish sticky solid (Fig. 10). The final purity of the fractions collected via column 
chromatography was confirmed by LC/MS and 31P NMR. 
Synthesis of Lipid Ester Conjugates of cCDF 
To CDF (1 equivalent), 20 mL of anhydrous DMF and 2.1 mL of dry DIPEA were 
added. The reaction flask was warmed using a heat gun to facilitate the dissolution of 
the CDF-DIPEA salt. The solvent was then removed under vacuum. To the residue, 20 
mL of anhydrous DMF, DIPEA (5 equivalent), the relevant lipid moieties (1.5 
equivalent) in dry DMF and PyBOP (2.1 equivalent) were added, and the reaction 
mixture was stirred under N2 at 45 °C for 24 h. The reaction was monitored by 31P NMR 
and additional portions of PyBOP were added as necessary (Fig. 11). After completion 
of the reaction, solvent was removed under vacuum, and the brownish-red residue was 
purified by the repetitive silica gel column chromatography using gradient solvent 
combination of dichloromethane and methanol to generate a white solid product (Fig. 
12). The final purity of the fractions collected via column chromatography was 
confirmed by LC/MS and 31P NMR. 
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Figure 9: Synthesis of (A) biotin lipid conjugates (B-C2, B-C6 and B-C12), and (B) biotin 
conjugated lipid ester of cyclic cidofovir (B-C2-cCDF, B-C6-cCDF, and B-C12-cCDF) 
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n=6,   B-C6 
n=12, B-C12 
n=2,   B-C2-cCDF 
n=6,   B-C6-cCDF 
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Figure 10: Structures of biotin conjugated lipid ester of cyclic cidofovir 
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Figure 11: Synthesis of lipid ester prodrug of cyclic cidofovir 
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HPLC Analysis 
HPLC methods for simultaneous analysis of CDF, its biotinylated lipid ester 
conjugtaes of cCDF (B-C2-cCDF, B-C6-cCDF and B-C12-cCDF) and lipid ester prodrugs 
(C6-cCDF, and C12-cCDF) were developed. Solubility, n-octanol/water partition 
coefficient, tissue partition coefficient, enzymatic reversion and nanoparticle release  
samples were analyzed by an HPLC system comprising of Waters 515 pump (Waters, 
Milford, MA), Alcott 718AL refrigerated autosampler, UV detector (RAININ, Dynamax, 
Absorbance Detector Model UV-C), HP 3395 integrator, Phenomenex C18 (4.6 × 250) 
column with C18 guard column. Mobile phases comprised of 20 mM phosphate buffer 
(pH 6.8) and methanol (90:10, V/V) for CDF and biotin conjugated lipid prodrugs of 
cCDF and 20 mM phosphate buffer (pH 6.8) and acetonitrile (50:50, V/V) for lipid 
conjugates of cCDF. All the compounds were detected at λmax 274 nm and flow rate of 
0.4 mL/min.  
LC-MS/MS Analysis 
MDS Sciex API 3200 Triple Quadrupole linear QTrap mass spectrometry 
(Applied Biosystems/MDS Sciex, Faster City, CA) system interfaced by turbo ion spray 
(TIS) with positive ion source in MRM mode was used for detection. Mass dependent 
parameters were tuned and optimized for CDF, B-C2-cCDF, B-C6-cCDF, B-C12-cCDF, C6-
cCDF, C12-cCDF and tenofovir. Tenofovir was used as an internal standard (IS) for 
analysis of biotin conjugated lipid prodrugs. Initially, full scan mass spectra were 
acquired in positive ion mode for all the compounds. During  a direct infusion 
experiment, the mass spectra for B-C2-cCDF, B-C6-cCDF, B-C12-cCDF and tenofovir 
peaks at mass to charge ratio (m/z) of 280.09, 531.18, 587.24, 671.37, and 288.13, 
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respectively, as a protonated molecular ions [M+H]+. The most stable abundant 
fragment ions observed in each product MS/MS spectrum were at m/z 262.30 for CDF, 
262.16 for B-C2-cCDF, 262.30 for B-C6-cCDF, 262.13 for B-C12-cCDF, and 270.03 for 
tenofovir. Quantitative determination was performed in MRM scan positive ion mode 
using the following mass transitions: 280.09→262.30 for CDF, 531.18→262.16 for B-C2-
cCDF, 587.24→262.30 for B-C6-cCDF, 671.37→262.13 for B-C12-cCDF and 
288.13→270.00 for tenofovir (IS). The method was developed over the linear (r2 > 0.99) 
concentration range 60-1000 ng/mL. Lower limit of quantification (LLOQ) of all the 
compounds were 30 ng/mL. 
Tenofovir disoproxilfumarate (Fig. 13) was used as an IS for the analysis of lipid 
prodrugs of cCDF. Similarly, a full scan mass spectra were acquired in positive ion mode 
for C6-cCDF, C12-cCDF, and tenofovir disoproxil fumarate peaks at m/z of 346.2, 
430.33, and 674.108, respectively as a protonated molecular ions [M+H]+. The most 
stable abundant fragment ions observed in each product MS/MS spectrum were at m/z 
262.20 for C6-cCDF, C12-cCDF and 326.103 for tenefovir disoproxil fumarate. 
Quantitative determination was performed in MRM scan positive ion mode using the 
following mass transitions: 346.2→262.20 for C6-cCDF, 430.336→262.20 for C12-cCDF, 
and 674.10→326.10 tenofovir disoproxil fumarate (IS). The method was developed 
over the linear (r2> 0.99) concentration range 30-1000 ng/mL. Lower limit of 
quantification (LLOQ) of all the compounds were 15 ng/mL. 
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Figure 13: Chemical structure of tenofovir disoproxil fumaric acid 
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Optimization of Sample Extraction Method 
For CDF and Biotinylated Lipid Ester Conjugates of cCDF 
CDF and biotinylated lipid ester conjugates of cCDF were possess somewhat 
hydrophilic properties which lead to very low extraction efficiency (< 10%) in the 
organic solvent. Hence, we opt for solid phase extraction method (Fig. 14) where drug 
and prodrugs were loaded on to the solid phase and eluted from it after washing other 
impurities. The solid phase extraction process contains following steps. 
 Wash and hydrate column with organic solvent and DDI water 
 Adjust the pH of the sample (for cationic/anionic exchange columns) and load 
onto column  
 Wash off unbound sample/impurities with organic solvent 
 Elution of sample from the column  
However, we required to optimize two steps in this process. First steps, which 
require optimization, will be loading of samples on to the column and second step, 
which requires optimization, will be elution of samples from the column. 
(i) Drug/Prodrug Binding on the Solid Phase 
Solid-phase cartridge is washed and activated with 1 mL of organic solvent 
(methanol) and DDI. The drug/prodrug samples were acidified with 
trifluroacetic acid (0.1-2% v/v). Acidified prodrugs (all at 25 µM concentrations) 
were loaded on the solid phase. Following binding, the unbound prodrugs were 
washed off from the cartridge with 1 mL of methanol (2X).  Elutes were analyzed 
for the unbound prodrugs and back calculated for the bound prodrugs via HPLC 
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method to determine the % of trifluroacetic acid required to maximize the 
binding of drug/prodrugs. 
(ii) Drug/Prodrugs Elution from Solid Phase 
For optimization of drug/prodrugs elution from the solid phase, all samples (25 
µM) were diluted with distilled 2% trifluroacetic acid in deionized water (DDW) 
upto 1 mL and then loaded on to the Bond EluteSAX cartridge pre-equilibrated 
with 2 mL of each methanol and DDW. Following loading of CDF and its biotin 
conjugated lipid ester prodrugs, the samples were eluted from Bond EluteSAX 
cartridge with 2 mL of methanol containing ammonium hydroxide (1-5 % v/v). 
The elutent phases were evaporated in Speed Vac® at 40 0C for 2 h and were 
analyzed by HPLC to determine the elution efficiency. 
For Lipid Ester Conjugates of cCDF 
Since, lipid ester conjugates of cCDF possess good lipophilicity therefore, we 
opted for solvent extraction method for these prodrugs. The method of extraction 
followed is given below. 
For extraction of lipid ester conjugates of cCDF, a 100 µL of lipid ester conjugates 
of cCDF samples were aliquoted into a 1.5 mL polypropylene microcentrifuge. To this 
twenty microliter of 10.0 µg/mL freshly prepared tenofovir disoproxil fumarate (IS) 
working solution (except for blank sample) was added. The mixture was vortexed for 
30 seconds. A 900 µL ice-cold ethyl acetate was added and vortexed for 1 min. Then, 
sample was centrifuged and 800 µl supernatant was aliquoted in microfuge tube. The 
ethyl acetate phase was evaporated in Speed Vac® at 40 0C for 4 h, following 
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reconstitution in 100 µl of mobile phase. A 10 µL of the resulting solution was injected 
in the LC-MS/MS for further analysis using XTerrs® MS C18 5µ column. 
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Figure 14: Solid-phase extraction method of biotin conjugated lipid ester prodrugs of 
cyclic cidofovir 
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3.3 Results 
31P NMR  
In this project, we have focused on synthesizing novel SMVT transporter 
targeted lipid ester and lipid ester conjugates of cCDF (Fig. 10 and Fig. 12). We have 
successfully synthesized and characterized these prodrugs. The characterization was 
performed using 31P NMR where, samples were dissolved in d6-DMSO to perform 31P 
NMR. The NMR results of all prodrugs are given below: 
B-C2-cCDF: was obtained as brownish sticky solid in 45% yield. 31P NMR (400 MHz, 
DMSO-d6) δ :  13.92 (s), 12.84 (s) (Fig. 15 A) , ESI-MS: m/z calculated 530.5, found 
531.4 (M + H)+ (Fig. 18A). 
B-C6-cCDF: was obtained as brownish sticky solid in 56% yield. 31P NMR (400 MHz, 
DMSO-d6) δ : 13.12 (s), 11.55 (s) (Fig. 15 B), ESI-MS: m/z calculated 586.6, found 587.2 
(M + H)+ (Fig. 19A). 
B-C12-cCDF: was obtained as brownish sticky solid in 61% yield. 31P NMR (400 MHz, 
DMSO-d6) δ :  13.84 (s), 12.6 (s) (Fig. 15 C), ESI-MS: m/z calculated 670.7, found 671.6 
(M + H)+ (Fig. 20A). 
C6-cCDF: was obtained as white solid in 65 % yield. 31P NMR (400 MHz, DMSO-d6) δ :  
12.92 (s), 11.66 (s) (Fig. 16 A) ESI-MS: m/z calculated 345.3, found 346.2 (M + H)+ (Fig. 
21A). 
C6-cCDF: was obtained as white solid in 62 % yield. 31P NMR (400 MHz, DMSO-d6) δ :  
13.47 (s), 12.20 (s) (Fig. 16B), ESI-MS: m/z calculated 429.5, found 430.3 (M + H)+ (Fig. 
22A) . 
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Figure 15: 31P NMR of (A) B-C2-cCDF, (B) B-C6-cCDF, and (C) B-C12-cCDF. δ = -6.0 ppm 
represent the peak for triphenyl phosphine (reference standard) 
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Figure 16: 31P NMR for (A) C6-cCDF, (B) C12-cCDF, δ = -6.0 ppm represent the peak for 
Triphenyl phosphine (reference standard) 
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HPLC Method Development 
The HPLC analytical methods for CDF, biotinylated lipid ester of cyclic cidofovir 
and lipid ester of cCDF were successfully developed. The method was selectivity (no 
interfering peaks were observed except solvent front peak in few cases) and with the 
linearity range (r2 > 0.998) of 5- 50 µg/mL for biotinylated lipid ester of cCDF and CDF 
and 2.5 µg/ml-40 µg/ml for lipid ester of cCDF (Fig. 17B, 18B, 19B, 20B, 21B, 22B). 
LC/MS MS Method Development 
The LC/MS methods for CDF, biotinylated lipid ester conjugates of cCDF and 
lipid ester conjugates of cCDF were successfully developed. The method was selectivity 
(no interfering peaks were observed except solvent front peak in few cases) and with 
the linearity range (r2 > 0.99) of 60-1000 ng/mL for CDF and biotinylated lipid ester 
conjugates of cCDF. Lower limit of quantification (LLOQ) of all the compounds were 30 
ng/mL. For quantitative analysis of lipid ester of cCDF, the method was developed over 
the linear (r2 > 0.99) concentration range of 30-1000 ng/mL. Lower limit of 
quantification (LLOQ) of all the compounds were 15 ng/mL. 
Optimization of Sample Extraction Method 
Since, the partition of biotinylated lipid ester conjugates of cCDF and CDF in 
organic solvent was very low to negligible, we optimized solid phase extraction method 
for these prodrugs. The optimized binding buffer was selected as 5% trifluroacetic acid 
in buffer and elution buffer was optimized to 3% ammonia in methanol. The binding 
efficiencies were ~ 70 %, 62% and 53 % for B-C2-cCDF, B-C6-cCDF and B-C12-cCDF,  
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respectively, whereas the elution buffer was ~ 56 %, 60% and 66% for B-C2-cCDF, B-
C6-cCDF and B-C12-cCDF, respectively (Fig. 23).  
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Figure 17: HPLC chromatogram of cidofovir (25 µg/mL) at ƛmax = 274 nm 
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Figure 18: (A) LC/MS infusion of B-C2-cCDF showing prominent peaks of [M+H+] = 
531.3, [M+Na+] = 553.3, and [M+K+] = 569.2. (B) HPLC chromatogram of B-C2-cCDF (25 
µg/mL) at ƛmax = 274 nm 
 
  
(A) 
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Figure 19: (A) LC/MS infusion of B-C6-cCDF showing prominent peaks of [M+H+] = 
587.4, [M+Na+] = 609.4 and [M+K+] = 625.5. (B)  HPLC chromatogram of B-C6-cCDF (25 
µg/mL) at ƛmax = 274 nm  
(A) 
(B) 
Solvent peak 
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Figure 20: (A) LC/MS infusion of B-C12-cCDF showing prominent peaks of [M+H+] = 
671.7 and [M+Na+] = 693.6. (B)  HPLC chromatogram of B-C12-cCDF (25 µg/mL) at 
ƛmax = 274 nm 
(A) 
(B) 
Solvent 
Prodrug 
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Figure 21: (A) LC/MS infusion of C6-cCDF showing prominent peaks of [M++H+] = 346.4 
and [M+Na+] = 368.4. (B)  HPLC chromatogram of C6-cCDF (25 µg/mL) at ƛmax =274 
nm 
(A) 
(B) 
Solvent 
Prodrug 
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Figure 22: (A) LC/MS infusion of C12-cCDF showing prominent peaks of [M++H+] = 
430.4, [M+Na+] = 452.5 and and [M+K+] = 468.5. (B)  HPLC chromatogram of C12-cCDF 
(25 µg/mL) at ƛmax = 274 nm 
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Figure 23: Optimization of (A) binding buffer and (B) elution buffer for solid 
phase extraction of B-C2-cCDF, B-C6-cCDF, and B-C12-cCDF 
 
 
 
(A) 
(B) 
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3.4 Discussion 
Among all the licensed and marketed antiviral drugs which are used for the 
treatment of CMV viral infections, three acyclic nucleoside phosphonates drugs i.e. CDF, 
adefovir, and tenofovir are very potent. Of those, cidofovir exhibits a uniquely broad 
spectrum of activity against wide types of virus including DNA viruses. However, an 
important limitation of CDF as a therapeutic agent is low bioavailability, which is 
attributed to ionization of its acidic groups at physiological pH. The cCDF displays 
decreased nephrotoxicity compared to CDF, while also exhibiting potent antiviral 
activity. The cCDF is only a monoanion at physiological pH, eliminating one site of 
negative charge relative to CDF, but it is also suffer from low bioavailability problems 
explains the need to mask the second P-OH. Hence, the aim of the present study was to 
synthesized and characterized biotinylated lipid ester prodrug of cCDF and lipid ester 
conjugates of cCDF in which all charge has been masked in the parent drug. Further, we 
have also developed HPLC and LC/MS methods for quantitative analysis of these 
prodrugs.  
We have synthesized three different transporter targeted prodrugs i.e. B-C2-
cCDF, B-C6-cCDF and B-C12-cCDF (Fig. 10), where C2, C6 and C12 represent length of 
lipid linker and B represent the biotin moiety. To delineate the effect of lipid prodrugs, 
we have also synthesized the lipid prodrugs of cCDF i.e. C6-cCDF and C12-cCDF (Fig. 
12). We have hypothesized that the presence of lipid raft will improve the interaction of 
these prodrugs with the cell membrane and transporter targeting moiety will further 
improve the translocation of these prodrugs across the plasma membrane. This may 
exhibit synergistic effect due to the simultaneous conjugation of lipid raft and 
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transporter targeted moiety which may ultimately improve the uptake of these 
prodrugs across the cell layers. These compounds might be subject to significant 
transport by either passive or active mechanisms, with SMVT mediation a reasonable 
possibility in the latter case, owing to the incorporation of the biotin (a very good 
substrate of SMVT). In contrast, we assume that in case of lipid prodrugs, we may not 
obtain the synergistic effect provided by the transporter in improving the cellular 
accumulation. The transporter targeted prodrugs will also impart the specificity, which 
is crucial in case of such drug, and can eliminate the severe toxicity like reduce in intra 
ocular pressure (IOP), uveitis (in case of ocular drug delivery) and nephrotoxicity (in 
case of systemic drug delivery).  
 The synthetic scheme was followed as shown in Fig. 9 for iotinylated lipid ester 
conjugates of cCDF and Fig. 11 for lipid ester conjugates of cCDF. The purity was 
determined by the 31P NMR and LC/MS. It is of interesting to note that when the lipid 
raft is conjugated with cCDF, a new chiral center is formed at the phosphorus group 
which results in formation of two diastereoisomers and hence, in 31P NMR shows two 
singlet peaks which correspond to diastereoisomeric set of prodrugs. The HPLC method 
was also developed and the retention time is as indicated in chromatograms (Fig. 17B, 
18B, 19B, 20B, 21B, 22B). Since, the developed HPLC method was developed on 
isocratic pump; we saw only a single peak for each of the prodrugs and not the different 
peaks for diastereoisomers. The analytical method was specific (no interfering peaks) 
with linearity (r2 > 0.99) range of 5-50 µg/mL for CDF and biotinylated lipid ester 
conjugates of cCDF, and 2.5-40 µg/mL for lipid ester conjugates of cCDF. 
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Due to inadequate organic solvent partition (from water/buffer/biological 
matrix) for biotinylated lipid ester conjugates of cCDF, we developed solid phase 
extraction method. There are two critical parameters for successful development of 
solid phase extraction method. First is the optimization of loading of prodrugs on the 
solid phase and second is the optimization of elution of prodrugs from the solid phase. 
We have choose solid anionic exchange (SAX) cartridge as prodrugs will have free –NH2 
group which can be protonated at acidic pH and can further have ionic interaction with 
anionic solid phase. Further, use of basic pH condition may leads to neutralization of 
protonated –NH2. The optimized loading buffer contain trifluroacetic acid (5% v/v) 
which give maximum loading (~ 65%) on the solid phase column, whereas the 
optimized elution buffer contain ammonia in methanol (3% v/v) which give elution  
(~ 70%) of the total prodrug loaded on the solid phase column (Fig. 23). A solid phase 
extraction method was successfully utilized for the separation of biotinylated lipid 
prodrugs from the biological matrix of retina-choroid and vitreous humor. 
3.5 Conclusion 
Three novel  biotinylated lipid ester conjugates of cCDF (B-C2-cCDF, B-C6-cCDF, 
and B-C12-cCDF) which incorporate biotin (ligand for SMVT transporter) conjugated to 
the cyclic form of cidofovir through the different length of lipid raft (C2, C6 and C12) 
and two lipid ester conjugates of cCDF (C6-cCDF and C12-cCDF)  have been successfully 
synthesized. The purity of all the prodrugs was determined by 31P NMR. A solid phase 
extraction (for biotinylated lipid ester conjugates of cCDF) and liquid-liquid extraction 
(for lipid ester of cCDF) methods were developed and successfully utilized for the 
separation of biotinylated lipid ester and lipid ester conjugates of cCDF from the 
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biological matrix. A HPLC and LC/MS methods were also developed to determine the 
physicochemical properties, cellular accumulation, transport and enzymatic reversion 
from biological matrix. 
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CHAPTER 4 
INTERACTION OF TRANSPORTER TARGETED LIPID ESTER OF CYCLIC CIDOFOVIR 
WITH MDCK-MDR1 
4.1 Rationale 
Human cytomegalovirus (HCMV), the prototype member of the herpesvirus 
family is a double-stranded DNA virus of approximately 220 kb. CMV infection in AIDS 
patients usually occurs as a result of reactivation from latency due to the suppression of 
CD4+ cell counts (<100 cells/µL). Cytomegalovirus was a familiar cause of hearing, 
vision, neurological, and developmental problems and in worst cases may cause death 
in advanced AIDS patients in western countries prior to the introduction of highly 
active antiretroviral therapy (HAART). Cidofovir (HPMPC, CDF) (and its cyclic form 
(cCDF)), a potent acyclic phosphonate nucleotide analogue of cytosine, is clinically used 
for the treatment of AIDS-related cytomegalovirus, herpes type and other type of viral 
infections. CDF has broad-spectrum antiviral activity against many DNA viruses and has 
shown therapeutic potential against herpes simplex virus, varcella-zoster virus, 
Epstein–Barr virus, and human herpes virus types 6, 7, and 8 as well as adeno-, 
papilloma-, polyoma-, and pox-virus infections [249, 250]. However, main drawbacks of 
CDF include poor oral bioavailability, low cellular uptake and nephrotoxicity due to its 
tendency to concentrate in the kidney proximal tubule (via OATP transporter) [251].  
Treatment with CDF requires routine use of prophylactic measures to prevent 
nephrotoxicity which includes hydration, use of probenecid and avoidance of 
simultaneous use of other nephrotoxic agents. Moreover, for orally administered drugs, 
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intestinal epithelial membrane forms the first rigid barrier to the drug absorption. 
Therefore, for a drug to be well absorbed in the gastrointestinal tract, it needs to 
possess ideal physicochemical properties in order to cross the epithelial membrane by 
passive/active diffusion.  
Over the past decade, transporter targeted prodrug approach has been gaining 
attention to improve oral drug delivery. Transporter (amino acid, peptide, vitamin, etc.) 
targeted prodrug strategies are typically employed to alter physicochemical properties, 
permeability, stability, and tissue specificity of the active drugs to improve its drug 
delivery properties and to reduce associated side effects [33]. However, major 
limitation of transporter targeted prodrug approach is the saturation of transporter 
which may leads to only partial improvement in bioavailability. Other approach 
involved lipid raft conjugates to increase the lipophilicity of polar molecules that allows 
passive drug diffusion via transcellular route. However, low aqueous solubility of many 
of these lipid raft conjugated prodrugs can limit application of this approach [252, 253]. 
Therefore, it is important to balance the increased lipophilicity of drugs necessary for 
its transcellular absorption with sufficient aqueous solubility otherwise, oral 
bioavailability will become dissolution rate limited. A balanced prodrug approach is 
needed to overcome the dissolution rate limited absorption and transporter saturation 
kinetics to improve oral drug bioavailability.  
Sodium dependent multivitamin transporter (SMVT) is dominantly expressed in 
the absorptive tissues such as intestine, kidney and placenta. Other tissues such as liver, 
brain, heart, eye and skin also have a significant expression of this carrier system. SMVT 
is an important transport system carrying vitamins such as biotin and cofactors, 
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essential for tissues. MDCK-MDR1 cell line is derived from the Madin-Darby canine 
kidney cells transfected with human MDR1 gene. This cell line was used in the current 
project because it has been widely employed as an alternative to Caco-2 model for high 
throughput screening of drug permeability, drug delivery and drug-drug interactions 
[254]. Moreover, our laboratory has shown the molecular expression of SMVT 
transporter on MDCK-MDR1 cells. It was observed that SMVT is a saturable transporter 
with Km of 13.0 µM, Vmax 21.5 of pmol min-1 (mg of protein)-1, and Kd of 0.12 µL min-1 
(mg of protein)-1 on MDCK-MDR1 cells [254]. Biotin prodrugs were able to utilize this 
low capacity and high affinity SMVT transporter to enhance the permeability of 
therapeutic drug conjugates. Our laboratory have previously reported that biotin 
conjugated sequinavir (Biotin-Seq) was recognized by SMVT transporter on MDCK-
MDR1 cells [254]. Therefore, to delineate our hypothesis of attaining synergetic effect 
by simultaneously conjugating both transporter targeted moiety (biotin) and lipid raft, 
we have synthesized and characterized several biotinylated lipid ester conjugates of 
cCDF to target SMVT transporter. We hypothesized that the lipid raft of synthesized 
targeted lipid ester prodrug will facilitates enhanced interaction with the cell 
membrane and thereby will assist docking of targeted moiety (i.e. biotin) into the 
binding domain of transporter (SMVT). The net effect will be rapid translocation of 
targeted lipid prodrug across the plasma membrane improving cellular absorption and 
oral bioavailability. These modifications will not only help to improve the permeability 
(via SMVT transporter and lipid raft), but will also attain desired antiviral efficacy of 
parent CDF (via improved oral absorption). Therefore, transporter targeted lipid 
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prodrug design might prove as a promising approach to improve cellular bioavailability 
and attain high antiviral drug efficacy. 
4.2 Materials and Methods 
Materials 
Cidofovir was a generous gift from the Gilead Science, Foster City, CA. Tenofovir 
Disoproxil Fumarate was purchased from Santa cruz biotechnology, inc. (Dallas, TX). 
[3H]-Biotin (35.6 Ci/mmol, radiochemical purity > 98.6%) was obtained from 
Amersham Biosciences (Pittsburgh, PA). Sprague dawley rat plasma was procured from 
Valley Biomedical (Winchester, VA).  Trifluroacetic acid, methanol and acetonitrile were 
purchased from Fisher scientific (Pittsburgh, PA). Distilled deionized water (DDW) was 
used to prepare buffer and mobile phase. Dulbecco's Modified Eagle Medium (DMEM) 
and fetal bovine serum (FBS) were purchased from Gibco (Invitrogen Corporation, 
Grand Island, NY). Culture flasks (75 cm2 growth area) and 12-well plates (3.8 cm2 
growth area per well) were procured from MidSci (St. Louis, MO).  
Cell Culture 
MDCK-MDR1 cells (passages 5–15) were cultured in DMEM supplemented with 
10% FBS (heat inactivated), 1% nonessential amino acids, penicillin (100 U/ml), 
streptomycin (100µg/ml), 20 mM HEPES, and 29 mM sodium bicarbonate adjusting pH 
7.4. Cells were grown and incubated at 37 °C in a culture incubator with 5% CO2. The 
medium was changed every alternate day. Cells were passage every 4 to 6 days till it 
reaches 80-90% confluency.  Cells were seeded at a density of 25,000/well in 12-well 
tissue culture-treated plates, at 10,000/well in 96-well plates and 25,000/well in 12-
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well plate collagen coated Transwell® permeable inserts (Costar®). These cells were 
then allowed to grow for 4-6 days and used for further studies. 
Cytotoxicity Studies 
MTT Assay 
Cytotoxicity of CDF and its prodrugs were evaluated in MDCK-MDR1 (Passage 5-
15) using an aqueous non-radioactive cytotoxicity kit. This kit is based on the principle 
of MTS assay and has been successfully used to study cytotoxicity of various prodrugs 
in our laboratory [255]. MDCK-MDR1 cells were cultured following procedure 
mentioned in the method section. Prior to the experiment, a fixed number of MDCK-
MDR1 cells (10000 cells/well) were plated in 96 well-plate for 24 h.  After 24 h, culture 
medium was replaced with 100 µl of freshly prepared filtered sterile solutions of CDF,  
its biotin conjugated lipid prodrugs (B-C2-cCDF, B-C6-cCDF, B-C12-cCDF) and lipid 
ester prodrugs (C6-cCDF and C12-cCDF) at different concentrations and cells were 
incubated for 48 h (in a humidified, 5% CO2 atmosphere). CDF and its prodrugs were 
tested in the concentration range of 50, 100, and 250 µM.  After 48 h, solution was 
removed and MTS dye was added and incubated for 2 h. At the end of 2 h, cell viability 
was calculated using color determination at 485 nm with a 96 well microtiter plate 
reader (SpectraFluor Plus, Tecan, Switzerland). Five percent triton-X 100 and culture 
medium were used as a positive and negative control respectively. 
Lactate Dehydrogenase Assay 
Lactate dehydrogenase (LDH) activity was used to assess cell damage induced by 
drug/prodrugs exposure to the cell. The method was followed according to the 
published protocol with minor modification [256]. The LDH released into the cell 
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culture medium was determined spectroscopically LDH Cytotoxicity Assay Kit (Thermo 
Scientific, Rockford, IL). Negative control was defined as LDH released untreated cells; 
positive control was defined as LDH released cells treated with Triton X-100 (5%). For 
this purpose MDCK-MDR1 cells were plated in 96-well plates at a density of 10,000 cells 
per well in 100 µL of DMEM for 24 h. Biotin conjugated lipid ester prodrugs of cyclic 
cidofovir was added at various concentrations (50-250 µM) diluted in 100 µL of DMEM. 
All plates were incubated for 48 h (37 °C, 5% CO2). 
In Vitro Rat Plasma Stability 
In vitro stability of biotinylated lipid ester prodrugs was conducted in rat 
plasma. The rat plasma was diluted to 80% with 0.05 M phosphate buffer saline (PBS, 
pH 7.4) at 37 °C. The stability studies were initiated by adding prodrugs (B-C2-cCDF, B-
C6-cCDF and B-C12-cCDF) into 1 ml of preheated (at 37 0C) plasma solution to yield a 
final concentration of 200 µM each. The assays were performed in a shaking water bath 
at 37 °C and conducted in triplicate. Samples (50 µL) were taken at 0, 5, 10, 15, 30, 45, 
60 and 90 min and added to 200 µL ice cold methanol in order to precipitate the 
plasma. The samples were vortexed for 1 min and then centrifuged at 4°C for 10 min at 
5000 X g. The clear supernatants were analyzed by HPLC. The values represent the 
mean ± SD and the experiment was performed in triplicate. 
The in vitro degradation rate constant (k) and plasma half life (t1/2) was calculated 
using the equation 1 and 2 as below.  
k = 2.303 × slope (log Cremaining vs. time)…………………………………………................Eq. 1 
t1/2 = 0.693/k ……………………………………………………………………….......................…Eq. 2 
 96 
 
Where, k is the slope found in the linear fit of the natural logarithm of fraction 
remaining of parent compound vs. incubation time. 
Interaction with SMVT Transporter 
Inhibition of Uptake of [3H]-Biotin 
This experiment was performed to investigate the interaction of biotinylated 
lipid ester conjugates of cCDF with the SMVT transporter. For this study, a model 
MDCK-MDR1 cell line was selected to delineate in vitro interaction with SMVT [254]. 
MDCK-MDR1 cells were cultured on the 12-well plates according to an earlier stated 
protocol in the method section. Biotin, a well-known substrate of SMVT transporter was 
selected for this study. After confluency, cells were washed with DPBS pH 7.4 two times 
for 10 min at 37 0C. The uptake study was initiated by adding 1 ml of [3H]-Biotin (0.25 
µCi/ml in DPBS pH 5.5) in the presence and absence of biotinylated lipid ester 
conjugates of cCDF solution (all at 50 µM concentration) as a competitive inhibitors. 
Uptake study was carried out for 10 min at 37 °C.  At the end of an incubation period, 
prodrug solutions were removed and the cells were washed with ice-cold stop solution 
(200 mM KCl and 2 mM HEPES) three times. Further, cells were lysed with 1 mL of lysis 
solution (0.1%, w/v, Triton X-100 in 0.3 N sodium hydroxide) and kept at room 
temperature overnight. Next day, 500 μL of aliquots were transferred to scintillation 
vials containing 3 mL scintillation cocktail. Finally, these samples were analyzed with a 
Beckman scintillation counter (Model LS-6500, Beckman Instruments, Inc.). Uptake was 
normalized to the protein content of each well. Protein content of cell lysate was 
quantified using BioRad assay. 
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Inhibition of Transport of [3H]-Biotin 
A transwell diffusion chamber system was utilized for this study. Prior to 
transport experiment, cell monolayers grown on Transwell™ inserts were rinsed with 
DPBS pH 7.4 and incubated at 37 0C for 10 min 2 times for both apical (AP) and 
basolateral (BL) sides. Transport was initiated by adding 500 µL of [3H]-Biotin (in DPBS 
pH 5.5) in presence and absence of biotinylated lipid ester conjugates of cCDF (all at 50 
µM concentration) towards AP side of the cells (donor chamber). The receiver chamber 
(BL side) contains DPBS, pH 7.4. Transport experiment was conducted for a total time 
period of 3 h. Sampling (100 µL) from the receiver chamber was done at predetermined 
time intervals of 15, 30, 45, 60, 90, 120, 150, and 180 min and fresh DPBS, pH 7.4 was 
replaced to maintain sink conditions in receiver chamber. All samples were then 
analyzed in a Beckman scintillation counter (Model LS-6500, Beckman Instruments, 
Inc.). All experiments are performed in triplicate. The permeability (P, cm/sec) of [3H]-
Biotin was determined according to equation 3. 
  P= (dM/dt)/(Cd * A *60)…….…………………………………………………………..Eq. 3 
Where dM/dt represents the rate of transport across the cell monolayer, A is the cross-
sectional area available for transport and Cd is the donor concentration. 
Affinity Measurements using [3H]-Biotin on MDCK-MDR1 Cells 
For dose response studies in which [3H]-Biotin uptake was inhibited in the 
presence of biotinylated lipid ester conjugates of cCDF, the inhibitory effect was 
calculated by equation 4. 
Y =   min +  max-min   ……………………………………………………………..…….Eq. 4 
1 + 10 (log IC50-x)*H 
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Where, x denotes the log concentration of biotin conjugated lipid ester prodrugs 
whereas, Y is the intracellular uptake of [3H]-Biotin. IC50 represents the inhibitor 
concentration where the uptake of [3H]-Biotin was inhibited by 50%, and H is the Hill 
constant. Y starts at a minimum (min) value (at low inhibitor concentration) and then 
plateaus at a maximum (max) value (at high inhibitor concentration) resulting in a 
sigmoidal profile.  
Non-Radioactive Cellular Accumulation 
Cellular accumulation study was performed on MDCK-MDR1. Cells were grown 
in monolayer on 12-well plates for 4-6 days (with confluency of 90-95%), the cellular 
accumulation of CDF, biotinylated lipid ester conjugates of cCDF and lipid ester 
conjugates of cCDF were initiated. Briefly, cells were washed with DPBS pH 7.4 and 1 ml 
of CDF, biotin conjugated lipid ester prodrugs or lipid ester conjugates of cCDF (all at 50 
µM in DPBS, pH 5.5) was added in the presence and absence of competitive inhibitor of 
biotin at 37 0C. At the end of experiment the drug/prodrugs solution was removed and 
cell monolayer was washed three times with ice cold stop solution (200 mM KCl and 2 
mM HEPES). Cells were lysed by three rapid freeze-thaw cycles. The samples were 
analyzed by LC-MS/MS after Bond Elute SAX solid phase extraction with 1% 
trifluroacetic acid-methanol (for CDF and biotinylated lipid ester conjugates of cCDF) 
and cold ethyl acetate extraction (lipid ester conjugates of cCDF).  All the samples were 
analyzed by LC-MS with tenofovir as an internal standard. All the experiments were 
performed in quadruplicate and cellular accumulation was normalized using protein 
count. 
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Statistical Analysis 
All experiments were conducted at least in triplicate and cellular accumulation 
studies were conducted in quadruplicate. Results are expressed as mean ± S.D. One-way 
ANOVA was used to compare responses between different treatment groups, * p<0.05, 
** p<0.01.  
4.3 Result 
Cytotoxicity Studies 
CDF and its prodrugs were studied for cytotoxicity studies in MDCK-MDR1 cell 
line. Prodrugs were found to be nontoxic up to 250 µM concentration for 48 h via MTT 
and LDH assay. Triton X-100 and culture medium were used as a positive and negative 
control respectively. Figure 24A and B summarizes the % cytotoxicity (MTS and LDH) 
of all the compounds studied.  
In Vitro Rat Plasma Stability 
A prodrug molecule is pharmacologically inactive and should not exhibit any 
therapeutic effect unless it converts into the parent drug. Therefore, we also performed 
the enzymatic stability studies of prodrugs in presence of rat plasma for oral delivery.  
Table 6 summarizes the apparent first order degradation rate constant indicating the 
loss of the prodrugs and conversion into the parent drug, i.e. CDF, in the rat plasma. 
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Figure 24: Cytotoxicity studies (A) MTS and (B) LDH assay of biotin-conjugated 
lipid ester prodrugs on MDCK–MDR1 at 48 h. Each data point represents mean ± 
SD (n = 6). ∗p < 0.05 
 
 
 
(A) 
(B) 
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Table 6: First-order rate constant (k x 10-3) and half-life (t1/2) of prodrugs in rat 
plasma homogenate at 37 0C 
 
Prodrug k (min-1) t ½ (min) 
B-C2-cCDF 8.1 ± 0.2 85.1 ± 1.7 
B-C6-cCDF 9.2 ± 0.4 75.3 ± 3.6 
B-C12-cCDF 15.7 ± 1.5 44.4 ± 4.2 
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Interaction with SMVT Transporter 
The presence of SMVT transporter on the MDCK-MDR1 cell line has been 
characterized previously from our laboratory [254]. This cell line is widely used 
because it possesses tight junctions, it is also easy to culture and have been used 
successfully for oral drug delivery [257]. All the biotinylated lipid ester conjugates of 
cCDF (50 µM) have shown significant reduction in uptake of [3H]-Biotin (0.25 Ci/ml in 
DPBS pH 5.5) (Fig. 25). Uptake of [3H]-Biotin was reduced by 50 %, 42% and 27% for B-
C2-cCDF, B-C6-cCDF and B-C12-cCDF, respectively, on MDCK-MDR1 cells. These results 
indicate the effect of lipid chain length of biotinylated lipid ester conjugates of cCDF on 
the inhibition of [3H]-Biotin uptake. Moreover, the affinity measurement of these 
prodrugs for SMVT transporter shows that all the prodrugs possess high affinity for 
SMVT transporters (Fig. 26). IC50 values are listed in Table 7. These values are 
calculated with GraphPad Prism software 5.04. In addition, we also performed the 
transport of [3H]-Biotin (0.5 µCi/mL, 10 nM) across MDCK-MDR1 monolayer using 
transwell. The result clearly indicates significant reduction in the transport of [3H]-
Biotin in presence of all the biotinylated lipid ester conjugates of cCDF (at 50µM 
concentration). The reduction in cumulative transport of [3H]-Biotin was higher in 
presence of B-C12-cCDF followed by B-C6-cCDF and B-C2-cCDF.  Cumulative transport 
of [3H]-Biotin across MDCK-MDR1 at the end of 180 min was reduced by 44%, 58% and 
70% in presence of B-C2-cCDF, B-C6-cCDF and B-C12-cCDF respectively (Fig. 27). We 
also performed the cellular accumulation of all the prodrugs on MDCK-MDR1 cells. 
Cellular accumulation of B-C2-cCDF, B-C6-cCDF, B-C12-cCDF, C6-cCDF, and C12-cCDF 
were 3.5-, 10.5-, 32-, 7- and 38-fold higher than the parent CDF, respectively (Fig. 28).   
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Figure 25: Cellular accumulation of [3H]-Biotin (0.25 µCi/mL) in presence of 
biotin-conjugated lipid prodrugs (50 µM) on MDCK–MDR1 cells. Each data point 
represents mean ± SD (n = 4). ∗p < 0.05. 
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Figure 26: Dose-dependent inhibition uptake of [3H]-Biotin (0.25 µCi/mL) in 
presence of (A) B-C2-cCDF, (B) B-C6-cCDF, and (C) B-C12-cCDF in MDCK–MDR1. 
Each data point represents mean ± SD (n = 4) 
(A) 
(B) 
(C) 
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Table 7: IC50 values calculated from the Graphpad Prism 5.0 for the biotin 
conjugated lipid prodrugs of cyclic cidofovir towards SMVT transporter 
 
 
 
 
 
 
  
 
* Calculated from Graphpad prism 5.04 
 
 
 
 
 
 
 
Drug IC50* Value (µM) 
B-C2-cCDF 31 ± 3 
B-C6-cCDF 11 ± 2 
B-C12-cCDF 2.9 ± 0.1 
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Figure 27: (A) Transport of [3H]-Biotin (0.25 µCi/mL) across MDCK–MDR1 cells 
in absence and presence of biotin-conjugated lipid prodrugs (50 µM). Control, B-
C2-cCDF, BC6-cCDF,B-C12-cCDF. Each data point represents mean ± SD (n = 4). 
(B) Cumulative transport at the end of 180 min. ∗p < 0.05 and ∗∗p < 0.01 
 
 
(A) 
(B) 
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Figure 28: Cellular accumulation of biotin conjugated lipid prodrugs [alone and in 
presence of Biotin (25 µM) and lipid prodrugs on MDCK-MDR1 cells at 60 mins. Each 
data point represents mean ± SD (n = 4). * p<0.05 and ** p<0.01 
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4.4 Discussion 
Although CDF and cCDF have shown potent activity against herpes and other 
type of viruses [258-260], its low oral bioavailability of less than 5% requires repeated 
intravenous administration, limiting its therapeutic scope [261, 262].  CDF is actively 
transported into renal proximal tubular cells more rapidly than it is secreted and thus 
may accumulate to toxic levels, causing renal insufficiency [262-264].  Therefore, there 
is an urgent need of development of an orally available form of CDF which will be less 
toxic and more effective analogue. 
For oral drug delivery, intestinal cells display high membrane lipophilicity and 
tight junctions which limits oral absorption of hydrophilic drug like CDF. So far, 
different approaches have been employed to enhance permeability of CDF such as lipid 
prodrugs [265]or transporter targeted prodrugs of CDF [239]. However, individually 
these approaches may exhibits limited advantages. In the present study we have 
synthesized various biotinylated lipid ester conjugates of cCDF. We hypothesized that 
the presence of lipid raft will improve the interaction of these prodrugs with the cell 
membrane and biotin, a transporter targeting moiety, will further improve the 
translocation of these prodrugs across the plasma membrane. This may exhibit 
synergistic effect due to the simultaneous conjugation of lipid raft and transporter 
targeted moiety which may ultimately improve the uptake of these prodrugs across the 
cell layers. SMVT targeted drug delivery which substantially improve the oral 
absorption has been reported previously [248]. Therefore, we sought to utilize SMVT 
transporter for our approach. We have successfully synthesized and characterized the 
biotinylated lipid ester conjugates of cCDF (B-C2-cCDF, B-C6-cCDF and B-C12-cCDF) 
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and lipid ester conjugates of cCDF (C6-cCDF and C12-cCDF) using 31P NMR, LC-MS/MS 
and HPLC. The general synthesis scheme for the prodrugs has been mentioned in Fig. 
10 and 12. All the prodrugs have exhibited >95% purity along with brownish sticky 
(biotin conjugated lipid ester conjugates) or white solid crystalline (lipid ester 
conjugates) appearance. 
We have performed MTT and LDH cytotoxicity assay for the biotinylated lipid 
ester conjugates of cCDF and observed that prodrugs as well as drug did not produce 
any toxic effect on MDCK-MDR1 for up to 48 h.  We have also performed enzymatic 
stability studies of all the prodrugs in the presence of rat plasma (80%) diluted with 
PBS. A rapid conversion of these prodrugs into parent drug in the rat plasma has been 
observed (Table 6). These results further indicate that all the prodrugs upon absorption 
from intestine converted into its parent moiety to exert its antiviral activity. The main 
reason for the decrease in half-lives in rat plasma homogenate was the presence of 
enzyme phosphoester, which efficiently cleaved the P-terminal ester. 
Another important objective of the present study was to target the SMVT 
transporter. Recognition of prodrugs by SMVT transporter may enhance their 
translocation and improved oral absorption which eventually results in a higher plasma 
concentration of CDF. Therefore, we performed in vitro uptake study using a model 
MDCK-MDR1 cell line. The results indicate that all the prodrugs show strong interaction 
with the SMVT transporter. An inhibition trend was observed in the following order: B-
C12-cCDF > B-C6-cCDF > B-C2-cCDF. These results clearly indicate that elongation of 
lipid chain causes stronger interaction of biotin conjugated lipid ester prodrugs with 
cell membrane. Moreover, a high percentage of transport inhibition of [3H]-Biotin in the 
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presence of B-C12-cCDF in comparison to B-C6-cCDF and B-C2-cCDF suggested the 
significant role of lipid raft. In addition, results of IC50 value clearly indicate the higher 
affinity of B-C12-cCDF towards SMVT transporter as compared to other prodrugs. Non-
radioactive cellular accumulation study shows that there is 3.5-, 10.5-, 32-, 7- and 42- 
fold increase in the uptake of B-C2-cCDF, B-C6-cCDF, B-C12-cCDF, C6-cCDF and C12-
cCDF, respectively, as compared to the parent CDF (Fig. 28). The observed cellular 
uptake of B-C6-cCDF and B-C12-cCDF was not more than their lipid ester prodrugs (i.e. 
C6-cCDF and C12-cCDF). Cellular uptake of B-C12-cCDF was found to be comparable to 
C12-cCDF, wherein, the lipid raft (C12) facilitates the enhanced interaction of B-C12-
cCDF with membrane protein and thereby assisting docking of biotin into the binding 
domain of SMVT transporter. The net effect will be rapid translocation across RPE cell 
membrane which will not be the case with lipid ester prodrugs. Thus our novel B-C12-
cCDF prodrug may significantly enhance the oral bioavailability of CDF across lipophilic 
intestine. In addition, the uptake of biotin conjugated lipid ester prodrugs across MDCK-
MDR1 was significantly inhibited by biotin (due to competitive inhibition). These 
results clearly indicate that improvement in uptake of biotin conjugated prodrugs was 
via SMVT interaction (Fig. 28). The overall results from the interaction of all 
biotinylated lipid ester conjugates of cCDF with SMVT transporters suggest that these 
compounds strongly recognized by SMVT transporter.   
4.5 Conclusion 
Overall these studies have shown that B-C12-cCDF is the most promising 
prodrug among all the synthesized compounds owing to its strong interaction with 
SMVT transporters, lowest IC50 value (high affinity for SMVT) and rapid conversion 
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into parent molecule (in plasma). Based on above findings we conclude that novel 
biotinylated lipid ester conjugates can be utilized as a viable strategy to improve oral 
bioavailability of hydrophilic molecules such as CDF.  
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CHAPTER 5  
INTERACTION OF TRANSPORTER TARGETED LIPID ESTER PRODRUGS OF CYCLIC 
CIDOFOVIR WITH ARPE-19 CELLS 
5.1 Rationale 
Cidofovir (CDF), an acyclic phosphonate nucleotide analogue of cytosine, 
exhibits potential antiviral activity against herpes simplex, voricella-zoster, adeno-, 
papilloma-, polyoma- and pox-viruses [239]. CDF and its cyclic form (cCDF) are highly 
potent and clinically indicated in the treatment of human cytomegalovirus (HCMV) 
infections [217]. HCMV is a major cause of opportunistic infections in patients with 
AIDS, congenital immunodeficiency or organ transplant recipients [266]. Although the 
incidence and prevalence of cytomegalovirus (CMV) retinitis in AIDS patients have 
declined primarily due to the highly active antiretroviral therapy (HAART), it remains a 
major cause of vision loss in 20-40 % AIDS patients [267]. Moreover, a longitudinal 
study of ocular complications of AIDS revealed that ocular findings in patients with 
newly diagnosed CMV retinitis in the post-HAART era resembled those prior to the 
introduction of HAART [268]. In addition, when CDF was directly compared for its 
efficacy with other antiviral drugs (acyclovir or ganciclovir), it proved clearly superior 
to acyclovir in mice model infected intracerebrally with HSV [269, 270]and to 
ganciclovir in both immune-competent and immune-deficient mice model of murine 
CMV [271-273]. Although, CDF has shown potential activity against CMV retinitis, major 
treatment failure is due to the lower oral bioavailability and emergence of resistance 
[274].  
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Therefore, there is an urgency to develop potential analogues of CDF which 
shows high permeability, low toxicity and simultaneously overcomes an incidence of 
drug resistance. In order to resolve such problems, researchers have synthesized lipid 
conjugates of cCDF (octadecyloxyethyl-cyclic-cidofovir) for intraocular administration 
to improve its vitreal half-life, bioavailability (via increasing lipophilicity) and antiviral 
efficacy [265].  However, the major limitation of lipid conjugates is higher retention in 
lipid bilayer of plasma membrane and inability to translocate into the cytoplasm due to 
which it is not effective in treating deeper tissue infection such as CMV retinitis. 
Moreover, the low aqueous solubility of lipid prodrugs can further restrict the 
application of this approach [253]. Therefore, it is important to balance the prodrug 
lipophilicity necessary for transcellular absorption with adequate aqueous solubility. 
Researchers have opted to synthesize peptide prodrug of cCDF to target peptide 
transporter in order to improve its antiviral efficacy and bioavailability following oral 
administration [247]. However, the major limitations for transporter targeted prodrugs 
are substrate specificity and transport capacity [252]. Therefore, lipid conjugates and 
transporter targeted prodrugs exhibit partial response since individually these 
strategies holds both advantages as well as limitations. Hence, a balanced approach is 
needed to produce better permeability via transporter targeted moiety along with 
suitable lipophilicity via lipid raft.  In this study, we hypothesized that combination of 
both transporter targeted moiety and lipid raft may provide synergistic effect.  
In our laboratory, various transporters have been investigated on the retina 
which can be utilized for the delivery of therapeutic agents. Transporters such as 
peptide/histidine [102], organic cationic tranporter [275], amino acid transporter [276, 
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277], folic acid [145], and sodium dependent multivitamin transporter (SMVT) have 
been reported on the human retinal pigment epithelium cells (ARPE-19) [95]. SMVT is 
an important transport system carrying vitamins such as biotin and cofactors essential 
for the ocular tissues. It was observed in our laboratory that SMVT is a saturable 
transporter with Km of 138 µM and Vmax of 38 pmol/min/mg protein on ARPE-19 cells 
[95]. Biotin prodrugs were able to utilize this low capacity and high affinity SMVT 
transporter to enhance the permeability of therapeutic drug conjugates. We have 
previously reported that biotin conjugated ganciclovir (Biotin-GCV) was recognized by 
SMVT transporter on ARPE-19 cells and rabbit retina. Moreover, Biotin-GCV has shown 
therapeutically desirable pharmacokinetics profile as compared to parent GCV [95]. 
Therefore, in the present study to delineate our hypothesis of attaining 
synergetic effect by simultaneously conjugating both transporter targeted moiety 
(biotin) and lipid raft, we have synthesized and characterized several biotinylated lipid 
ester conjugates of cCDF to target SMVT transporter on the retina for the treatment of 
HCMV retinitis. We hypothesized that the lipid raft of synthesized targeted lipid 
prodrug will facilitates enhanced interaction with the cell membrane and thereby will 
assist docking of targeted moiety (i.e. biotin, B) into the binding domain of transporter 
(SMVT). The net effect will be rapid translocation of targeted lipid prodrug across the 
plasma membrane improving cellular absorption. These modifications will not only 
help to improve the permeability (via SMVT transporter and lipid raft), but will also 
attain desired antiviral efficacy of parent CDF. Therefore, transporter targeted lipid 
prodrug design may be a promising approach to treat HCMV retinitis. 
5.2 Materials and Methods 
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Materials 
CDF was a generous gift from the Gilead Science, Foster City, CA. Tenofovir and 
Tenofovir Disoproxil Fumarate was purchased from Santa Cruz Biotechnology, inc. 
(Dallas, TX). [3H]-Biotin (35.6 Ci/mmol, radiochemical purity > 98.6%) was obtained 
from Amersham Biosciences (Piscataway, NJ). Trifluroacetic acid, methanol and 
acetonitrile were purchased from Fisher scientific. Distilled deionized water (DDW) 
was used to prepare buffer and mobile phase. Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (1:1) (DMEM/F12) and fetal bovine serum (FBS) were purchased 
from Gibco (Invitrogen Corporation, Grand Island, NY). Culture flasks (75 cm2 growth 
area) and 12-well plates (3.8 cm2 growth area per well) were procured from MidSci (St. 
Louis, MO).  
Animals 
 Adult male New Zealand albino rabbits weighing between 2-2.5 kg were 
obtained from Harlan Laboratory (Indianapolis, IN). Ketamine HCl and Rompun 
(Xylazine®) were purchased from Fort Dodge Animal Health (Fort Dodge, IA) and 
Bayer Animal Health (Shawnee Mission, KS) respectively. Protocol for performing all 
the surgical procedure was approved by Institutional Animal Care and Use Committee 
(IACUC) of the University of Missouri–Kansas City. 
Cell Culture 
 ARPE-19 cells (passages 20–30) were cultured in DMEM/F-12 containing 10% 
FBS (heat-inactivated), 15 mM HEPES, 29 mM sodium biocarbonate, penicillin (100 
units/mL), streptomycin (100 μg/mL), and were maintained at 37 °C, in a humidified 
atmosphere of 5% CO2. The medium was replaced every two days. For uptake studies, 
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cells were plated at a density of 25,000/well on 12-well culture plates, for transport 
studies cells were plated at a density of 25,000 cells/well in 12-well collagen coated 
transwell, and for cytotoxicity studies cells were plated at a density of 10,000/well in 
96-well plates. For uptake and transport studies cells were grown and maintained for 
21 days for sufficient expression of SMVT transporter. 
Cytotoxicity Studies 
MTT Assay 
Cytotoxicity of CDF and its prodrugs was evaluated in human retinal cells (ARPE-
19, Passage no 15-25) using an aqueous non-radioactive cytotoxicity kit. This kit is 
based on the principle of MTS assay and has been successfully used to study 
cytotoxicity of various prodrugs in our laboratory [255]. ARPE-19 cells were cultured 
following procedure mentioned in the method section. Prior to the experiment, a fixed 
number of ARPE-19 cells (10,000 cells/well) were plated in a 96 well-plate for 24 h. 
After 24 h, culture medium was replaced with 100 µL of freshly prepared solutions of 
CDF and its biotinylated lipid ester conjugates of cCDF (B-C2-cCDF, B-C6-cCDF, B-C12-
cCDF) at different concentrations and cells were incubated for 48 h (in a humidified, 5% 
CO2 atmosphere). CDF and its conjugates were tested in the concentration range of 50, 
100, and 250 µM. After 48 h, the solution was removed and the MTS dye was added and 
incubated for 2 h. At the end of 2 h, cell viability was calculated using color 
determination at 485 nm with a 96 well microtiter plate reader (SpectraFluor Plus, 
Tecan, Switzerland). Five percent triton-X 100 and culture medium were used as a 
positive and negative control respectively. 
Lactate Dehydrogenase Assay 
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Lactate dehydrogenase (LDH) activity was used to assess damage induced by 
drug/prodrugs expose to the cell. The method was followed according to the published 
protocol with minor modification [256]. LDH released into the cell culture medium was 
determined spectroscopically with LDH Cytotoxicity Assay Kit (Rockford, IL). Negative 
control was defined as a LDH released from untreated cells, positive control was 
defined as LDH released from cell treated with Triton X-100 (5%). For this purpose 
ARPE-19 cells were plated in 96-well plates at density of 10,000 cells per well in 100 µL 
of DMEM-F12 for 24 hrs. Biotinylated lipid ester conjugates of cCDF was added at 
various concentrations (50-250 µM) diluted in 100 µl of DMEM-F12. All plates were 
incubated for 48hr (37°C, 5% CO2). 
Pro-Inflammatory Cytokines Release 
Biotinylated lipid ester conjugates of cCDF mediated release of IL-6 and IL-8 
from ARPE-19 cells were quantified according to the previously published protocol 
with modification [278]. Briefly, ARPE-19 cells were seeded in a 24-well culture plates 
at a density of 1 × 106 per well and maintained in DMEM/F12 medium containing 10% 
FBS for 2 days. Before prodrugs exposure, cells were serum starved for 24 hours in a 
serum-free medium. ARPE-19 cells were incubated in a serum-free medium with 25 μM 
and 50 µM prodrugs (n=4). Following prodrug exposure, cell-free supernatants were 
recovered and stored at −70 °C until assay. The cytokines concentrations were 
determined using Legend Max® human IL-6 and IL-8 sandwich ELISA kit (BioLegend®, 
San Diego, CA) according to the manufacturer protocol.  IL-6 and 8 standard controls 
(100 pg/mL-3.125 pg/mL), negative control (cell culture medium) and positive control 
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(lipopolysaccharide, LPS (0.1 µg/mL)) were also quantified simultaneously. Absorbance 
was measured at 450 nm (excitation) and 570 nm (emission) wavelengths. 
Aqueous Solubility and n-Octonal/Buffer Partition Coefficient 
Aqueous solubility study was performed by following previously published 
protocol from our laboratory [90]. Briefly, excess amount of CDF, its biotinylated lipid 
ester conjugates of cCDF (B-C2-cCDF, B-C6-cCDF and B-C12-cCDF) and lipid ester 
conjugates of cCDF (C6-cCDF and C12-cCDF) were added to 1 mL of distilled deionized 
water in glass vials. These vials were kept in shaker bath for 24 h at 37 0C. After 24 h, 
the content of the vial was carefully transferred in an eppendorf tube and centrifuged 
for 10 min at 5000 X g. The supernatant was collected and filtered through 0.45 μm 
Nalgene syringe filter membrane. The supernatant was immediately stored in -20 0C 
refrigerator until analysis was done using HPLC. All the experiments were conducted in 
triplicate.  
A partition coefficient study was performed with n-octanol and DPBS (pH 7.4) as 
per previously published protocol from our laboratory [279]. Briefly, n-octanol and 
DPBS were pre-saturated for 48 h with each other. After pre-saturation, 1 ml aliquots of 
pre-saturated DPBS was placed in glass vial and stock solution of CDF, its biotinylated 
lipid ester conjugates of cCDF (100 µM) and lipid ester conjugates of cCDF (100 µM) 
were added. The mixture was vortexed and an initial sample was collected (Caqu). After 
equilibration, 1 ml aliquot of pre-saturated n-octanol was added. The glass vial was kept 
at constant temperature shaker bath (37 0C) for 24 h. Samples were collected from 
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aqueous and organic phase for the determination of partition coefficient and log P 
values using equation 5 and 6 respectively. 
Partition coefficient = (Coct/Caqu)……....…………………………………………………….………...Eq. 5 
Log P = log (Coct/Caqu)…………………………………………………………………………..…………..Eq. 6 
Stability Studies 
Buffer Stability 
Prodrugs need to display a good stability and must be absorbed intact across 
tissue. Simultaneously, the prodrug should be converted to parent molecule following 
its active/passive transport in target tissue to exhibit therapeutic activity. Chemical 
stability studies will help to screen an ideal prodrug candidate for in vivo studies. The 
chemical stability of prodrugs where studied in various buffers at different pH (1.4-7.4). 
For pH 1.4 hydrochlorate buffer (8.5 mL of 0.2 M hydrochloric acid and 5.0 mL of 0.2 M 
potassium chloride), pH 4.0 acetate buffer (0.3 g sodium acetate trihydrate and 3.9 mL 
of 2 N acetic acid), pH 6.0 phosphate buffer (50 mL of 0.2 M monobasic potassium 
phosphate and 5.6 mL of 0.2 M sodium hydroxide) and pH 7.4 phosphate buffer (50 mL 
of 0.2 M monobasic potassium phosphate and 39.1 mL of 0.2 M sodium hydroxide) were 
prepared within the range of ± 0.05 units [280]. The buffer strength was kept constant 
at 100 mM. To initialize the study, 4.8 mL of buffer was taken in a glass vial and 200 µL 
of freshly prepared prodrug solution (10 mg/mL) in methanol was added. The glass 
vials were kept in the water bath at 37 °C and 60 rpm. Aliquots (100µL) were taken at 
pre-determined time interval and immediately added to 100 µL of ice-cold methanol 
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containing 0.1% v/v trifluroacetic acid to stop hydrolytic degradation. Samples were 
stored at −80 °C until further analysis by HPLC. Experiments were performed in 
triplicate. 
Ocular Tissues Hydrolysis 
 Previously published protocol was followed to separate the ocular tissues from 
the animals [281, 282]. Briefly, New Zealand white male albino rabbits were euthanized 
with sodium pentobarbital injection through the marginal ear vein. Both eye balls were 
enucleated immediately and rinsed with pH 7.4 DPBS. Both ocular segments were 
carefully separated by making an incision at the scleral–limbus junction. The posterior 
segment ocular tissues such as conjunctiva, sclera, choroid-retina and vitreous humor 
were separated. These tissues were stored at −80 °C prior to use. Target tissue was 
retina for bioreversion and the therapeutic action of prodrugs. So, the retina was 
homogenized in ice bath and the homogenate was collected. Protein concentration of 
supernatant was measured with a BioRad protein estimation kit (BioRad, Hercules, CA). 
In all the stability studies, protein concentration of 1.0 mg/ml was employed. To initiate 
the study, 2.8 ml of supernatant was taken in a glass vial and 200 µl of prodrugs 
solution (1 mg/ml of stock solution of prodrugs) was added. At predetermined time 
interval, 100 µl of sample was taken and immediately diluted with 100 µl of ice-cold 
methanol containing 0.1% v/v trifluroacetic acid to terminate enzyme activity. Samples 
were immediately centrifuged and supernatant was stored in −80 °C until HPLC 
analysis. Finally, apparent first-order rate constants (k) from equation 1 (Chapter 3) 
and half-life (t1/2) from equation 2 (Chapter 3) were calculated and corrected for any 
chemical hydrolysis observed with the control. This experiment was done in triplicate. 
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Interaction with SMVT Transporter 
Inhibition of [3H]-Biotin Uptake 
This experiment was performed to investigate the interaction of biotinylated 
lipid ester conjugates of cCDF with the SMVT transporter. For this study, a human 
retinal pigment epithelium cells, ARPE-19 cell line was selected to delineate in vitro   
interaction with SMVT [95]. ARPE-19 cells were cultured on 12-well plates according to 
an earlier stated protocol from the method section. Biotin, a well-known substrate of 
SMVT transporter was selected for this study. After the confluency, cells were washed 
with DPBS pH 7.4 for 10 mins (2X) at 37 0C. The uptake study was initiated by adding 1 
ml of [3H]-Biotin (0.25 µCi/ml in DPBS pH 5.5) in the presence and absence of 
biotinylated lipid ester conjugates of cCDF solution (all at 50 µM concentration) as a 
competitive inhibitors. Uptake study was carried out for 7 min at 37°C. At the end of an 
incubation period, drug solutions were removed and the cells were washed with ice-
cold stop solution (200 mMKCl and 2 mM HEPES) three times. Further, cells were lysed 
with 1 ml of lysis solution (0.1%, w/v, Triton X-100 in 0.3N sodium hydroxide) and kept 
at room temperature overnight. Next day, 500 μL of aliquots were transferred to 
scintillation vials containing 3 ml scintillation cocktail. Finally, these samples were 
analyzed with a Beckman scintillation counter (Model LS-6500, Beckman Instruments, 
Inc.). Uptake was normalized to the protein content of each well. Protein content of cell 
lysate was quantified using BioRad assay. 
Inhibition of [3H]-Biotin Transport 
Transwell diffusion chamber system was utilized for this study. Prior to a 
transport experiment, ARPE-19 cell grown on the Transwell™® inserts were rinsed with 
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DPBS pH 7.4 and incubated at 37 0C for 10 min for 2 times for both apical (AP) and 
basolateral (BL) sides. Transport was initiated by adding 500 µL of [3H]-Biotin (in DPBS 
pH 5.5) in presence and absence of biotinylated lipid ester conjugates of cCDF (all at 50 
µM concentration) towards AP side of cells (donor chamber). The receiver chamber (BL 
side) contains DPBS pH 7.4. Transport experiment was conducted for a total time 
period of 3 h. Sampling (100 µl) from the receiver chamber was done at predetermined 
time intervals of 15, 30, 45, 60, 90, 120, 150, and 180 min and fresh DPBS pH 7.4 was 
replaced to maintain sink conditions in receiver chamber. The samples were then 
analyzed in a Beckman scintillation counter (Model LS-6500, Beckman Instruments, 
Inc.). All experiments are performed in triplicate. The permeability (P, cm/sec) of [3H]-
Biotin was determined according to equation 3 (Chapter 3).  
Affinity Measurements Using [3H]-Biotin on ARPE-19 Cells                                               
For dose response studies in which [3H]-Biotin uptake was inhibited in the presence of 
biotinylated lipid ester conjugates of cCDF, the inhibitory effect was calculated by 
equation 4 (Chapter 3). 
Non-Radioactive Cellular Accumulation 
Cellular accumulation study was performed on ARPE-19. Cells were grown in 
monolayer on 12-well plates for 20-21 days (with confluency of 90-95%), the cellular 
accumulation of CDF, biotinylated lipid ester conjugates of cCDF and lipid ester 
conjugates of cCDF were initiated. Briefly cells were washed with DPBS pH 7.4 and 1 ml 
of CDF, biotin conjugated lipid ester prodrugs and lipid ester conjugates of cCDF (all at 
50 µM in DPBS pH 5.5) was added in the presence and absence of competitive biotin 
inhibitor at 37 0C. At the end of an experiment, the drug/prodrugs solution was 
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removed and cell monolayer was washed with ice cold stop solution. Cells were lysed 
by rapid freeze-thaw cycle (3 times). The samples were analyzed by LC-MS/MS after 
Bond Elute SAX solid phase extraction with 1% v/v trifluroacetic acid-methanol and 
cold ethyl acetate extraction. All the experiments were performed in quadruplicate and 
cellular accumulation was normalized using protein count. 
Tissue Partition Coefficient 
Previously published protocol was followed to separate the posterior segment 
ocular tissues from New Zealand rabbits [281, 282]. The retina-choroid and sclera were 
removed carefully and placed in pre-weighed vials on ice. A 990 µL of isotonic 
phosphate buffer saline (IPBS) pH 7.4 was added to the vials containing retina-choroid 
and incubated at 37 0C for 15 min for tissue equilibration. Ten µL of drug and prodrugs 
solution was spiked, gently vortexed and incubated for 6 h. At the end of incubation, the 
vials were centrifuged at 2000 X g for 2 min and the supernatant and tissue pellet were 
collected in different microfuge tubes and stored at -80 0C for further analysis. One 
hundred µL of supernatant was mixed with ice cold methanol for protein precipitation 
(Caq). Tissue pellet was homogenized with DPBS pH 7.4 and immediately mixed with the 
ice cold methanol for protein precipitation and terminating enzymatic degradation 
before analysis (Ctis). Tissue partition calculation was calculated using equation 5 
(Chapter 3). All the analysis was performed by HPLC or LC-MS/MS.  
Computational modeling of hsmvt protein and docking of biotinylated lipid ester 
conjugates of cCDF 
The entire SMVT protein Sequence (Q9Y289) was retrieved from the UNIPROT 
database [283]. This sequence was submitted to the I-Tasser homology model-building 
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server for model calculation [284-286]. The selected model had an I-Tazzer score of -
0.10. A Stereo chemical quality check was performed on the returned model. All of the 
biotin conjugated structures were sketched using Gauss View [287]. Autodock Vina was 
used to perform the docking studies using default settings. The receptor grid was 
centered at the center of the protein (X: -1.8245; Y: 1.8034; Z: 0.4063). The grid was 
maximized (X: 60.9131; Y: 72.4244; Z: 72.8405) to encompass the entire protein. Each 
structure was independently docked to the targeted protein to produce nine different 
docking poses with the highest affinities. Autodock Vina docking scores are derived by 
utilizing a scoring function as described in Trott et al. [288]. 
Statistical Analysis 
All experiments were conducted at least in triplicate and cellular accumulation 
studies were conducted in quadruplicate. Results are expressed as mean ± S.D. One-way 
ANOVA was used to compare responses between different treatment groups, * p<0.05, 
** p<0.01.  
5.3 Results 
Cytotoxicity Studies 
CDF, biotinylated lipid ester conjugates of cCDF and lipid ester conjugates of 
cCDF were studied for cytotoxicity studies on ARPE-19 cell line. Prodrugs were found to 
be nontoxic up to 250 µM concentration for 48 h. Triton X-100 and culture medium 
were used as a positive and negative control respectively. Fig. 29 A and B summarizes 
the % cytotoxicity (MTS and LDH) of all the compounds studied.  
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Pro-Inflammatory Cytokines Release 
CDF and all the biotinylated lipid ester conjugates of cCDF were studied for 
cytokines releaseonARPE-19 cell line. ARPE-19 is known to release cytokines due to 
external stimulation [278]. Prodrugs were found to be non-sensitive towards 
stimulating the release of cytokines up to 250 µM concentration for 48 h from ARPE-19 
cells. Lipopolysaccharide (LPS) (0.1 µg/mL) and culture medium were used as a 
positive and negative control respectively. Fig. 30 A and B summarizes the release of 
cytokines (IL-6 and IL-8) due to exposure to prodrugs from ARPE-19 cells. 
Aqueous Solubility and n-Octanol-Water Partition Coefficient 
Aqueous solubility of biotinylated lipid ester conjugates of cCDF and lipid ester 
conjugates of cCDF were determined in DDW at 37 0C. The aqueous solubility and 
partition coefficient values are mentioned in Table 8. As expected, the solubility of 
biotin conjugated lipid ester conjugates of cCDF was found to be lower with increasing 
carbon chain length of lipid raft. Whereas, drastic reduction in the solubility of lipid 
prodrugs of cCDF has been observed compared to biotinylated lipid ester conjugates of 
cCDF. The reduction in solubility was about 1.5, 4.5, and 5.5 fold for B-C2-cCDF, B-C6-
cCDF, and B-C12-cCDF respectively. However, reduction in solubility was about 56 and 
74 fold for C6-cCDF and C12-cCDF respectively. Octanol-buffer partition studies reveal 
log P value of CDF to be -1.86. Thus, by conjugating the lipid raft and transporter 
targeting moiety (Biotin), the lipophilicity has been increased by 18, 26 and 53 fold for 
B-C2-cCDF, B-C6-cCDF, and B-C12-cCDF, respectively. These results clearly indicate an 
improvement in the lipophilicity of prodrugs due to the presence of lipid raft 
conjugation. 
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Buffer and Tissue Homogenate Stability 
Buffer (at various pH) and ocular tissue homogenate stability studies aids in the 
screening of the ideal prodrug candidates for the further studies. 
Buffer Stability 
Chemical stability was determined for all the biotin conjugated lipid prodrugs in 
different pH buffers (pH 1.4 to 7.4). We did not observe any appreciable degradation of 
prodrugs at pH 1.4 (data not shown).  Upon raising pH towards alkaline range, an 
accelerated degradation has been observed. Fig. 31 and table 9 summarize the apparent 
first order degradation rate constants at various pH. B-C2-cCDF was found to be more 
stable than B-C6-cCDF and B-C12-cCDF.  
Ocular Tissue Homogenate Stability 
A prodrug molecule is pharmacologically inactive and hence would not exhibit 
any therapeutic effect unless it converts into the parent drug. Therefore, we also 
performed the enzymatic stability studies of prodrugs in presence of retina-choroid and 
vitreous humor homogenate (posterior segment tissue).  Fig. 32 and Table 10 
summarize the apparent first order degradation rate constant indicating the loss of the 
prodrugs in the retina-choroid and vitreous.   
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Figure 29: Cytotoxicity studies (A) MTS, and (B) LDH assay of biotin-conjugated 
lipid ester prodrugs on ARPE-19 cells at 48 h. Each data point represents mean ± SD 
(n = 6). One-way ANOVA were used to compare LPS-treated cells to controls; *P < 
0.05 
 
 
(A) 
(B) 
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Figure 30: Proinflammatory mediators secreted by ocular pigment epithelial cells 
(ARPE-19). ARPE-19 cells were exposed to 0.1 μg/mL of LPS (positive control), 
prodrugs (50 µM) or medium (negative control). At 48 hours, conditioned media were 
collected and analyzed for cytokines (A) IL-6 and (B) IL-8 by ELISA. Data are expressed 
as the mean ± SD (n = 6). One-way ANOVA were used to compare LPS-treated cells to 
controls; *P < 0.05. 
 
(A) 
(B) 
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Table 8: Physicochemical properties (aqueous solubility and log P) of biotin conjugated 
lipid ester and lipid ester prodrugs of cyclic-cidofovir 
 
Prodrugs 
Solubility (mg/mL) in 
DDW* 
Log P 
Predicted¥ Calculated¶ 
CDF 72 ± 3 -2.89 -1.86 ± 0.39 
B-C2-cCDF 56 ± 2 0.23 -0.64 ± 0.24 
B-C6-cCDF 17 ± 1 1.04 -0.47 ± 0.18 
B-C12-cCDF 13 ± 1 2.61 -0.16 ± 0.04 
C6-cCDF 1.3 ± 0.5 3.64 2.84 ± 0.56 
C12-cCDF 1 ± 0.4 4.23 3.89 ± 1.23 
 
* Distilled deionized water 
¶ Log P = Log [(ConcentrationOctanol )/ ConcentrationWater )]  
¥ Log P from Chem draw 
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Table 9: First-order rate constant (k x 10-2) and half-life (t1/2) of biotin conjugated lipid 
prodrugs in various pH at 37 0C 
 
 pH 4.0 pH 6.0 pH 7.4 
 k (hr-1) t ½ (hr) k (hr-1) t ½ (hr) k (hr-1) t ½ (hr) 
B-C2-cCDF 1.4 ± 0.2 505 ± 67 2.2 ±0.2 318 ± 32 3.6 ± 0.3 193 ± 16 
B-C6-cCDF 6.1 ± 1.1 116 ± 23 1.8 ± 0.5 391 ± 17 1.4 ± 0.2 486 ± 18 
B-C12-cCDF 1.7 ± 0.2 406 ± 8 1.8 ± 0.4 388 ± 9 7.6 ± 0.4 90 ± 12 
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Figure 31: pH dependent degradation of (A) B-C2-cCDF, (B) B-C6-cCDF, and (C) B-C12- 
cCDF at pH 4.0,pH 6.0 and pH 7.4. Each data point represents mean ± SD (n = 4). 
 
 
(A) 
(B) 
(C) 
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Table 10: First-order rate constant (k x 10-2) and half-life (t1/2) of biotin conjugated 
lipid prodrugs in ocular tissue homogenate at 37 0C 
 
 
Retina-Choroid Vitreous humor 
 
k (hr-1) t 1/2 (hr) k (hr-1) t 1/2 (hr) 
B-C2-cCDF 2.8±0.2 24±2 1.1±0.2 65±7 
B-C6-cCDF 2.7±0.3 26±2 1.2±0.1 58±4 
B-C12-cCDF 3.9±0.4 18±2. 1.2±0.2 68±8 
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Figure 32: Enzymatic degradation in (A) Retina-choroid tissue homogenate, and (B) 
Vitreous humor homogenate of B-C2-cCDF, B-C6-cCDF, and B-C12-cCDF. Each data 
point represents mean ± SD (n = 4). 
 
 
 
(A) 
(B) 
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Interaction with SMVT Transporter 
The presence of SMVT transporter on the ARPE-19 cell line has been 
characterized previously from our laboratory. This cell line is widely used as in vitro   
model for human retinal pigment epithelium. All the biotinylated lipid ester conjugates 
of cCDF (50 µM) have shown significant reduction in uptake of [3H]-Biotin (0.25 Ci/mL 
in DPBS pH 5.5) (Fig. 33). Uptake of [3H]-Biotin was reduced by 1.32, 1.87 and 3.25 fold 
for B-C2-cCDF, B-C6-cCDF and B-C12-cCDF respectively on ARPE-19 cells. These results 
indicate the effect of lipid chain length of biotinylated lipid ester conjugates of cCDF on 
the inhibition of [3H]-Biotin uptake. Moreover, the affinity measurement of these 
prodrugs for SMVT transporter shows that all the prodrugs possess high affinity for 
SMVT transporters (Fig 34). IC50 values are listed in Table 11. These values are 
calculated with GraphPad Prism software 5.04. In addition, we also performed the 
transport of [3H]-Biotin (10 nM) across ARPE-19 monolayer using transwell. The result 
clearly indicates significant reduction in the transport of [3H]-Biotin in presence of all 
the biotinylated lipid ester conjugates of cCDF (at 50 µM concentration). However, the 
reduction in cumulative transport of [3H]-Biotin was higher in presence of B-C12-cCDF 
followed by B-C6-cCDF and B-C2-cCDF.  Cumulative transport of [3H]-Biotin across 
ARPE-19 at the end of 180 min was reduced by 44%, 58% and 70% in presence of B-C2-
cCDF, B-C6-cCDF and B-C12-cCDF respectively (Fig. 35). We also performed the cellular 
accumulation of all the prodrugs on ARPE-19 cells. Cellular accumulation of B-C2-cCDF, 
B-C6-cCDF, B-C12-cCDF, C6-cCDF, and C12-cCDF were 1.7-, 2.7-, 12.1-, 3.2- and 14.6- 
fold higher than the parent CDF, respectively (Fig. 36). 
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Figure 33: Cellular accumulation of [3H]-Biotin (0.25 µCi/mL) in the presence of 
biotinylated lipid ester prodrugs of cyclic cidofovir (50 µM) on ARPE-19 cells. Each data 
point represents mean ± SD (n = 4). * p<0.05. 
 
 
 
 
 
 
 136 
 
 
 
 
Figure 34: Dose-dependent inhibition uptake of [3H]-Biotin (0.25 μCi/mL) in the 
presence of (A) B-C2-cCDF, (B) B-C6-cCDF, and (C) B-C12-cCDF in ARPE-19 cells. Each 
data point represents mean ± SD (n = 4) 
 
 
 
(A) 
(B) 
(C) 
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Table 11: IC50 values of biotinylated lipid ester cyclic cidofovir prodrugs on 
ARPE-19 cells 
 
Prodrugs IC50* Value (µM) 
B-C2-CDF 447 ± 30 
B-C6-CDF 194 ± 30 
B-C12-CDF 70 ± 12 
 
* Calculated using graphpad prism 5.04 software. 
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(A) 
 
(B) 
 
Figure 35:  (A) Transport of [3H]-Biotin (0.25 μCi/ml) across ARPE-19 cells in 
absence and presence of biotinylated lipid ester conjugates of cCDF (50 µM). Each 
data point represents mean ± SD (n = 4). (B) Permeability comparison for control 
([3H]-Biotin) alone and in presence of B-C2-cCDF, B-C6-cCDF and B-C12-cCDF (all 
at 50 µM). 
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Figure 36: Cellular accumulation of biotin conjugated lipid prodrugs [alone and in 
presence of biotin (25 µM and 50 µM)] and lipid prodrugs on ARPE-19 cells for 60 mins. 
Each data point represents mean ± SD (n = 4). * p<0.05 and ** p<0.01 
 
 
 
 
 
 
* * * * * * 
** 
** 
** 
** 
** 
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Tissue Partition Coefficient 
Following intravitreal injection into vitreous body, the prodrugs needs to 
partition into retina-choroid in order to exert their antiviral activity. Therefore, we have 
performed the tissue partitioning experiments with biotinylated lipid ester conjugates 
of cCDF for retina-choroid and the results for all the prodrugs are listed in Table 12. 
Results indicate about 3-, 5- and 10-fold improvement in the partition of these prodrugs 
into retina-choroid relative to parent CDF. This improvement is mainly due to an 
increase lipophilicity of these conjugates. 
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Table 12: Tissue (retina-choroid) partition coefficient of biotinylated lipid ester 
prodrugs of cyclic-cidofovir 
 
Drug Partition coefficient (Retina-choroid) Fold increase 
CDF 0.29 ± 0.06 1 
B-C2-cCDF 0.89 ± 0.27 3.07 
B-C6-cCDF 1.42 ± 0.45 4.90 
B-C12-cCDF 2.84 ± 0.96 9.80 
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Computational Results 
A docking analysis was performed to examine the affinity of the biotinylated 
prodrugs towards SMVT the highest Vina docking score for each prodrug is shown in 
Table 13. The binding affinity and docking score are inversely related, meaning that a 
lower docking score corresponds with a greater binding affinity. The B-C12-cCDF 
prodrug had the greatest binding affinity for SMVT.  The B-C2-cCDF prodrug had the 
lowest binding affinity for SMVT. Fig. 37 shows each ligand in its preferred docking 
pose. Amino acid residues within 3 Å of the prodrug are shown in this figure. 
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Table 13: Docking scores of biotinylated lipid ester prodrugs of cyclic cidofovir towards 
SMVT transporter 
Structure of Prodrug Highest Docking Score 
N
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(A) 
 
(B) 
 
(C) 
 
Figure 37: Binding pose of the highest scoring prodrug conformation with SMVT. 
Each figure shows amino acid residues within 3 Å of the prodrug. (A) B-C2-cCDF; 
(B) B-C6-cCDF; and (C) B-C12-cCDF 
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5.4 Discussion 
CDF is one of the most potent drug molecule indicated in the treatment of HIV-
induced opportunistic infections such as CMV retinitis. Posterior segment delivery of 
CDF is challenging because of its high hydrophilicity and poor permeability across the 
retina (target tissue for the CMV retinitis). RPE cells display high membrane 
lipophilicity and tight junctions. So far, different approaches have been employed to 
enhance permeability of CDF such as lipid prodrugs or transporter targeted prodrugs of 
cCDF. However, individually these approaches have exhibited limited advantages. In the 
present study we have synthesized various biotinylated lipid ester conjugates of cCDF. 
We hypothesized that the presence of lipid raft will improve the interaction of these 
prodrugs with the cell membrane and transporter targeting moiety will further improve 
the translocation of these prodrugs across the plasma membrane. This may exhibit 
synergistic effect due to the simultaneous conjugation of lipid raft and transporter 
targeted moiety which may ultimately improve the uptake of these prodrugs across the 
cell layers. Our laboratory has previously confirmed the presence of SMVT transporter 
on the apical side of RPE [95]. Therefore, we sought to utilize SMVT transporter for our 
approach. We have successfully synthesized and characterized the biotinylated lipid 
ester conjugated and lipid prodrugs of cCDF (B-C2-cCDF, B-C6-cCDF, B-C12-cCDF, C6-
cCDF and C12-cCDF) using 31P NMR, 1H NMR, LC-MS/MS and HPLC (chapter 3). The 
general synthesis scheme for the prodrugs has been mentioned in chapter3. All the 
prodrugs have exhibited >95% purity along with brownish sticky (biotin conjugated 
prodrugs) or white solid crystalline (lipid prodrugs) appearance. 
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 It is well-known that the rate-limiting barrier for the uptake and transport of 
highly hydrophilic drugs like CDF is the lipophilic bilayer of the cell membrane. Hence, 
we performed the solubility and n-octanol/buffer partition coefficient studies of these 
prodrugs. The results have indicated that the solubility of biotinylated lipid ester 
conjugates of cCDF were significantly lowered relative to the parent CDF. However, 
higher water solubility of Biotinylated lipid ester conjugates of cCDF have been 
attributed due to the addition of water soluble vitamin such as biotin as the transporter 
targeting moiety to the lipid ester conjugates of cCDF. Moreover, partition coefficient 
study has shown an increment in log P value for biotin conjugated lipid prodrugs. Since, 
the lipophilic RPE prevents the entry of relatively hydrophilic antiviral drugs following 
systemic or intravitreal administration. The improved lipophilicity of synthesized 
biotinylated lipid ester conjugates of cCDF will enhance their ocular bioavailability by 
overcoming this limitation. Moreover, an enhanced lipophilicity of these prodrugs may 
enhance the melanin binding in the retina which will form the depot in the retina-
choroid for longer residence and therefore may prolong the antiviral activity [289]. 
 Furthermore, we have determined the chemical stability of all the prodrugs in 
different pH buffers (pH 1.4 to 9.4). We did not observe any appreciable degradation of 
all the prodrugs at pH 1.4. However, upon rising pH towards alkaline range, the 
degradation appears to be faster. Table 9 summarizes the apparent first order 
degradation rate constant indicating the loss of the prodrugs. The B-C12-cCDF showed 
faster degradation relative to B-C6-cCDF and B-C2-cCDF. We hypothesized that this 
could be due to steric hindrance caused by the presence of CDF and biotin at the 
terminals. This may leads to the low accessibility of phosphoester group to nucleophilic 
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attack by hydroxyl ion. Therefore, it is likely that due to the steric hindrance, 
nucleophilic attack on B-C2-cCDF is slow as compared to B-C6-cCDF and B-C12-cCDF.  
We have also performed enzymatic stability studies of all the prodrugs in the 
presence of retina-chorid and vitreous tissue homogenates. A rapid conversion of these 
prodrugs into parent drug in the retina-choroid relative to vitreous homogenates has 
been observed (Fig. 32 and Table 10). These results further indicate that all the 
prodrugs remain stable for longer duration upon intravitreal administration. Following 
active transport across deeper tissue in the retina, prodrugs will convert into its parent 
moiety to exert its antiviral activity. 
Another important objective of the present study was to target the SMVT 
transporter. Recognition of prodrugs by SMVT transporters may enhance their 
translocation within inner retinal tissues and eventually a higher concentration of drug 
can be achieved at the target site. Therefore, we performed in vitro   uptake study using 
a human retinal pigment epithelium cells ARPE-19. The results indicate that all the 
prodrugs show strong interaction with the SMVT transporter. An inhibition trend was 
observed in the following order: B-C12-cCDF > B-C6-cCDF > B-C2-cCDF. These results 
clearly indicate that elongation of lipid chain causes stronger interaction of biotin 
conjugated prodrugs with cell membrane. Moreover, high % of transport inhibition of 
[3H]-Biotin in the presence of B-C12-cCDF in comparison to B-C6-cCDF and B-C2-cCDF 
suggested the significant role of lipid raft. In addition, results of IC50 value clearly 
indicate the higher affinity of B-C12-cCDF towards SMVT transporter as compared to 
other prodrugs. Non-radioactive cellular accumulation study shows that there is 3.5, 
10.5, 32, 7 and 42 fold increase in the uptake of B-C2-cCDF, B-C6-cCDF, B-C12-cCDF, C6-
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cCDF and C12-cCDF respectively as compared to the parent CDF (Fig. 36). The observed 
cellular uptake of B-C6-cCDF and B-C12-cCDF was not more than their lipid prodrugs 
(i.e. C6-cCDF and C12-cCDF). Biotinylated lipid ester conjugates of cCDF have exhibited 
higher water solubility which may have leads to the reduced cell bilayer partitioning 
relative to the lipid prodrugs. Cellular uptake of B-C12-cCDF was found to be 
comparable to C12-cCDF wherein, the lipid raft (C12) facilitates the enhanced 
interaction of B-C12-cCDF with membrane protein and thereby assisting docking of 
biotin into the binding domain of SMVT transporter. The net effect will be rapid 
translocation across RPE cell membrane which will not be the case with lipid prodrugs. 
Thus our novel B-C12-cCDF prodrug may significantly enhance the delivery of CDF 
across lipophilic RPE.  In addition, the uptake of biotin conjugated lipid prodrugs across 
ARPE-19 was significantly inhibited by biotin (due to competitive inhibition). These 
results clearly indicate that improvement in uptake of biotin conjugated prodrugs was 
via SMVT interaction (Fig. 36). The overall results from the interaction of all biotin 
conjugated lipid prodrugs with SMVT transporters suggest that these compounds 
strongly recognized by SMVT transporter.  Moreover, results further clarify that upon 
increasing the lipid chain length of the biotinylated lipid ester conjugates of cCDF, an 
interaction with the SMVT transporter can be enhanced.  
 The major limiting factor for in vivo absorption of hydrophilic molecules is their 
low tissue partitioning. The parent drug CDF is highly hydrophilic in nature and 
following intravitreal administration a large fraction may remain in the vitreous body 
and may not partition enough into lipophilic retina-choroid. However, the tissue/water 
partition study of biotinylated lipid ester conjugates of cCDF clearly indicates an 
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improvement in the uptake into retina-choroid tissue. Since, all the prodrugs have high 
lipophilicity; these compounds may partition into retina-choroid as compare to the 
parent CDF. Moreover, due to the strong interaction with SMVT transporter, these 
prodrugs may accumulate into the deeper tissue of retina/choroid thereby improving 
the therapy. 
A docking analysis was performed to examine the affinity of the biotinylated 
prodrugs towards SMVT the highest Vina docking score for each prodrug is shown in 
Table 13. The binding affinity and docking score are inversely related, meaning that a 
lower docking score corresponds with a greater binding affinity. The B-C12-cCDF 
prodrug had the greatest binding affinity for SMVT.  The B-C2-cCDF prodrug had the 
lowest binding affinity for SMVT. Hence, it can be assumed that binding affinity for the 
prodrugs increased as more carbons were inserted between biotin and the cyclic 
cidofovir. Figure 37 shows each ligand in its preferred docking pose. Amino acid 
residues within 3 Å of the prodrug are shown in this figure. 
5.5 Conclusion 
Overall these studies have shown that B-C12-cCDF is the most promising 
prodrug among all the synthesized compounds owing to its higher lipophilicity among 
all biotinylated lipid ester conjugates of cCDF, strong interaction with SMVT 
transporters, lowest IC50 value (high affinity for SMVT), higher tissue/water partition 
coefficient, rapid conversion into parent molecule (in retina-choroid) and preferred 
docking score. Based on above findings we conclude that novel transporter targeted 
lipid prodrugs can be utilize as a viable strategy for the treatment of HCMV retinitis.  
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CHAPTER 6 
ANTIVIRAL EFFICACY OF TRANSPORTER TAREGETED LIPID ESTER AND LIPID ESTR 
PRODRUG OF CYCLIC CIDOFOVIR 
6.1 Rationale 
Human cytomegalovirus (HCMV) infection continues to be a major cause of 
morbidity in bone-marrow, solid-organ transplant recipients and patient with advanced 
HIV infection and is reported to be the most-frequent congenital infection worldwide 
occurring in 0.2%–2.5% of all live births [290].  At present, there are many therapeutics 
(e.g. Ganciclovir, Cidofovir and Foscarnet ) approved for treatment of HCMV, but in 
many cases long-term therapy is ineffective and may result in the development of 
resistance or of serious adverse effects that requires termination of treatment [291]. 
These problems clearly indicate the need for better antiviral agents against HCMV.  
Cidofovir (CDF) and its cyclic form (cCDF) is a broad spectrum antiviral agent 
active against herpes-, adeno-, polyoma-, and pox-viruses [218]. It is currently licensed 
as Vistide® for the treatment of HCMV retinitis [34]. CDF contains an ionizable 
phosphonic acid group, which exists as a dianion at physiological pH, resulting in low 
lipid membrane permeability and low bioavailability across cell and tissue. However, 
due to lack of hydrophilic nature, CDF requires administration via intermittent 
intravenous infusion and this treatment often results in significant nephrotoxicity. 
Moreover, topical ocular administration of cidofovir causes significant reduction of 
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intraocular pressure. To address this problem, biotinylated lipid ester conjugates of 
cCDF has been synthesized (Chapter 3).The prodrug strategy has been used to increase 
the selectivity of drugs for their intended target to improve drug efficacy and to reduce 
unwanted tissue/organ-specific toxicity. By definition, a prodrug does not possess any 
intrinsic biological activity and in theory, these prodrugs must be either chemically or 
enzymatically active to release parent drug. The biotinylated lipid ester conjugates of 
cCDF were designed to be stable in the vitreous humor upon intravitreal injection and 
can have enhanced transport properties across retina. Upon reaching target site of 
retina prodrug must immediately cleaved to parent CDF to exert its pharmacological 
effect. While antiviral activity of prodrug itself is not absolutely necessary, several 
conjugates (Fig. 10 and 12) were evaluated for antiviral activity against Herpesviridae 
(human cytomegalo virus, varicella-zoster virus, HSV-1 and HSV-2), Papovaviridae (BK 
and JC virus), and Poxviridae (vaccina and cow pox virus). These experiments were 
conducted by National Institute of Allergy and Infectious Disease (NIAID) via National 
Institute of Health (NIH) support project. 
6.2 Materials and Methods: 
Materials 
CDF was generously provided by Gilead Pharmaceuticals, biotinylated lipid ester 
conjugates of cCDF (B-C2-cCDF, B-C6-cCDF, B-C12-cCDF) and lipid ester conjugates of 
cCDF (C6-cCDF and C12-cCDF) were synthesized as described elsewhere (Chapter 3). 
Cell Culture   
Human foreskin fibroblast (HFF) cells were prepared from human foreskin 
tissue. The tissue was incubated at 4 °C for 4 h in Clinical Medium and then placed in 
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phosphate buffered saline (PBS) to remove the red blood cells, and resuspended in 
trypsin/EDTA solution. The tissue suspension was incubated at 37 °C and gently 
agitated to disperse the cells, which were collected by centrifugation. Cells were 
resuspended in 4 ml Clinical Medium and placed in a flask and incubated at 37 °C in a 
humidified CO2 incubator for 24 h. The media was then replaced with fresh Clinical 
Medium and the cell growth was monitored daily until a confluent monolayer has 
formed. The HFF cells were then expanded through serial passages in standard growth 
medium of MEM with Earl’s salts supplemented with 10% FBS and antibiotics. The cells 
were passaged routinely and used for assays at or below passage 10. 
Primary Cytopathic Effect (CPE) Reduction Assay 
Low passage (3-10) HFF cells were trypsinized, counted, and seeded into 96 well 
tissue culture plates in 0.1 ml of MEM supplemented with 10% FBS. The cells were then 
incubated for 24 h at 37oC. The media was then removed and 100 µl of MEM containing 
2% FBS was added to all but the first row. In the first row, 125 µl of media containing 
the experimental drug was added in triplicate wells. Media alone was added to both cell 
and virus control wells. The drug in the first row of wells was then diluted serially 1:5 
throughout the remaining. The plates were then incubated for 60 min and 100 µl of a 
virus suspension was added to each well, excluding cell control wells which received 
100 µl of MEM. The plates were then incubated at 37oC in a CO2 incubator for three days 
for HSV-1 and HSV-2, 10 days for VZV, VACV and CPXV, or 14 d for CMV. After the 
incubation period, media was aspirated and the cells stained with crystal violet in 
formalin for 4h. The stain was then removed and the plates were rinsed until all excess 
stain was removed. The plates were allowed to dry for 24 h and the amount of CPE in 
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each row determined using a BioTek Multiplate Autoreader. EC50 and CC50 values 
were determined by comparing drug treated and untreated cells using a computer 
program. 
Secondary Plaque Reduction Assay 
Monolayers of HFF cells were prepared in six-well plates and incubated at 37°C 
for 2 d to allow the cells to reach confluency. Media was then aspirated from the wells 
and 0.2 mL of virus was added to each of three wells to yield 20-30 plaques in each well. 
The virus was allowed to adsorb to the cells for 1 h and the plates were agitated every 
15 minutes. Compounds were diluted in assay media consisting of MEM with Earl’s salts 
supplemented with 2% FBS, and antibiotics.  Solutions ranging from 300 µM to 0.1 µM 
were added to duplicate wells and the plates were incubated for various times, 
depending on the virus used. For HSV-1 and -2, the monolayers were then stained with 
1% crystal violet in 20% methanol and the unbound dye removed by washing with 
dH20. For assays with HCMV and VZV, the cell monolayers were stained with 1% 
Neutral Red solution for 4 h then the stain was aspirated and the cells were washed 
with PBS. For all assays, plaques were enumerated using a stereomicroscope and the 
concentration of compound that reduced plaque formation by 50% (EC50) was 
interpolated from the experimental data. 
Screening Assays for EBV 
Primary DNA Hybridization Assay 
Assays for EBV were performed in Akata cells that were induced to undergo a 
lytic infection. Experimental compounds were diluted in 96-well plates to yield 
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concentrations ranging from 20 to 0.0064 µM. Akata cells were added to the plates, 
induced to undergo a lytic infection and incubated for 72 h.   
For all assays, an alkaline denaturation buffer was added to each well to denature the 
DNA and a 50 µL aliquot was aspirated through a nylon membrane. The membranes 
were then allowed to dry before equilibration in DIG Easy Hyb (Roche Diagnostics, 
Indianapolis, IN) at 56 °C for 30min. Specific digoxigenin (DIG)-labeled probes were 
prepared for each virus and corresponded to coordinates 96802–97234 in EBV 
genome. Membranes with EBV DNA were hybridized overnight and followed by 
sequential washes 0.2 × SSC with 0.1% SDS and 0.1 × SSC with 0.1% SDS at the same 
temperature. Detection of specifically bound DIG probe was performed with anti-DIG 
antibody using the manufacturer’s protocol (Roche Diagnostics). An image of the 
photographic film was captured and quantified with QuantityOne software (Bio-Rad) 
and compound concentrations sufficient to reduce the accumulation of viral DNA by 
50% (EC50), were interpolated from the experimental data. 
Secondary PCR Assay 
Secondary assays for EBV were also performed in Akata cells with the following 
modification.  First, each compound was evaluated in triplicate wells and a wider range 
of compound concentrations was evaluated.  Second, Akata cells were induced to 
undergo lytic replication for 1 h prior to the addition of test compounds to identify 
compounds that inhibit the induction step.  Finally, total DNA is purified using a Wizard 
SV 96 well purification kit (Promega) and viral DNA was quantified by real time PCR. 
The primers 5'-CGG AAG CCC TCT GGA CTT C-3' and 5'-CCC TGT TTA TCC GAT GGA 
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ATG-3' were used with the fluorescent probe, 5’-6FAM-TGT ACA CGC ACG AGA AAT GCG 
CC-TAMRA-3' corresponding to coordinates 155959–155981 in the EBV genome. A 
plasmid containing the amplified region was used to provide absolute quantification. 
PCR Assays for BKV and JCV 
Primary assays for BK virus were performed in 96-well plates containing 
monolayers of HFF cells.  Compound dilutions were prepared in plates containing cells 
which were subsequently infected at with the Gardner strain of BK virus. After a 7 d 
incubation, total DNA was prepared with a Wizard SV 96 well purification kit and 
genome copy number was quantified by real time PCR using the primers 5’- AGT GGA 
TGG GCA GCC TAT GTA-3’, 5’- TCA TAT CTG GGT CCC CTG GA-3’ and probe 5’-6-FAM 
AGG TAG AAG AGG TTA GGG TGT TTG ATG GCA CAG TAMRA-3’. Plasmid pMP526 
served as the DNA standard for quantitation purposes. Compounds that were positive 
in this assay were confirmed in a similar assay in 96-well plates with the compounds 
added 1h following infection to identify compounds that inhibit early stages of 
replication including adsorption and penetration. Genome copy number was 
determined by methods described above. 
Primary evaluation of compounds against JC virus were also performed by 
methods similar to those for BK virus primary assays but were done in COS7 cells and 
utilized the 1-4 strain of JCV in COS7 cells.  Viral DNA was quantified using primers 5’-
CTG GTC ATG TGG ATG CTG TCA-3’ and 5’-GCC AGC AGG CTG TTG ATA CTG-3’ and 
probe 5’-6-FAM-CCC TTT GTT TGG CTG CT-TAMRA-3 together with the plasmid 
pMP508 to provide a standard curve for absolute quantification. Secondary assays 
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against JCV were also performed in COS7 cells by methods similar to those for BK virus 
to identify compounds that inhibited adsorption or penetration of the virus. 
Cytotoxicity Assays 
Every antiviral assay included a parallel cytotoxicity assay with the same cells 
used for each virus, the same cell number, the same drug concentrations, and the same 
incubation times to provide the same drug exposure. To ensure that the cytotoxicity of 
all compounds could be compared directly, we also performed a standard neutral red 
uptake cytotoxicity assay for all compounds in confluent HFF cells with a 7 d incubation 
period. 
Neutral Red Uptake Cytotoxicity Assays 
Briefly, HFF cells were seeded into 96-well tissue culture plates at a 2.5 x 104 
cells/well in standard growth medium.  After 24 h of incubation, medium was replaced 
with MEM containing 2% FBS, and compounds were added to the first row and then 5-
fold serial dilutes were used to generate a series of compound concentrations with a 
maximum of 300 μM. Assay plates were then incubated for 7 d and 100 μl of a 0.66 
mg/ml neutral red solution in PBS was added to each well and the plates incubated for 
1 h. The stain was then removed, the plates rinsed with PBS and the dye internalized by 
viable cells was solubilized in PBS supplemented with 50% ethanol and 1% glacial 
acetic acid. The optical density was then determined at 550 nm and CC50 values were 
interpolated from the experimental data. 
For all plaque reduction assays, neutral red cytotoxicity assays are performed on 
a parallel set of 6-well plates containing HFF cells that received the same compound 
concentrations as used for the antiviral assays, but remained uninfected. The 
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cytotoxicity plates were removed from the incubator on the same day as each antiviral 
assay and the cell monolayer was stained for 6 h with 2 ml of a neutral red solution at a 
concentration of 0.165 mg/ml in PBS. The dye was then removed, residual dye rinsed 
from the cells with PBS, and cell monolayers were inspected visually for any signs of 
toxicity. 
Cytotoxicity in Lymphocyte Assays 
Cell viability in all assays with lymphocytes was assessed with the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega). Briefly, assay plates were incubated at 
ambient temperature for 30 min then 50 µL of CellTiter-Glo reagent was added to each 
well and the plates were mixed for 2 min on an orbital shaker to lyse the cells. Plates 
were then incubated for an additional 10 min at ambient temperature and the 
luminescence was quantified on a luminometer. Standard methods were used to 
calculate drug concentrations that inhibited the proliferation of Akata, HSB-2, BCLB-1, 
or Molt-3 cells by 50% (CC50). 
Cell Proliferation Assays 
HFF Cells were seeded at a low density into six-well plates using 2.5 x 104 
cells/well and standard culture medium. After 24 h, the medium was aspirated, and a 
range of compound solutions in the growth medium was prepared starting at 300 µM, 
and added to duplicate wells. The plates were incubated for 72 h at 37 °C, the cells were 
then dislodged with trypsin and counted on a Beckman Coulter Counter. Compound 
concentrations that reduced cell proliferation by 50% were interpolated from 
experimental data.  
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Assessment of Antiviral Activity 
To determine if each compound has sufficient antiviral activity that exceeds its 
level of toxicity, a selectivity index (SI) was calculated according to CC50/EC50. 
6.3 Results 
The in vitro antiviral potencies of the parent drug, CDF, and the prodrugs, B-C2-
cCDF, B-C6-cCDF, B-C12-cCDF, C6-cCDF and C12-cCDF were determined against various 
herpes type of viruses, Papovaviridae and Poxviridae. The compounds were screened 
against human cytomegalovirus (HCMV), herpes simplex virus 1 and 2 (HSV-1 and HSV-
2), varicella - zoster virus (VZV), Epstein - Barr virus (EBV), BK and JC viruses, Vaccina 
(VACV) and Cow pox viruses (CXPV). Summary of viral strains, cell lines, and 
concentration ranges and assay methods employed for antiviral screening against all 
viruses are listed in Table 14. CDF serves as a control against all the virus strains and 
EC50 (effective concentration to inhibit virus by 50%), EC90 (effective concentration to 
inhibit virus by 90%), and SI (selective index) were determine and based on the results 
whether the prodrugs possess high, moderate, low or no antiviral efficacy were 
determined (Table 15-19). Human foreskin fibroblast (HFF)were infected with HCMV, 
HSV-1, HSV-2, VZV, BK and JC virus (on COS7 cells), Vaccina and Cow pox viruses, and 
EBV virus. The antiviral activities of biotinylated lipid ester conjugates of cCDF, lipid 
ester conjugates of cCDF and CDF were assessed by cytopathic effect (CPE) via crystal 
violet (plaque reduction assay), secondary plaque reduction assay and DNA 
hybridization assay. The cytotoxic effect of prodrugs on HFF and COS7 cells by Neutral 
red uptake cytotoxicity assays and cell proliferation assay were also determined. The 
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antiviral outcomes revealed that B-C12-cCDF shows good in vitro antiviral efficacy with 
2 to 25 fold decreases in EC50 value against HCMV, HSV-2 and BK virus compare to 
parent drug CDF (Table 15, 16, 17). B-C6-cCDF shows good in vitro antiviral efficacy 
with 1.2 to 4.5 fold decreases in EC50 values against HCMV and HSV-2 viruses (Table 
15, 16). C12-cCDF also shows high in vitro antiviral efficacy with 3 to 30 fold decreases 
in EC50 values against HSV-2, BK, JC, VACV and CXPV viruses (Table 16, 17). 
Interestingly, B-C2-cCDF and C6-cCDF did not show good in vitro antiviral efficacy 
against any of the tested viruses. 
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Virus tested HCMV HSV-1 HSV-2 BK Virus JC Virus VACV CPV VZV EBV 
Virus Strain AD169 E-377 MS MAD3 MAD4 Copenhagen Brighton Ellen Akata 
Cell line HFF HFF HFF HFF COS7 HFF HFF HFF Akata 
Vehicle DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO 
Control 
Concentration 
(µM) 
0.032-100 0.032-100 0.032-100 0.032-100 0.032-100 0.032-100 0.032-100 0.032-100 0.032-100 
Prodrug 
Concentration 
(µM) 
0.096-100 0.032-100 0.032-100 0.096-100 0.096-100 0.096-100 0.096-100 0.096-100 0.032-100 
Assay Method 
Crystal 
Violet 
(Plaque 
reduction) 
Crystal 
Violet 
(Plaque 
reduction) 
Crystal 
Violet 
(Plaque 
reduction) 
Quantitative 
PCR 
Quantitative 
PCR 
Neutral red 
(Plaque 
reduction) 
Neutral red 
(Plaque 
reduction) 
Neutral red 
(Plaque 
reduction) 
DNA 
hybridization 
Table 14: List of viral strains, cell lines, concentration ranges and assay methods used for antiviral prodrugs screening
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Table 15: In vitro antiviral activity (EC50 and EC90), cytotoxicity (CC50) and their 
selectivity indices (SI50) of prodrugs against human cytomegalovirus (HCMV)  
 
Drug/Prodrug 
Virus 
strain 
EC50 EC90 CC50 SI50 Activity 
Cidofovir HCMV 1.24 1.95 183.2 148 HI 
B-C2-cCDF HCMV 2.06 3.12 254.3 123 HI 
B-C6-cCDF HCMV 1.03 1.7 >300 >291 HI 
B-C12-cCDF HCMV 0.57 2.78 >300 >536 HI 
C6-cCDF HCMV >60 >60 267.9 <4 NA 
C12-cCDF HCMV >60 >60 114.3 <2 NA 
 
EC50 = Drug/prodrug concentration that reduces viral replication by 50%, in units of μM concentration 
EC90 = Drug/prodrug concentration that reduces viral replication by 90%, in units of μM concentration 
CC50 = Drug/prodrug concentration that reduces cell viability by 50%, in units of μM concentration 
SI50  = Selectivity index calculated as the CC50/EC50 
Activity     HI= High activity, MOD= Moderate activity, LOW= Low activity, NA= No activity 
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Table 16: In vitro antiviral activity (EC50 and EC90), cytotoxicity (CC50) and their 
selectivity indices (SI50) of prodrugs against Herpes simplex virus (HSV-1) and Herpes 
simplex virus (HSV-2).  
 
Drug/Prodrug 
Virus 
strain 
EC50 EC90 CC50 SI50 Activity 
Cidofovir HSV-1 <0.096 >300 >300 >3125 HI 
B-C2-cCDF HSV-1 59.38 >300 >300 >5 LO 
B-C6-cCDF HSV-1 1.09 >300 >300 >275 HI 
B-C12-cCDF HSV-1 >300 >300 >300 1 NA 
C6-cCDF HSV-1 >300 >300 >300 1 NA 
C12-cCDF HSV-1 1.39 2.17 >300 >216 HI 
Cidofovir HSV-2 54.41 >300 >300 >6 LO 
B-C2-cCDF HSV-2 18.93 >300 >300 >16 MOD 
B-C6-cCDF HSV-2 12.16 29.18 >300 >25 HI 
B-C12-cCDF HSV-2 2.16 >3.71 >300 >139 HI 
C6-cCDF HSV-2 >300 >300 >300 1 NA 
C12-cCDF HSV-2 2.09 158.7 >300 >144 HI 
 
EC50 = Drug/prodrug concentration that reduces viral replication by 50%, in units of μM concentration 
EC90 = Drug/prodrug concentration that reduces viral replication by 90%, in units of μM concentration 
CC50 = Drug/prodrug concentration that reduces cell viability by 50%, in units of μM concentration 
SI50  = Selectivity index calculated as the CC50/EC50 
Activity     HI= High activity, MOD= Moderate activity, LOW= Low activity, NA= No activity 
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Table 17: In vitro antiviral activity (EC50 and EC90), cytotoxicity (CC50) and their 
selectivity indices (SI50) of prodrugs against BK and JC virus.  
 
Drug/Prodrug 
Virus 
strain 
EC50 EC90 CC50 SI50 Activity 
Cidofovir BKV 28.6 >300 >300 >10.5 MOD 
B-C2-cCDF BKV 23.8 >300 >300 >12.6 MOD 
B-C6-cCDF BKV 31.4 >300 >300 >9.6 MOD 
B-C12-cCDF BKV 13.8 >300 >300 >21.6 HI 
C6-cCDF BKV 248.8 >300 >300 >1.2 NA 
C12-cCDF BKV 1.4 31.8 >300 >214 HI 
Cidofovir JCV 6.61 34.91 131.1 20 MOD 
B-C2-cCDF JCV 10.54 267 182.6 17 MOD 
B-C6-cCDF JCV 35.93 >300 >300 >8 LO 
B-C12-cCDF JCV >60 >60 175.6 <3 NA 
C6-cCDF JCV 145 269 >300 >2 NA 
C12-cCDF JCV 0.23 2.06 11.27 49 HI 
  
EC50 = Drug/prodrug concentration that reduces viral replication by 50%, in units of μM concentration 
EC90 = Drug/prodrug concentration that reduces viral replication by 90%, in units of μM concentration 
CC50 = Drug/prodrug concentration that reduces cell viability by 50%, in units of μM concentration 
SI50  = Selectivity index calculated as the CC50/EC50 
Activity     HI= High activity, MOD= Moderate activity, LOW= Low activity, NA= No activity 
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Table 18: In vitro antiviral activity (EC50 and EC90), cytotoxicity (CC50) and their 
selectivity indices (SI50) of prodrugs against Epstein-Barr (EBV) and Varicella-Zoster 
virus (VZV).  
 
Drug/Prodrug 
Virus 
strain 
EC50 EC90 CC50 SI50 Activity 
Cidofovir EBV 9.16 44 >60 >6.6 HI 
B-ACV EBV 22.3 52.8 >60 >2.69 MOD 
B-C2-cCDF EBV 53.45 >60 >60 >1.1 NA 
B-C6-cCDF EBV >60 >60 >60 1 NA 
B-C12-cCDF EBV 39.92 >60 >60 >1.5 NA 
C6-cCDF EBV >60 >60 >60 1 NA 
C12-cCDF EBV >60 >60 >60 1 NA 
Cidofovir VZV 0.11 0.34 241.7 2197 HI 
B-C2-cCDF VZV 0.17 1.53 >300 >1765 HI 
B-C6-cCDF VZV 0.9 >300 >300 >333 HI 
B-C12-cCDF VZV 3.3 11.17 >300 >91 HI 
C6-cCDF VZV 1.35 11.58 >300 >222 HI 
C12-cCDF VZV >60 >60 208 <3 NA 
 
EC50 = Drug/prodrug concentration that reduces viral replication by 50%, in units of μM concentration 
EC90 = Drug/prodrug concentration that reduces viral replication by 90%, in units of μM concentration 
CC50 = Drug/prodrug concentration that reduces cell viability by 50%, in units of μM concentration 
SI50  = Selectivity index calculated as the CC50/EC50 
Activity     HI= High activity, MOD= Moderate activity, LOW= Low activity, NA= No activity 
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Table 19: In vitro antiviral activity (EC50 and EC90), cytotoxicity (CC50) and their 
selectivity indices (SI50) of prodrugs against Vaccina (VACV) and Cow-pox virus 
(CPXV).  
 
Drug/Prodrug 
Virus 
strain 
EC50 EC90 CC50 SI50 Activity 
Cidofovir VACV 9.08 >300 >300 >33 MOD 
B-C2-cCDF VACV >300 >300 >300 1 NA 
B-C6-cCDF VACV 276.4 >300 >300 >1 NA 
B-C12-cCDF VACV >300 >300 >300 1 NA 
C6-cCDF VACV >300 >300 >300 1 NA 
C12-cCDF VACV 1.5 >300 >300 >200 HI 
Cidofovir CPXV 4.25 >300 >300 >71 HI 
B-C2-cCDF CPXV >300 >300 >300 1 NA 
B-C6-cCDF CPXV 205.6 >300 >300 >1 NA 
B-C12-cCDF CPXV >300 >300 >300 1 NA 
C6-cCDF CPXV >300 >300 >300 1 NA 
C12-cCDF CPXV 1.44 >300 >300 >208 HI 
 
EC50 = Drug/prodrug concentration that reduces viral replication by 50%, in units of μM concentration 
EC90 = Drug/prodrug concentration that reduces viral replication by 90%, in units of μM concentration 
CC50 = Drug/prodrug concentration that reduces cell viability by 50%, in units of μM concentration 
SI50  = Selectivity index calculated as the CC50/EC50 
Activity     HI= High activity, MOD= Moderate activity, LOW= Low activity, NA= No activity 
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6.4 Discussion 
 Based on our hypothesis of transporter targeted and lipid mediated cellular 
accumulation of our novel biotinylated lipid ester conjugates of cCDF, we tested the 
antiviral efficacy of our prodrugs against herpesviridae (HCMV, HSV-1 and 2, EBV, VZV), 
papovaviridae (BK and JC virus) and poxviridae (VACV and CPXV) viruses. Our results 
shows that B-C12-cCDF shows excellent antiviral efficacy with the range of 2 to 25 fold 
decrease in EC50 value against HCMV, HSV-2 and BK viruses. Cidofovir is indicated in 
treatment of HCMV (EC50 = 1.24 µM) and our data suggest that B-C12-cCDF has 2.17 
fold (EC50 = 0.57 µM) decrease in EC50 values.  In addition, cidofovir is generally not 
indicated in treatment of HSV-2 (EC50 = 54.41 µM) but B-C12-cCDF shows 25 fold 
reduction in EC50 value (EC50 = 2.16 µM) and in case of BK viruses also there was 2 
fold reduction in EC50 value (for CDF EC50 = 28.6 µM, for B-C12-cCDF EC50 = 13.8 µM). 
Hence, data from previous studies and EC50 values suggest that our hypothesis of 
transporter mediated active and lipid raft mediated passive diffusion can lead to 
synergistic effect on cellular accumulation and can also improve the antiviral efficacy. 
B-C6-CDF also shows some marginal improvement in in vitro antiviral efficacy with 1.2 
to 4.5 fold decrease in EC50 values against HCMV and HSV-2. Interestingly, C12-cCDF 
shows excellent in vitro antiviral efficacy with 3 to 30 fold decrease in EC50 value 
against BK, JC, HSV-2, CPXV and VACV with the highest reduction in EC50 value against 
JC virus (for CDF EC50 = 6.61 µM , for C12-cCDF EC50 = 0.23 µM). Upon careful analysis 
of the in vitro antiviral method for BK and LC virus and comparing them with HCMV, 
HSV-1 and 2, EBV and VZV, it was observed that the former case involves incubation of 
virus strains with the prodrugs to inhibit the entry and replication of the viruses, 
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whereas, in the latter case the virus strain was incubated first and then the prodrugs 
solution were added to reduce the replication of the virus. Now, since the lipid ester 
conjugates of cCDF have higher lipophilicity compare to biotinylated lipid ester 
conjugates of cCDF and hence in case of BK and JC viruses the lipid ester conjugates of 
cCDF will have higher cellular interaction compare to biotinylated lipid ester conjugates 
of cCDF and hence can inhibit the entry of virus faster. In contrast, in vitro antiviral 
efficacy of HCMV, HSV-1 and 2, EBV and VZV, the cell were incubated with virus first 
and then the prodrugs solution were added and hence, in these cases B-C12-cCDF 
shows comparable in vitro antiviral efficacy to C12-cCDF. Moreover, overall biotinylated 
lipid ester conjugates of cCDF has high enzymatic reversion or half life time (in hours) 
and hence, it may be possible that these prodrugs may take longer time to shows it 
antiviral efficacy. 
6.5 Conclusion 
In summary, these novel biotinylated lipid ester conjugates of cCDF exhibited 
excellent antiviral activity against HCMV, HSV-2, BK and JC viruses. These biotinylated 
lipid ester conjugates of cCDF appear to be promising drug candidates for the treatment 
of HCMV, HSV-2 and JC virus and may lower CDF mediated side effects such as ocular 
inflammation and lowering of intraocular pressure (IOP) and can improve the patient 
compliance. 
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CHAPTER 7 
CIDOFOVIR AND PRODRUG LOADED POLY LACTIDE POLY GLYCOLIDE (PLGA) 
NANOPARTICLE FORMULATION FOR SUSTAINED DELIVERY 
7.1 Rationale 
Cidofovir (CDF) and its cyclic form (cCDF) represent a new class of antiviral 
agent with potent in vitro and in vivo activity against broad spectrum of herpes viruses 
[292]. Cytomegalovirus (CMV) retinitis is the most common opportunistic infection 
affecting the eye in patients with the acquired immune deficiency syndrome (AIDS) 
[293]. CMV retinitis, a sight threatening ocular infection, occurs in 20% to 40% of HIV 
infected patients. Previously, therapeutic treatment regimens for CMV infection include 
parenteral ganciclovir or foscarnet, oral ganciclovir and local or intravitreal injections 
of either of these agents. In patients who are intolerant to these drugs or resistant to the 
antiviral activity of these agents, few therapeutic options have been available in the 
past. CDF is a new nucleotide analogue that is highly active against CMV. Both 
intravitreal and intravenous CDF have been shown to be comparable to the standard 
therapies of intravenous or intravitreal ganciclovir or foscarnet in delaying the 
progression of CMV retinitis of patients with AIDS [294]. Moreover, distinct from 
ganciclovir and other nucleoside analogs currently used for clinical therapy of CMV 
infection, CDF does not require virally encoded thymidine kinase for conversion to the 
active metabolite [295]. In addition, an intravitreal administration of CDF has been 
shown to be effective in the treatment CMV infection in animal models [296].  However, 
there are reports available which suggest that 20 µg dose of intravitreal CDF causes 
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uveitis and a slight lowering of the intraocular pressure which appear to be associated 
with an effect on ciliary body [297, 298]. Moreover, other studies showed that the 
intravitreal injection of 20 µg/0.1 mL CDF every 5 weeks resulted in a median time of 
retinitis progression of 63 days, which compares favorably with the outcomes achieved 
with the daily intravenous administration of ganciclovir or foscarnet.  
Many of these inconveniences such as ocular side effects and frequent 
intravitreal injection can be overcome by the use of sustained/controlled drug delivery 
dosage forms which allows a reduction in the number of injections as well as reduced 
ocular side effects. Among, sustained drug delivery systems like, gel, liposomes, 
microparticle and nanoparticle, the nanoparticle drug delivery has demonstrated 
promising results in ophthalmic drug delivery over a decade. Over the past years, it has 
been observed that nanoparticles did not induce inflammatory reactions in the retinal 
tissue or disturb the organization of the surrounding ocular tissues.  Moreover, various 
studies have also shown that intravitreal administration of poly-lactic acid–co-glycolic 
acid (PLGA) nanoparticles did not generate organ-specific autoimmune phenomena 
[299].  Compelling the aforementioned information into account, it was hypothesized 
that CDF and their prodrug-loaded PLGA nanoparticles could lead to controlled release 
of the drug following a single intravitreal injection and achieve the same effect as 
multiple injections of the conventional agent. Moreover, a reduction in the number of 
injections and sustained release may reduce its ocular side effects and improve the 
patient’s compliance. Therefore, the primary objective of the present study was to 
prepared PLGA encapsulated nanoparticle of CDF and their biotinylated lipid ester and 
lipid ester conjugates of cCDF for the intravitreal administration. 
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7.2 Materials and methods 
Materials 
Poly-lactic acid–co-glycolic acid (PLGA) 50/50 (molecular weight  40,000), PLGA 
75:25 (molecular weight 66,000) and PLGA 85:15 (molecular weight 50,000-75,000) 
was purchased from Sigma-Aldrich (St. Louis, MO). Poly (vinyl alcohol) (PVA) with an 
average molecular weight of 30,000–70,000 was obtained from Sigma-Aldrich (St. 
Louis, MO). CDF was a gift sample from Gilead Science and prodrugs were synthesized 
according to describe previously (Chapter 3). All the solvent were of HPLC grades.  
PLGA Nanoparticles of CDF 
Preliminary batch W1/O/W2 multiple emulsification method (Fig. 38): For the 
preliminary experiments, PLGA polymer such as 50:50 were utilized to prepare CDF 
encapsulated nanoparticles. Nanoparticles were prepared according to published 
protocol with minor modifications [300]. In brief, CDF (each 2.5 mg) and PLGA (10 mg) 
were dissolved separately in 150 µL and 600 µL of DDI and dichloromethane, 
respectively. Aqueous solution of drug and prodrug were emulsified (W1/O) into 
organic phase by adding drop wise to the polymeric solution (organic phase) under 
sonication (2 watt) (Fisher 100 Sonic Dismembrator, Fisher Scientific) for 45 sec. This 
was followed by addition of primary emulsion (W1/O) in to the 1.2 mL of 2% PVA 
solution drop wise under sonication (2 Watt) for 45 s to generate multiple emulsion 
(W1/O/W2). The multiple emulsions was finally diluted with 3.8 mL of 2 % PVA and 
stirred at room temperature for 5 min. During sonication, samples were kept in ice bath 
to prevent any overheating. Subsequently, samples were gently stirred at room 
temperature for 4 h followed by exposure to low pressure for 1 h to ensure complete 
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removal of residual solvent. Resulting nanoparticles were centrifuged (22000g, 60 
mins) and washed 3 times with distilled deionized water to remove unentrapped 
prodrug and residual PVA. Nanoparticles were freeze dried over 24 h in 5% w/v of 
mannitol solution and stored at -20°C for further characterization.   
Final batch of nanoparticle: For the final batches similar protocol (as mentioned 
above) was employed to prepare CDF entrapped nanoparticles utilizing PLGA (50:50), 
at the drug to polymer ratios of 1:10, 1:15 and 1:20. Nanoparticles were freeze dried 
over 24 h in 5% w/v of mannitol solution and stored at -20 °C for further 
characterization for their entrapment efficiency, loading, size, zeta potential and 
morphology. Nanoparticles from all the batches were employed for in vitro release in 
phosphate buffer pH 7.4. 
PLGA Nanoparticle of Biotinylated Lipid Ester Conjugates of cCDF (B-C12-cCDF) 
Preliminary batch W1/O/W2 multiple emulsification method (Fig. 38): For the 
preliminary experiments, PLGA polymer such as 75:25 were utilized to prepare 
Biotinylated lipid ester prodrug of cyclic Cidofovir (B-C12-cCDF) encapsulated 
nanoparticles. Nanoparticles were prepared according to published protocol with 
minor modifications [300]. In brief, B-C12-cCDF (each 2.5 mg) and PLGA (10 mg) were 
dissolved separately in 150 µL and 600 µL of DDI:DCM (80:20) and dichloromethane, 
respectively. Aqueous solution of drug and prodrug were emulsified (W1/O) into 
organic phase by adding drop wise to the polymeric solution (organic phase) under 
sonication (2 watt) (Fisher 100 Sonic Dismembrator, Fisher Scientific) for 45 sec. This 
was followed by addition of primary emulsion (W1/O) in to the 1.2 ml of 2% PVA 
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solution drop wise under sonication (2 Watt) for 45 sec to generate multiple emulsion 
(W1/O/W2). The multiple emulsions was finally diluted with 3.8 mL of 2 % PVA and 
stirred at room temperature for 5 min. During sonication, samples were kept in ice bath 
to prevent any overheating. Subsequently, samples were gently stirred at room 
temperature for 4 h followed by exposure to low pressure for 1 h to ensure complete 
removal of residual solvent. Resulting nanoparticles were centrifuged (22000g, 60 
mins) and washed 3 times with distilled deionized water to remove un-entrapped 
prodrug and residual PVA. Nanoparticles were freeze dried over 24 h in 5% w/v of 
mannitol solution and stored at -20 °C for further characterization.   
Final batch of nanoparticle: For the final batches similar protocol (as mentioned 
above) was employed to prepare B-C12-cCDF entrapped nanoparticles utilizing PLGA 
(75:25), at the prodrug to polymer ratios of 1:10, 1:15 and 1:20. Nanoparticles were 
freeze dried over 24 h in 5% w/v of mannitol solution and stored at -20 °C for further 
characterization for their entrapment efficiency, loading, size, zeta potentail and 
morphology. Nanoparticles from all the batches were employed for in vitro release in 
phosphate buffer pH 7.4. 
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Figure 38: Schematic diagram of cidofovir and B-C12-cCDF loaded PLGA nanoaprticle 
preparation. 
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PLGA Nanoparticle of Lipid Ester Conjugates of cCDF (C12-cCDF) 
Preliminary experiment (O/W single emulsion) (Fig. 39): Different grade of 
PLGA polymer such as PLGA 85:15, 75:25 and 50:50 were utilized to prepare prodrug 
(C12-cCDF) encapsulated nanoparticles. Nanoparticles were prepared according to 
published protocol with minor modifications [300]. In brief, C12-cCDF (2.5 mg) and 
PLGA (25 mg) were dissolved separately in 250 µL and 750 µL of dichloromethane, 
respectively followed by vigorous mixing of both the solutions to prepare organic 
phase. Organic phase was added drop-wise in an aqueous phase (20 mL) containing 2% 
w/v of PVA. O/W primary emulsion was generated by applying constant sonication 
(Fisher 100 Sonic Dismembrator, Fisher Scientific) at a power output of 5 W for 5 min. 
During sonication, samples were kept in ice bath to prevent any overheating. 
Subsequently, samples were gently stirred at room temperature for 4 h followed by 
exposure to low pressure for 1 h to ensure complete removal of residual solvent. 
Resulting nanoparticles were centrifuged (22000g, 60 mins) and washed 3 times with 
distilled deionized water to remove unentrapped prodrug and residual PVA. 
Nanoparticles were freeze dried over 24 h in 5% w/v of mannitol solution and stored at 
-20 °C for further characterization.  
Final batch of nanoparticle: For the final batches similar protocol (as mentioned 
above) was employed to prepare C12-cCDF entrapped nanoparticles utilizing PLGA 
(85:15), at the prodrug to polymer ratios of 1:10, 1:15 and 1:20. Nanoparticles were 
freeze dried over 24 h in 5% w/v of mannitol solution and stored at -20 °C for further 
characterization for their entrapment efficiency, loading, size, zeta potential and 
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morphology. Nanoparticles from all the batches were employed for in vitro release in 
phosphate buffer pH 7.4. 
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Figure 39: Schematic diagram of C12-CDF loaded PLGA nanoparticle preparation  
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Entrapment Efficiency (EE) 
The entrapment efficiency was estimated by dissolving 10 mg of NP in 200 µL of 
DMSO followed by sonication to ensure complete dissolution of NP and later 800 µL of 
DDW was added in order to precipitate polymer chains (for CDF and B-C12-cCDF). 
Similarly, in case of C12-cCDF, 10 mg of NP were dissolved in 1 mL of dichloromethane. 
Finally, the polymer suspension/solution was centrifuged at 5000 X g at 4 °C for 30 min 
and clear supernatant was analyzed for prodrug content by HPLC assay method 
reported elsewhere. EE and loading efficiency were calculated using Equations 7 and 8, 
respectively: 
Entrapment efficiency (%)   =
Amount of prodrug in nanoparticles
Initial amount of prodrug
X   100
.....................Eq. 7 
Loading efficiency   =
Weight of prodrug in nanoparticles
Weight of nanoparticles
X   100
 .......................Eq. 8 
In Vitro Prodrug Release Study 
In vitro prodrug release studies for CDF, B-C12-cCDF and C12-cCDF 
encapsulated NP were carried out at 37 °C utilizing an equilibrium dialysis method. In 
brief, a known amount of NP (equivalent of 500 µg of CDF, B-C12-cCDF and C12-cCDF) 
were suspended in 500 µL of phosphate-buffered saline (PBS, pH 7.4) and subsequently 
introduced in a dialysis membrane with a 2000 Da molecular weight cut-off. Dialysis 
was performed against 5 mL of PBS. Vials were placed in a shaker water bath at 37 ± 0.5 
°C and 60 oscillations/min. At predetermined time intervals, samples were collected 
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and entire release medium was replaced with equal volume of fresh PBS to maintain 
sink condition. Amount of released was analyzed by HPLC assay method. Experiments 
were carried out in triplicates. The results were plotted as mean ± SD. The release data 
was fitted for zero order first order, Higuchi and Korsmeyer-Peppas model to 
determine the kinetics of drug/prdrug release. 
Particle Size and Zeta Potential 
  Nanoparticle size and polydispersity were estimated by diluting freeze-dried 
nanoparticles in DDW and the resulting samples were analyzed by a dynamic light 
scattering technique (Zetasizer Nano ZS, Malvern Instruments Ltd, Worcestershire, UK) 
at room temperature (RT). Zeta potential of the nanoparticles was estimated in 
triplicates by employing similar instrumental technique.   
Surface Morphology 
  Scanning electron microscopy (SEM) images were obtained to study morphology 
of nanoparticles. A few mg of freeze dried nanoparticles was placed on a nucleopore 
filter in a hand-pumped vacuum chamber with a permeable membrane supporting the 
filter. Vacuum was applied to enhance the filtration rate. Filters were mounted on SEM 
stubs with double-sticky carbon tabs and the edges were coated with colloidal silver for 
conductivity. The samples were then sputter-coated with platinum for 1 min at 20 mA 
current. Images were taken on a Hitachi S4700 field-emission SEM at accelerating 
voltages of 5 and 10 KV. 
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7.3 Results 
PLGA NanoparticleS for CDF 
PLGA 50:50 is more hydrophilic because of equal percentage of lactide and 
glycolide monomers in polymer chains. Hydrophilic interactions between the CDF and 
polymer (PLGA 50:50) can impart higher entrapment and loading efficiency relative to 
other grades of PLGA. Hence, we prepared nanoparticles of CDF using PLGA 50:50. The 
initial nanoparticle formulation showed higher entrapment and loading efficiency for 
cidofovir and therefore, polymer PLGA 50:50 were utilized for further optimization. 
Effect of drug to polymer ratios (drug:polymer, 1:10, 1:15 and 1:20) on various 
formulation parameters were studied  by employing polymer PLGA 50:50 to formulate 
nanoparticles. Nanoparticles prepared with previously described drug to polymer 
ratios demonstrated mean particle size ranging from ~310 nm to ~320 nm (Fig. 40). 
W1/O/W2 emulsion/solvent evaporation method resulted in bi-model size distribution, 
except in case of with drug to polymer ratio 1:20 and polydispersity varying from 
~0.185 to ~0.300 (Fig. 40). Since, the size of nanoparticle were measured after freeze-
drying, we assume that during freeze-drying the nanoparticle may have aggregated. 
Whereas, zeta potentials observed for all three nanoparticle batches were between ~ -
19.7 to ~-21.3 (Table 20). No significant effects of drug to polymer ratios were 
observed with respect to particle size, polydispersity and zeta potential. Moreover, EE 
for all three cases of drug to polymer ratios were ranging from ~32% to ~40% with 
significant difference as the drug to polymer ratio increase (Table 20). Moreover, 
changes in drug to polymer ratio exhibited noticeable effect on drug loading. 
Nanoparticle batch with higher polymer content (1:20) showed the lowest drug loading 
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(~1.55%) and with lower polymer (1:10) content exhibited the highest loading 
efficiency (~2.96%) (Table 20). Nanoparticles exhibited a biphasic release profile with 
initial burst (rapid) release followed by a constant or sustained release phase. In case of 
drug to polymer ratio of 1:10 the drug release was sustained for ~12 days, for drug to 
polymer ratio of 1:15 the drug release was sustained for ~14 days and for drug to 
polymer ratio of 1:20 the drug release was sustained for ~20 days (Fig. 41). Since, the 
nanoparticles prepared with drug to polymer ratio of 1:20 contained higher amount of 
polymer, drug release profile was sustained for longer period of time compare to 1:10 
and 1:15. Though, nanoparticle prepared with drug to polymer ratio of 1:10 and 1:15 
unexpectedly show no significant difference. SEM image (drug:polymer 1:20) further 
confirmed the uniformity in size and spherical shape with smooth texture (Fig. 42). 
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Table 20: Characterization of CDF loaded PLGA nanoparticle formulation. 
Prodrug: 
PLGA  
Ratio 
% Entrapment 
Efficiency % Loading 
Average 
Size 
(nm) 
PDI Zeta Potential 
(mV) 
1:10 32.6 ± 5.2 2.9 ± 0.4 318.2 0.299 -19.7 
1:15 35.1 ± 4.8 2.2 ± 0.2 307.7 0.241 -20.9 
1:20 39.1 ± 3.7 1.6 ± 0.1 309.1 0.184 -21.3 
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Figure 40: Particle size distribution of CDF loaded PLGA nanoparticle Drug : Polymer 
ratio (A) 1:10, (B) 1:15, (C) 1:20. 
 
(A) 
(B) 
(C) 
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Figure 41: In vitro release of cidofovir loaded PLGA (50:50) nanoparticles in PBS buffer 
(pH 7.4) at 37 °C. The values are represented as mean ± standard deviation of n = 3 
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Figure 42: SEM image of CDF loaded PLGA nanoparticles (Drug:Polymer 1:20) 
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PLGA Nanoparticles for B-C12-cCDF 
PLGA 75:25 is more hydrophilic then PLGA 85:15 because of less percentage of 
lactice monomer in polymer, however more hydrophobic then PLGA 50:50 because of 
more percentage of lactide monomers in polymer chains. PLGA 75:25 will have in 
between properties of PLGA 85:15 and PLGA 50:50, which is similar to the 
physicochemical properties of B-C12-cCDF. Hence, we assume that PLGA 75:25 can 
impart higher entrapment and loading efficiency relative to other grades of PLGA. The 
initial nanoparticle formulation showed higher entrapment and loading efficiency for B-
C12-cCDF for PLGA 75:25 and was higher than PLGA 65:35. Therefore, polymer PLGA 
75:25 were utilized for further nanoparticle formulation optimization. 
Effect of drug to polymer ratios (Prodrug:polymer, 1:10, 1:15 and 1:20) on 
various formulation parameters were studied  by employing polymer PLGA 75:25 to 
formulate nanoparticles. Nanoparticles prepared with previously described drug to 
polymer ratios demonstrated mean particle size ranging from ~290 nm to ~300 nm 
(Fig. 43). W1/O/W2 emulsion/solvent evaporation method resulted in bi-model size 
distribution, except in case of with drug to polymer ratio 1:20 and polydispersity 
varying from ~0.177 to ~0.216 (Fig. 43). Since, the size of nanoparticle were measured 
after freeze-drying, we assume that during freeze-drying the nanoparticle may have 
aggregated. Whereas, zeta potentials observed for all three nanoparticle batches were 
between ~-18.9 to ~-22.3 (Table 21). No significant effects of drug to polymer ratios 
were observed with respect to particle size, polydispersity and zeta potential. 
Moreover, EE for all three cases of drug to polymer ratios were ranging from ~62 to 
~65% with no significant difference (Table 21). However, changes in drug to polymer 
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ratio exhibited noticeable effect on drug loading. Nanoparticle batch with higher 
polymer content (1:20) showed the lowest drug loading (~4.0%) and with lower 
polymer (1:10) content exhibited the highest loading efficiency (~6.25%) (Table 21). 
Irrespective of the prodrug to polymer ratio, B-C12-cCDF loaded all PLGA nanoparticles 
exhibited a biphasic release profile with initial burst (rapid) release followed by a 
constant or sustained release phase up to ~22 days (Fig. 44). Interestingly unlike CDF 
loaded PLGA nanoparticle, B-C12-cCDF nanoparticles prepared with drug to polymer 
ratio of 1:20 which contained higher amount of drug, the drug release profile were 
unexpectedly similar with nanoparticles prepared with the ratios of 1:10 and 1:15. SEM 
images further confirmed the uniformity in size and spherical shape with smooth 
texture (Fig. 45). 
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Table 21: Characterization of B-C12-cCDF loaded PLGA nanoparticle formulation. 
 
Prodrug: 
PLGA  Ratio 
% Entrapment 
Efficiency % Loading 
Average 
Size (nm) 
PDI Zeta Potential 
(mV) 
1:10 64.4 ± 2.2 6.3 ± 0.2 300.5  0.216 -21.7 
1:15 62.1 ± 2.8 4.9 ± 0.2 290.7  0.177 -18.9 
1:20 65.1 ± 4.0 4.0 ± 0.2 292.1 0.209 -22.3 
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Figure 43: Particle size distribution of B-C12-cCDF loaded PLGA nanoparticle Drug : 
Polymer ratio (A) 1:10, (B) 1:15, (C) 1:20. 
 
(A) 
(B) 
(C) 
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Figure 44: In vitro release of B-C12-cCDF loaded PLGA (75:25) nanoparticles in PBS 
buffer (pH 7.4) at 37 °C. The values are represented as mean ± standard deviation of 
n=3 
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Figure 45: SEM image of B-C12-cCDF loaded PLGA nanoparticles (Prodrug:Polymer 
1:20) 
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PLGA Nanoparticles for C12-cCDF 
PLGA 85:15 is the most hydrophobic because of high percentage of lactide then 
glycolide monomers in polymer chains. Hydrophobic interactions between the C12-
cCDF and polymer (PLGA 85:15) can impart higher entrapment and loading efficiency 
relative to other grades of PLGA. Hence, we prepared nanoparticles of C12-cCDF using 
PLGA 85:15. The initial nanoparticle formulation showed higher entrapment and 
loading efficiency for C12-cCDF and therefore, polymer PLGA 85:15 were utilized for 
further optimization. 
Effect of drug to polymer ratios (Prodrug:polymer, 1:10, 1:15 and 1:20) on 
various formulation parameters were studied  by employing polymer PLGA 85:15 to 
formulate nanoparticles. Nanoparticles prepared with previously described drug to 
polymer ratios demonstrated mean particle size ranging from ~290 nm to ~300 nm 
(Fig. 46).  O/W emulsion method resulted in uni-model size distribution in all case of  
prodrug to polymer ratio 1:10 with overall polydispersity varying from ~0.064 to 
~0.109 (Fig. 46). Zeta potentials for all three nanoparticle batches were observed in 
range of ~-18.6 to ~-23.3 (Table 22). No significant effects of prodrug to polymer ratios 
were observed with respect to particle size, polydispersity and zeta potential. 
Moreover, EE for all three cases of drug to polymer ratios were ranging from ~52% to 
~58% with significant difference when prodrug to polymer ratios were changed (Table 
22). Moreover, changes in drug to polymer ratio exhibited noticeable effect on prodrug 
loading. Nanoparticle batch with higher polymer content (1:20) showed the lowest 
prodrug loading (~3%) and with lower polymer (1:10) content exhibited the highest 
loading efficiency (~5.0%) (Table 22). In case of drug to polymer ratio of 1:10 the 
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prodrug release was sustained for ~16 days, for prodrug to polymer ratio of 1:15 the 
drug release was sustained for ~22 days and for prodrug to polymer ratio of 1:20 the 
drug release was sustained for ~26 days (Fig. 47). Since, the nanoparticles prepared 
with prodrug to polymer ratio of 1:20 contained higher amount of polymer, prodrug 
release profile was sustained for longer period of time compare to 1:10 and 1:15. Also, 
nanoparticle prepared with drug to polymer ratio of 1:10 and 1:15 show significant 
difference suggesting increase in the polymer amount has effect on sustaining the 
release of C12-cCDF from the polymeric matrix. SEM images further confirmed the 
uniformity in size and spherical shape with smooth texture (Fig. 48) 
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Table 22: Characterization of C12-cCDF loaded PLGA nanoparticle formulation. 
Prodrug: 
PLGA  
Ratio 
% Entrapment 
Efficiency % Loading 
Average 
Size 
(nm) 
PDI Zeta Potential 
(mV) 
1:10 51.4 ± 2.2 4.9 ± 0.3 224.7 0.109 -18.6 
1:15 56.1 ± 2.7 3.6 ± 0.6 237.2 0.045 -20.9 
1:20 58.1 ± 3.0 2.8 ± 0.7 225.1 0.064 -23.3 
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Figure 46: Particle size distribution of C12-cCDF loaded PLGA nanoparticle Drug : 
Polymer ratio (A) 1:10, (B) 1:15, (C) 1:20. 
 
(A) 
(B) 
(C) 
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Figure 47: In vitro release of C12-cCDF loaded PLGA (85:15) nanoparticles in PBS 
buffer (pH 7.4) at 37 °C. The values are represented as mean ± standard deviation of 
n = 3 
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Figure 48: SEM image of C12-cCDF loaded PLGA nanoparticles (Prodrug:Polymer 1:20) 
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Figure 49: CDF release model from PLGA (A) Zero order release (B) First order release 
(C) Higuch model and (D) Krosmeyer-peppas model 
 
(A) 
(B) 
(C) 
(D) 
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Table 23: Kinetic parameters for CDF release from PLGA (50:50) nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zero order First order Higuchi Krosmeyer-peppas 
r2 K1 (day-1) r2 K1 (day-1) r2 KH (day-1) r2 n Kkp (day-1) 
0.9146 4.0532 0.9246 0.0811 0.9809 20.671 0.9966 0.5855 1.5086 
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Figure 50: B-C12-cCDF release model from PLGA (A) Zero order release (B) First order 
release (C) Higuch model and (D) Krosmeyer-peppas model 
(A) 
(B) 
(C) 
(D) 
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Table 24: Kinetic parameters for B-C12-cCDF release from PLGA (75:25) nanoparticles 
Zero order First order Higuchi Krosmeyer-peppas 
r2 K1 (day-1) r2 K1 (day-1) r2 KH (day-1) r2 n Kkp (day-1) 
0.958 4.1364 0.8433 0.0759 0.9782 21.09 0.9852 0.5046 1.3331 
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Figure 51: C12-cCDF release model from PLGA (A) Zero order release (B) First order 
release (C) Higuch model and (D) Krosmeyer-peppas model 
 
(A) 
(B
) 
(C) 
(D) 
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Table 25: Kinetic parameters for C12-cCDF release from PLGA (85:15) nanoparticles 
Zero order First order Higuchi Krosmeyer-peppas 
r2 K1 (day-1) r2 K1 (day-1) r2 KH (day-1) r2 n Kkp (day-1) 
0.9716 3.4763 0.9422 0.05322 0.9683 19.42 0.9412 0.5089 1.3904 
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7.4 Discussion 
Treatment of CMV infections requires sustained delivery of anti-viral agents to 
the posterior segment of the eye. Frequent delivery of such anti-viral agent 
intravitreally has limitations due to side effects such as endophthalmitis, retinal 
detachment and other undesirable events related to repeated injections. However, 
sustained drug delivery formulation is a promising or alternative approach for the 
intravitreal drug delivery. 
In the present study, a series of PLGA polymers of varying lactide/glycolide 
ratios (50:50 to 85:15) were employed in the preparation of nanoparticles of 
drug/prodrug. The PLGA nanoparticles of CDF, B-C12-cCDF and C12-cCDF were 
prepared using different grade of PLGA polymer were characterized (% entrapment 
efficiency, % loading, particle size, zeta potential, and surface morphology) and 
performed in vitro drug release profiles in phosphate buffer saline (PBS, pH 7.4). 
Nanoparticles containing drug/prodrugs exhibited uniform size distribution with low 
polydispersity. In vitro drug/ prodrug release from nanoparticles exhibited a biphasic 
pattern with an initial burst phase followed by a sustained release phase. In all cases of 
nanoparticle, the drug to polymer ratio of 1:20 shows the significant sustained release 
of drug/prodrug from nanoparticle matrix this may be attribute to the high amount of 
polymeric matrix leading to slow and sustained release of drug molecules. Moreover, 
the burst release was also lowest in case of drug to polymer ratio of 1:20 which may 
again attribute to the high amount of polymer and low amount of surface bound 
drug/prodrugs. For CDF the sustained drug delivery was obtained for ~19 days, 
whereas in case of B-C12-cCDF and C12-cCDF were around ~22 and ~26 days 
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approximately. Such delivery systems may generate therapeutic levels from low doses 
of Cidofovir, B-C12-cCDF and C12-cCDF at the retina/choroid reducing inflammation, 
toxicity and providing sustained drug delivery.  
Drug release from nanoparticles generally follows diffusion/degradation or a 
combination of diffusion and degradation mediated release phenomena [301].In the 
present study, we analyzed the release of cidofovir, B-C12-cCDF and C12-cCDF from 
PLGA loaded nanoparticle at drug to polymer ratio of 1:20 (which gives sustained drug 
release in all cases). Analysis of drug release kinetics correlated well with Korsmeyer-
peppas model in case of CDF and B-C12-cCDF. The drug release correlation with 
Krosmeyer-peppas model suggested that drug release depended primarily on diffusion 
from the nanoparticles matrix rather than erosion process of the copolymer. A diffusion 
exponent from Krosmeyer-peppas model 0.485<n<0.869 suggest anomalous diffusion 
mechanism from cidofovir (n = 0.5855) (Fig. 49 and Table 23) and B-C12-cCDF (n = 
0.5046) (Fig. 50 and Table 24) nanoparticles matrixes. Whereas in case C12-cCDF, the 
release kinetics follows zero-order kinetics, which suggests that release of C12-cCDF 
was slow and sustained from the polymeric matrix (Fig. 51 and Table 25). The release 
kinetic of C12-cCDF revealed that the release of C12-cCDF was at constant rate and was 
independent of prodrug concentration in polymeric matrix. 
7.5 Conclusion 
CDF, B-C12-cCDF and C12-cCDF loaded PLGA nanoparticle were prepared at 
different drug/prodrug to polymer ratio (1:10, 1:15 and 1:20). The drug/prodrug to 
polymer ratio can influence the entrapment efficiency, loading, size and drug release 
profile from nanoparticles and here in all cases at drug to polymer ratio of 1:20, a 
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sustained release profile was observed. This suggests that drug/prodrug loaded PLGA 
NPs can be an excellent approach for intravitreal sustained drug delivery for the 
treatment of posterior segment ocular ailments.   
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CHAPTER 8 
SUMMARY AND RECOMMENDATIONS 
8.1 Summary 
Cidofovir (CDF) and its cyclic form (cCDF) are potent new antiviral agent shown 
to have in vitro and in vivo activity against a broad spectrum of herpesviruses, CMV, 
HSV-1, HSV-2, varicella-zoster virus, Epstein-Barr virus, adenoviruses, and various 
orthopoxviruses. It has been widely evaluated for its antiviral efficacy against CMV 
retinitis and HSV keratitis. Although cidofovir has shown potent activity, against wide 
variety of viruses, its low oral bioavailability of less than 5% necessitates frequent 
intravenous administration leading to well-known nephrotoxicity and thus limiting its 
therapeutic scope. The low bioavailability of cidofovir is attributing to its hydrophilic 
nature (high water solubility 170mg/mL and log p: -3.9) and may lead to low 
permeability.  
Therefore, the broad overall objective of the present study was to improve the 
bioavailability of CDF via novel transporter targeted lipid conjugates of cCDF. We have 
tested a novel hypothesis assuming that cellular uptake of CDF can be significantly 
enhanced by designing transporter targeted lipid prodrugs where CDF can be linked to 
the ligand for a cell membrane transporter via lipid linker. The lipid raft facilitates 
enhanced interaction of prodrug with cell membrane and thereby assisting docking of 
targeted ligand into the binding domain of transporter. Therefore, current novel 
approach combines both lipids mediated facilitate diffusion and transporter targeted 
delivery to generate synergistic drug effect for treating ocular diseases. Total of five 
novel prodrugs, three biotinylated lipid ester conjugates of cCDF (B-C2-cCDF, B-C6-
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cCDF, and B-C12-cCDF) and two lipid ester conjugates of cCDF (C6-cCDF and C12-cCDF) 
that incorporate biotin (ligand for SMVT transporter) conjugated to the cCDF through 
the different length of lipid raft (C2, C6 and C12)  have been successfully synthesized. 
The purity of all the prodrugs was determined by 31P NMR. A solid phase extraction (for 
biotinylated lipid ester conjugates of cCDF), liquid-liquid extraction (for lipid ester 
conjugates of cCDF) HPLC and LC/MS methods were also developed to determine the 
physicochemical properties, cellular accumulation, transport and enzymatic reversion 
from biological matrix. 
Physicochemical properties such as solubility, partition coefficient (n-
octanol/water and ocular tissue (retina-choroid)), bioreversion kinetics, interaction 
with SMVT transporter and docking studies with SMVT transporter have been 
determined. Among these novel conjugates, B-C12–cCDF has shown higher interaction 
to SMVT transporter with lowest half maximal inhibitory concentration value, higher 
cellular accumulation, high tissue partitioning, rapid enzymatic reversion and lowest 
docking scores. Improvement in physicochemical properties, lipophilicity, and 
interaction with transporter was observed in the trend of increasing the lipid chain 
length, that is, B-C12–cCDF > B-C6–cCDF > B-C2–cCDF.  
In vitro antiviral efficacy was determined against HSV-1, HSV-2, CMV, VZV, BK 
and JC viruses. In vitro   antiviral activity of B-C12-cCDF prodrugs demonstrated 2.5- to 
25-fold increase in antiviral activity against Herpesviridae (human cytomegalovirus  
[CMV], varicella-zoster virus, HSV-1 and HSV-2) viruses and 1.5- to 3-fold increase in 
antiviral activity against Papovaviridae (BK and JC) viruses relative to CDF.  Whereas, in 
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vitro   antiviral activity of C12-cCDF shows ~26 fold increase in antiviral efficacy against 
HSV-2, ~ 40-70 fold increase in antiviral efficacy against BK and JC virus.  
Based on these observations, we have also formulated PLGA nanoparticle (NP) 
formulation of cidofovir and their prodrugs (B-C12-cCDF and C12-cCDF) to achieve 
sustained drug delivery following intravitreal injection. These NP were able to sustain 
the release of prodrug for ~ 3-4 weeks indicating an excellent approach for intravitreal 
delivery of CDF prodrug for the treatment of CMV retinitis. Overall, these findings 
indicate that transporter-targeted lipid analogue of CDF could be a viable strategy for 
the treatment of CMV retinitis. 
8.2 Recommendation 
Transporter targeted lipid prodrug approach may serve as an alternative 
strategy to deliver hydrophilic drug molecules with high water solubility and low 
permeability across ocular tissues. Based on results from biotinylated lipid ester 
conjugates of cCDF following recommendations can be made to further continue this 
work. 
 An alternative transporter such as amino acid transporter, peptide transporter, 
monocarboxylate transporter, organic anion transporter (OAT), organic cation 
transporter (OCT) can also be utilized in order to improve the transporter 
mediated uptake or transport across cell membrane of transporter targeted lipid 
prodrugs. 
 A branched lipid raft of varying carbon length can also be utilized to improve the 
lipid mediated improved cellular interaction of transporter targeted lipid 
prodrugs. 
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 Various other hydrophilic drug candidates should also be chemically modified 
with transporter targeted lipid prodrug strategy to observe the trend we show in 
the case of cidofovir i.e. B-C2 < B-C6 < B-C12 shows improvement in 
physicochemical properties, interaction with transporter, shows ideal prodrug 
properties and enhanced antiviral efficacy. 
 We can study the effect of lipid mediated improved lipophilicity of transporter 
targeted lipid prodrugs by using various chain length of lipid raft such as C8, 
C10, C12, C14 and C16. 
  In docking analysis, we can compare the four diasteromers, confirm the activity 
of each stereoisomers and can derived the  molecular mechanincs indicating 
which stereoisomer is more active. 
 We have utilized PLGA polymer to prepared sustained release nanoparticle 
formulation of drug and prodrugs (for intravitreal administration) and the 
sustained release was achieved up to maximum of ~ 3-4 weeks in all cases. 
However, we can also utilize other polymers such as novel pentablock polymers 
(US Patent US20110250283 A1, Dr. Ashim K Mitra) to improve the 
encapsulation efficiency and achieved up to ~2-3 months of sustained release 
following intravitreal injection. This can improve the patient compliance and 
efficacy of therapy. 
 We can also utilize PLGA or pentablock polymeric nanoparticle of drug or 
prodrugs entrapped into the thermo-sensitive gelling polymer in order to reduce 
the burst release (along with relevant side effects of burst release drug or 
prodrugs) and can achieve zero order release kinetics for up to ~ 4-6 months.  
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